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Current knowledge suggests that a continued elevated acute phase response (APR), which is 
often referred to as low-grade inflammation, occurs during insulin resistance. The levels of 
acute phase proteins (APPs), such as plasminogen activator-inhibitor-1 (PAI-1), C-reactive 
protein (CRP), and serum amyloid A (SAA) are significantly increased during this response, 
hence why they are commonly used as biological markers for type 2 diabetes (T2D). In the 
liver, APPs are regulated by the peripheral mediators of stress (i.e., endogenous glucocorticoids 
(GCs)) and inflammation (i.e., pro-inflammatory cytokines), with both implicated in the 
development of insulin resistance. Exogenous GCs are routinely prescribed in the management 
of inflammatory disorders. However, long-term GC treatment can exaggerate insulin resistance 
as it could possibly disrupt the interplay between endogenous GCs and cytokines, leading to a 
recurrent, chronic APR. Current knowledge suggests that when it comes to the APR, GCs, 
which are traditionally known for its anti-inflammatory properties, exert more pro-
inflammatory behaviour, by further strengthening cytokine-induced APP expression. Whilst 
this cooperative regulation by GCs and pro-inflammatory cytokines have been extensively 
studied and demonstrated for SAA, fewer have studied this phenomenon in regards to PAI-1 
and CRP, especially in the liver. In addition, previous studies investigating the possible co-
regulation of PAI-1 and CRP by GCs and pro-inflammatory cytokines, included only 
interleukin-6 (IL-6) or tumour necrosis factor-alpha (TNF-α) as representative pro-
inflammatory cytokine, respectively. Therefore, the current study examined the expression of 
both PAI-1 and CRP in response to GCs (synthetic and endogenous) in the presence of either 
pro-inflammatory cytokine, TNF-α or IL-6, in a murine (BWTG3)- and human (HepG2) liver 
cell line. The effects were investigated at both the mRNA- and intracellular protein level, using 
real-time semi-quantitative polymerase chain reaction (qPCR) and western blotting, 
respectively. In addition, the potential underlying molecular mechanism governing the action 
of these biological mediators to affect APP expression were investigated, using a luciferase 
promotor-reporter assay. PAI-1 and CRP levels generally remained elevated in response to 
individual and combinatorial treatments with GCs and pro-inflammatory cytokines, at 
intracellular protein- and promotor level. However, only under certain conditions, 
cooperativity was displayed between the test compounds, where PAI-1 and CRP expression 
were further potentiated, more than what was observed with either test compound alone. APPs 
are secreted proteins; therefore, the rate of protein synthesis and export presumably plays a role 




intra- and extracellular APP expression, the latter of which the current study did not determine. 
In addition, the increase in PAI-1 and CRP promoter activity does suggest that the molecular 
mechanism of action whereby GCs and pro-inflammatory cytokines increase PAI-1 and CRP 
levels is at the promoter level. Whether only the proximal promotor is involved remains to be 
elucidated. Taken together, the findings of the current study give credence to the current 
knowledge available on the subject of cooperative regulation of APPs by GCs and pro-
inflammatory cytokines. It is clear that GCs favour an increase in APP expression, at times 
enhancing the cytokine-induced PAI-1 and CRP expression. However, GCs were also able to 
antagonise the cytokine-induced PAI-1 and CRP expression, which is in line with their anti-
inflammatory role. Ultimately, our findings highlight the diversity and complexity to the often-
contradictory nature of GCs and their crosstalk with inflammatory mediators.  
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Bestaande kennis dui daarop dat ’n verhoogde akute fase reaksie (AFR), ook bekend as lae-
graadse inflammasie, tydens insulienweerstandigheid voorkom. Die vlakke van akute fase 
proteïene (AFPe), soos plasminogeen aktiveerder-inhibeerder-1 (PAI-1), C-reaktiewe proteïen 
(CRP) en serum amiloïed A (SAA) word aansienlik verhoog tydens hierdie reaksie, en word 
dus gereeld gebruik as biologiese merkers vir tipe 2 diabetes (T2D). In die lewer word AFPe 
deur die perifere molekules van stres (endogene glukokortikoïede (GKe)) en inflammasie (pro-
inflammatoriese sitokiene) gereguleer, met beide wat ook in die ontwikkeling van 
insulienweerstandigheid geïmpliseer word. Eksogene GKe word gereeld voorgeskryf in die 
behandeling van inflammatoriese afwykings. Langtermyn GK-behandeling kan egter 
insulienweerstandigheid vererger, omdat dit dalk die wisselwerking tussen endogene GKe en 
sitokiene kan versteur, wat tot ’n herhaalde, chroniese AFR kan lei. Bestaande kennis dui 
daarop dat, met betrekking tot die AFR, GKe, wat tradisioneel bekend is vir hul anti-
inflammatoriese eienskappe, geneig is om meer pro-inflammatories op te tree deur sitokien-
geïnduseerde AFP-uitdrukking verder te versterk. Hoewel hierdie samewerkende regulering 
deur GKe en pro-inflammatoriese sitokiene vir SAA breedvoerig bestudeer en gedemonstreer 
is, is daar minder studies oor dié verskynsel ten opsigte van PAI-1 en CRP, veral in die lewer. 
Daarby het vorige studies ook slegs interleukin-6 (IL-6), in die geval van CRP, of  tumor 
nekrose faktor-alfa (TNF-α), in die geval van PAI-1, gebruik as verteenwoordiger sitokien in 
kombinasie met die GK. Die huidige studie ondersoek dus die uitdrukking van beide PAI-1 en 
CRP in reaksie op GKe (sinteties en endogeen) in die teenwoordigheid van óf pro-
inflammatoriese sitokien, TNF-α of IL-6, in ’n muriene (BWTG3) en menslike (HepG2) 
lewersellyn. Die uitwerkings is op beide mRNA- en intrasellulêre proteïenvlak ondersoek, met 
behulp van onderskeidelik intydse semi-kwantitatiewe polimerase kettingreaksie en western 
klad. Daarbenewens is die moontlike onderliggende molekulêre meganisme ondersoek, wat die 
aksie van hierdie biologiese molekules beheer om die uitdrukking van beide AKPe te 
beïnvloed, met behulp van ’n lusiferase promotor-verslaggewer toets. Die vlakke van PAI-1 en 
CRP was meestal verhoog in reaksie op individuele en gesamentlike behandelings met GKe en 
pro-inflammatoriese sitokiene, op proteïen- en promotorvlak. Maar samewerking tussen die 
toetsverbindings is slegs onder sekere omstandighede getoon, waar PAI-1- en CRP-uitdrukking 
verder versterk was, meer as wat met elke toetsverbinding op sy eie waargeneem was. AFPe is 
afgeskeide proteïene; daarom speel die tempo van proteïensintese en -uitvoer vermoedelik ’n 




intra- en ekstrasellulêre AFP-uitdrukking te bepaal, waarvan laasgenoemde nie in die huidige 
studie uitgevoer is nie. Verder dui die toename in PAI-1- en CRP promotor-aktiwiteit daarop 
dat die molekulêre aksiemeganisme waardeur GKe en pro-inflammatoriese sitokiene die 
vlakke van PAI-1- en CRP verhoog, op die promotorvlak is. Of slegs die proksimale promotor 
betrokke is, moet nog bepaal word. Gesamentlik gee die bevindinge van die hierdie studie 
geloofwaardigheid aan die beskikbare kennis oor die onderwerp van samewerkende regulering 
van AFPe deur GKe en pro-inflammatoriese sitokiene. Dit is duidelik dat GKe ’n toename in 
AFP-uitdrukking verkies, wat onder sekere omstandighede die sitokien-geïnduseerde PAI-1- 
en CRP-uitdrukking verbeter. GKe kan ook egter die sitokien-geïnduseerde PAI-1- en CRP-
uitdrukking teenstaan, wat in lyn is met hul anti-inflammatoriese rol. Ten slotte, beklemtoon 
ons bevindings die diversiteit en kompleksiteit van die dikwels teenstrydige aard van GKe en 
hul kruiskommunikasie met inflammatoriese molekules. 
 
Sleutelwoorde: akute fase-proteïene, akute fase reaksie, C-reaktiewe proteïen, 
glukokortikoïede, hepatiese insulienweerstandigheid, inflammasie, ko-regulering, 
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Over the last few decades, the incidence of diabetes mellitus (DM) has been rapidly expanding, 
making it one of the leading public health challenges not only in South Africa but worldwide. 
The global prevalence of diabetes is projected to increase from 463 million in 2019 to 700 
million by 2045, denoting a net increase of 51% [1]. In addition, it is among the top ten leading 
causes of death worldwide, with the World Health Organization (WHO) projecting DM to be 
the seventh leading cause of death in the world by 2030 [2]. Currently DM is classified as 
either: i) gestational DM, ii) type 1 DM (T1D) or iii) type 2 DM (T2D). The latter, previously 
called adult-onset diabetes or non-insulin-dependent, is the predominant form, comprising 90% 
of all DM cases. T2D is traditionally considered a metabolic disorder and a major non-
communicable disease, which is mainly attributed to the initial development of insulin 
resistance [3]. The term ‘insulin resistance’ implies a reduced sensitivity of peripheral target 
tissues, which include adipose, muscle, and liver tissues, to normal circulating concentrations 
of insulin [4]. The liver is especially of interest, since it is not only the first organ reached by 
secreted insulin but also the first organ where insulin resistance is presumably initiated [5]. In 
the liver, insulin resistance is manifested by the inhibition of glycogen synthesis and impaired 
suppression of hepatic glucose output [6]. This causes chronic hyperglaecemia, which if 
persists, could lead to the body failing to launch an effective immune response against 
infection, ultimately leading to sepsis and death [7]. Although it is well established that insulin 
resistance is central to the pathogenesis of T2D, it remains unclear how this abnormality arises 
at a molecular level. Contrasting data exist on what the principal molecular defects are which 
lead to insulin resistance.  
 
Although numerous factors contribute to the development of T2D, including obesity, a 
common theme throughout literature portrays inflammation and stress as key role players. A 
close link exists between chronic inflammation and insulin resistance [8], hence why T2D is 
currently regarded as a chronic, low grade inflammatory state [9]. Inflammation is regulated 
by several biochemical mediators, of which cytokines are the most important. Studies have 
implicated pro-inflammatory cytokines, including tumour necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6), in the pathophysiology of insulin resistance and its complications 
[10][11]. Similarly, glucocorticoids (GCs), steroidal stress hormones, have been demonstrated 
to cause insulin resistance in vivo [12]. Stress via GC signalling can activate the acute phase 




It has been reported that an elevated APR occurs during insulin resistance [13]. Acute phase 
proteins (APPs) which significantly increase during the APR, are also associated with insulin 
resistance, and predict the development of T2D [14]–[20]. The levels of the APPs, plasminogen 
activator inhibitor-1 (PAI-1), C-reactive protein (CRP), and serum amyloid A (SAA) are 
upregulated during the diabetic state, hence why these compounds are commonly also used as 
biological markers for T2D [21]. The inducibility of these APPs by both the early- (pro-
inflammatory cytokines) and late (GCs) -stage acute phase mediators suggest that they are 
synthesized and presumably play an essential role throughout the APR. The fact that certain 
APPs can be induced by both pro-inflammatory cytokines and GCs is interesting considering 
GCs are more known for their anti-inflammatory properties [22]. Traditionally GCs and the 
majority of pro-inflammatory cytokines are well known to antagonize each other’s activity 
[23]. However, current knowledge suggest that GCs selectively regulate gene expression. 
When it comes to innate immune responses such as the APR, GCs exert more pro-inflammatory 
behaviour, converging their signal with that of pro-inflammatory cytokine signalling, to further 
increase the expression of certain APPs. Ultimately, by doing so, GCs reinforce the innate 
immune system and APR [24].  
 
Taking the above-mentioned associations with insulin resistance into account, three smaller 
projects forming part of a larger study within our research group have been initiated (Fig. 1.1). 
We speculate that APPs may be the correlative link between the physiological elements (stress 
and inflammation) and the development of insulin resistance. Speelman et al. investigated the 
effect of APPs (PAI-1, CRP, and SAA) on the hepatic insulin signalling pathway [25]. Here, 
the findings suggested that certain APPs possibly play a pivotal role in the development of 
hepatic insulin resistance, as it was found that PAI-1 and CRP attenuated key proteins in the 
insulin signalling pathway, leading to the downregulation of hepatic insulin signalling. In the 
current study these earlier observations are extended by investigating the possible co-regulation 
of the APPs, PAI-1 and CRP, by GCs and pro-inflammatory cytokines. In addition, the 
modulation of of either pro-inflammatory cytokine action by the GC and the modulation of the 
GC action by either pro-inflammatory cytokine will be analysed. It is important to examine 
regulation from both perspectives, as it has become abundantly clear that both the stress and 
immune system have bidirectional effects on each other [26]. The modulation of the stress 
system by the immune system has not been well studied, especially at the peripheral level. 




been extensively studied [27], mostly reporting from the former perspective, fewer have 














Figure. 1.1. The current study forms part of a larger project within the Verhoog research group. Acute 
phase proteins may be the correlative link between the physiological elements, stress (represented by 
glucocorticoids) and inflammation (represented by pro-inflammatory cytokines) and the development of hepatic 
insulin resistance. Three smaller projects were initiated, with the common goal to bring more evidence to this 
argument.  Image created by author using BioRender. 
 
In this literature review, the knowledge linking insulin resistance to each of the following 
components: inflammation, the stress system, the APR, and APPs, will be reviewed. In 
addition, a summary of each component will be provided. The last section in this chapter will 
provide an overview of the current knowledge available on cooperative regulation of APPs by 
the GCs and pro-inflammatory cytokines.  
1.2. Inflammation and its role in insulin resistance 
Inflammation is at the root of most chronic health conditions; this is no different in the 
pathophysiology of T2D. Several lines of evidence have reported a link between chronic 
inflammation and insulin resistance [21], however the precise mechanism by which chronic 
inflammation can evoke insulin resistance remains unclear. The argument has been made that 
the link between DM and inflammation can be explained by the presence of obesity [28]. In 
fact, adipose tissue is a source of low-grade inflammation, releasing both the pro-inflammatory 
cytokines, TNF-α and IL-6 [28]. Dandona and colleagues have proposed that chronic over-




might impair insulin action by suppressing insulin signal transduction [29]. It is however 
important to note that inflammation is a heterogenous concept, and the association between 
different inflammatory markers and the incidence of DM vary. Today, systemic low-grade 
inflammation is widely accepted to be associated with T2D [30][31]. 
 
Inflammation is regulated by numerous biochemical signals, which include three major 
categories of inflammatory mediators: 1) cytokines; 2) GCs, and 3) growth factors [32]. 
Cytokines are multi-functional molecules, which primarily function as stimulators of APP gene 
expression. They can be divided into three categories: i) pro-inflammatory cytokines (TNF-α, 
IL-1-α/β, IL-8), ii) anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGF-β 3) and iii) IL-6-
type cytokines (IL-6, IL-11) which have a dual function as both pro- and anti-inflammatory 
[33]. On the other hand, GCs (discussed in the next section) together with growth factors, such 
as insulin, function as modulators of cytokine action. In T2D, the balance between anti-
inflammatory and pro-inflammatory cytokines are shifted towards pro-inflammation, 
potentially causing or amplifying the health complications found in this disease state [34].  
 
Since pro-inflammatory cytokines have been associated with insulin resistance and T2D, the 
section below will review the role each cytokine plays in the development of insulin resistance. 
In addition, this section will provide an overview of the TNF-α and IL-6 general signalling 
pathways. However, it must be emphasized, that the cytokine signalling networks are very 
complex. Although we will evaluate the individual biological profiles of both TNF-α and IL-
6, it must be kept in mind that cytokines interact in a complex fashion with each other as well 
as other factors to regulate gene expression. 
 
‘Individual cytokines can be thought of as words which bear informational content. 
Although individual cytokines may, on occasion, communicate a complete message, 
more commonly the actual messages received by cells probably resemble sentences, in 
which it is the combination and sequence of words which convey information.’ – 
Kushner, Irving (1993) [35] using a crude simile to describe the complexity of the 
cytokine signalling language 
1.2.1. Tumour necrosis factor-α (TNF-α) 
TNF-α is a pleiotropic cytokine, primarily secreted by immune cells, such as macrophages and 




a myriad of diverse functions, including energy metabolism, cell differentiation, proliferation, 
apoptosis, and the regulation of innate immunity. Importantly TNF-α is also involved in 
pathological processes such as systemic inflammation [36] where it has the important role in 
orchestrating the release of pro-inflammatory cytokines, including IL-6. In hepatocytes, TNF-α 
participates in promoting APP synthesis during the APR [37]. 
1.2.1.1. TNF-α signalling 
Human TNF-α is produced as a homotrimer transmembrane protein which has two isoforms. 
It is synthesized as a membrane integrated 27 kDa protein (mTNF-α) that undergoes proteolytic 
cleavage, resulting in a bioactive 17 kDa soluble molecule (sTNF-α). The latter being the form 
in which TNF-α circulates throughout the body and executes its potent endocrine function, i.e., 
‘the ability to act at physiological sites, far away from the site of its synthesis’ [38].  
 
TNF-α signals through two transmembrane TNF-α receptors, TNFR1 (p55/60) and TNFR2 
(p75/80). TNFR1 is constitutively expressed across all human tissues and when it comes to 
TNF-α signalling is presumed to be its main mediator. Whereas, TNFR2 expression is typically 
found in cells of the immune system, and plays a major role in the lymphoid system [38]. Since 
the majority of TNF-α’s biological effects are mediated via TNFR1 activation, the following 
discussion will focus mainly on the effects of TNFR1 signalling and the pathways involved 
(Fig. 1.2). It should also be stressed that these pathways are extraordinarily complex.  
 
Whereas TNFR2 generally mediates the effects of the mTNF precursor, TNFR1 is the main 
receptor for sTNF. Thus sTNF-α binding to TNFR1 leads to the induction of diverse intricate 
signalling pathways: i) NF-κB, ii) p38/JNK and iii) caspase signalling (Fig. 1.2). The NF-κB 
and p38/JNK pathways are activated to help maintain cell survival and promote inflammation 
by increasing gene transcription of cytokines, cytokine receptors, growth factors, among others. 



























Figure 1.2. Schematic illustration of TNFR1-induced signalling via complex I and II. TNF-α (sTNF) binding 
to TNFR1 leads to the recruitment of TRADD, TRAF2 and RIP1, forming complex I (1). Complex I subsequently 
activate specific MKKs (2) as well as the IKK complex, consisting of three subunits (3). MKKs activate the 
MAPKs, p38 and JNK (4) via dual phosphorylation. This allows both MAPKs to translocate to the nucleus where 
they enhance the transcriptional activity of transcription factors, like AP-1 via phosphorylation (5) The IKKβ 
subunit of the IKK complex phosphorylates NF-κB-bound IκBα leading to its proteasomal degradation (6). This 
allows NF-κB, consisting of two heterodimers, p50/p65, to translocate to the nucleus (7), where it induces the 
transcription of many genes. Complex II is formed after FADD and procaspase-8 binds to complex I (8). The 
clustering of procaspase-8 results in its autoactivation, which enables it to activate several effector caspases (9), 
and signals toward apoptosis. Image was reproduced and adapted from Wullaert et al., 2007 [39]. Note: sTNF-α 
= soluble tumor necrosis factor-alpha, mTNF-α = membrane-bound tumor necrosis factor-alpha TNFR1/2 = 
Tumor necrosis factor receptor 1/2, TRADD = TNF receptor type 1-associated death domain, RIP1 = Receptor-
interacting protein 1, TRAF2 = TNF receptor-associated factor 2, FADD = Fas Associated Via Death Domain, 
NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells, JNK = c-Jun N-terminal kinase, MKKs 
= mitogen-activated protein kinase kinases, IKKs = IκB kinases, AP-1 = Activator protein-1 
 
i. NF-κB pathway 
TNF-α signal complex I is formed upon TNF-α binding to TNFR1, which leads to the 
recruitment of TNF receptor type 1-associated death domain (TRADD), TNF receptor-
associated factor 2 (TRAF2), and receptor-interacting protein 1 (RIP1) as illustrated in Fig. 1.2. 
This complex by default phosphorylates and triggers the activation of IκB kinases (IKK)-αβγ 
complex. Next, the IKKβ subunit phosphorylates the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB)-bound IκBα, leading to its proteasomal degradation. This allows 
the transcription factor, NF-κB, consisting of p65 (RelA)/p50 heterodimers, to translocate into 




genes [39]. Subsequently, NF-κB regulates the expression of many different genes, including 
those associated with cell survival and the production of pro-inflammatory cytokines, such as 
IL-6 [40]. Moreover, NF-κB itself can transcriptionally induce tnf, as well as traf2, and thereby 
further amplify the TNF-α/TNFR1 signalling pathways. Despite TNF-α signalling not yet 
being fully understood, the pro-inflammatory effects of TNF-α are predominantly understood 
to be because of its ability to activate NF-κB [41].  
ii. p38/JNK/AP-1 pathway 
As shown in Fig. 1.2, TNF-α signal complex I also induces the activation of mitogen-activated 
protein kinases (MAPKs), such as c-Jun N-terminal kinase (JNK) and p38. Both are activated 
by dual phosphorylation on tyrosine and threonine residues via mitogen-activated protein 
kinase kinases (MKKs). Upon activation, they translocate into the nucleus, where they 
phosphorylate and enhance the transcriptional activity of transcription factors, including 
activator protein-1 (AP-1). The AP-1 protein, consisting of the c-Jun and c-Fos subunits, is an 
important promotor of inflammation by regulating the production of pro-inflammatory 
cytokines, proliferation as well as prevention of apoptosis [41].  
iii. Caspase pathway 
When the survival pathway is inhibited, TNFR1 can induce a cell death response, since it 
contains a death domain (DD). Binding of fas associated via the death domain (FADD) and 
procaspase-8 to complex I, results in the formation of complex II or otherwise known as the 
death-inducing signalling complex (DISC) (Fig. 1.2). The clustering of procaspase-8 results in 
its autoactivation, which enables it to activate several effector caspases, which ultimately 
signals toward apoptosis and necrosis [39]. 
1.2.1.2. The role of TNF-α in insulin resistance 
Amongst the broad-spectrum of pro-inflammatory cytokines, TNF-α, was the first to be 
implicated in the pathogenesis of T2D as it was found to interfere with insulin signalling [10]. 
Since then studies have emerged indicating serum levels of TNF-α to be positively correlated 
with the pathophysiology of insulin resistance [13][42][43], with the general consensus that 
elevated TNF-α can cause insulin resistance. TNF-α is also seen as a mediator of insulin 
resistance in obesity, as it is overexpressed in human and rodent adipose tissue, and can block 
the action of insulin in vitro and in vivo [10]. In support of this, studies have found animal 




to their lean counterparts, whilst also revealing a strong correlation between TNF-α levels and 
obesity (BMI = body mass index) [10][44] 
 
In murine models of obesity and T2D where TNF-α was found to be markedly increased, 
pharmacological or genetic neutralization of TNF-α or its receptors improved insulin 
signalling, leading to reduced gluconeogenesis in fat and muscle [45][46]. In support of this 
finding, Hotamisligil et al. found that when TNF-α was neutralized in obese rats, the peripheral 
uptake of glucose in response to insulin was significantly increased [10]. In addition, a study 
by the same research group in TNF-α receptor knockout mice showed increased insulin 
sensitivity and an improved glucose tolerance [44].  
 
Several potential mechanisms by which TNF-α directly impairs insulin signalling have been 
proposed. The majority of studies suggest that TNF-α contributes to the development of insulin 
resistance through induction of serine kinases that attenuate insulin receptor (IR) and insulin 
receptor substrate (IRS)-1/2 signalling pathways [47]–[49]. In vitro studies reported that 
exposure of cultured adipocytes, hepatoma and Chinese hamster ovary (CHO) cells to TNF-α 
caused insulin resistance by activating JNK and IKKβ signalling cascades. This resulted in an 
increase in the inhibitory serine phosphorylation of IRS-1, making IRS-1 a poor substrate for 
insulin receptor-activating kinases, ultimately impairing insulin action [44][50]–[53]. 
Additionally, in vivo studies in muscle and fat tissue of obese rats also showed TNF-α to 
promote insulin resistance by inducing serine phosphorylation of IRS-1, ultimately inhibiting 
the IR tyrosine kinase activity [44][54]. The abovementioned findings have shown that chronic 
exposure to TNF-α impairs insulin signalling in major insulin-sensitive tissues, such as the 
skeletal muscle and adipose tissue. The mechanism by which TNF-α impairs hepatic insulin 
signalling is not clearly defined.  
1.2.2. Interleukin-6 (IL-6) 
IL-6 is a pleiotropic cytokine, produced after TNF-α and IL-1 stimulation [55], by numerous 
different cell types, including those found in the immune system [56]. Outside of the immune 
system, hepatocytes among various other cells, are targets of IL-6. The biological effects of 
IL-6 differ according to target tissues, and ranges from immune regulation, proliferation, and 
differentiation of hematopoietic cells to inflammation at sites of tissue injury [36]. In the liver, 




the hypothalamic pituitary adrenal (HPA)-axis to produce cortisol in humans, the feedback of 
which inhibits the production of IL-6 [55].   
 
1.2.2.1. IL-6 signalling 
Human IL-6 is produced as a 26 kDa four helix-bundle cytokine [58]. IL-6-mediated effects 
are exerted through two pathways known as classic and trans-signalling. In the former pathway, 
IL-6 binds to the membrane-bound IL-6R (mIL-6R, R refers to receptor), whereas in the latter 
pathway IL-6 binds to a soluble form (sIL-6R). It is believed that IL-6 classic signalling is 
important for the APR and promotes anti-inflammatory and regenerative effects, while IL-6 
trans-signalling promotes pro-inflammatory responses [59]–[61].  
 
Under normal conditions, circulating IL-6 prefers to bind to sIL-6R, but during some 
inflammatory conditions, where plasma IL-6 levels are elevated, IL-6 acts via trans-signalling 
[62]. Generally speaking, IL-6 binds to the α-chain of its cognate receptor, mIL-6R 
(CD126/gp80). Only a few cell types, including hepatocytes, express mIL-6R on their cell 
surface, and therefore can directly respond to IL-6. Subsequently, this ligand-receptor complex 
associates with two subunits of gp130, a membrane glycoprotein and signal transducing 
receptor, triggering its homodimerization (Fig. 1.3). This forms a stimulatory complex (IL-
6/IL-6R/gp130), which can now induce autophosphorylation and activation of Janus kinases 
(JAKs), (JAK1, JAK2) [63]. Activated JAKs can activate two major pathways: i) JAK1/STAT3 
and ii) Ras/ERK/MAPK (Fig. 1.3). As a result APP expression, adhesion molecules, 
chemokines, anti-apoptotic proteins and cytokines are induced [36][64]. Additionally, the 
complex can activate other signalling pathways, such as phosphoinositide 3-kinases 
(PI3K)/Akt, but this pathway will not be discussed as it is primarily involved in prostate cancer 

































Figure 1.3. Schematic illustration of IL-6 signalling. The IL-6 receptor complex activates gp130-associated 
JAKs via autophosphorylation (1). Activated JAKs recruit SHP2 and Grb2 (2), which then stimulates activation 
of the Ras/ERK/MAPK (3) and PI3K/Akt (4) pathways, respectively. Activation of Akt can either lead to 
activation of mTOR (5) which upregulates SOCS-3 transcription or it can activate the IKK complex (6). IKKβ 
subunit of the IKK complex phosphorylates NF-κB-bound IκBα leading to its proteasomal degradation (7). This 
allows NF-κB, consisting of two heterodimers, p50/p65, to translocate to the nucleus (8), where it transcriptionally 
induces many genes. In addition, activation of the ERK/MAPK pathway can activate transcription factors, such 
as C/EBP-β. Furthermore, activated JAKs leads to the recruitment, phosphorylation and translocation of STAT3 
to the nucleus (10). Here STAT3 dimers bind to DNA and induce APP and SOCS-3 expression (11). In addition, 
SOCS-3 inhibits JAKs (12), acting as negative regulator of IL-6 signalling. Image was reproduced and adapted 
from Taub, 2004 [66] & Akbari et al., 2018 [62]. Note: APP = acute phase proteins, APR = acute phase response, 
C/EBP-β = CCAAT/Enhancer binding protein beta, gp130 = glycoprotein 130, Grb2 = Growth factor receptor-
bound protein 2, IKKs = IκB kinases, IL-6 = interleukin-6, IL-6R = interleukin-6 receptor, JAK1 = Janus kinase 
1, ERK/MAPK = extracellular signal-regulated kinases/mitogen-activated protein kinase, mTOR = mammalian 
target of rapamycin, NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells, PI3K = 
Phosphoinositide 3-kinases, SHP2 = Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2, 
SOCS-3 = Suppressor of cytokine signaling 3,  SOS = son of sevenless, STAT3 = Signal transducer and activator 
of transcription 3 
 
 
i. JAK/STAT pathway 
Receptor activation by IL-6 initiates the activation of JAK1, which in turn leads to tyrosine 
phosphorylation and activation of the transcription factors, signal transducer and activator of 
transcription 3 (STAT3) and src homology region 2 (SH2)-containing protein tyrosine 
phosphatase 2 (SHP2), the latter triggering the MAPK pathway (Fig. 1.3). Beyond the tyrosine 
phosphorylation of STAT3, which leads to its dimerization and translocation to the nucleus, 




Several protein kinases, including mammalian target of rapamycin (mTOR), have been 
reported to phosphorylate STAT3 at its serine residue [67]. Fully activated STAT3 is now able 
to translocate to the nucleus as a dimer where it binds to specific response elements in the 
promotors of IL-6 responsive genes. One of these genes encodes  the suppressor of cytokine 
signalling (SOCS) protein, which is rapidly induced by IL-6 via the JAK/STAT pathway [67]. 
Thereby, acting as a negative feedback inhibitor of this pathway in order to prevent excessive 
inflammation by terminating IL-6 signalling. SOCS proteins bind directly to tyrosine-
phosphorylated JAK1 or activated cytokine receptors to suppress cytokine signalling [67]. This 
statement is supported by in vivo studies in the liver, reporting that deletions of SOCS-3 led to 
prolonged STAT3 activation following IL-6 stimulation [68]. Ultimately, the 
IL-6/JAK1/STAT3 pathway regulates the expression of several genes leading to an increase in 
cell growth, differentiation, and survival [69]. In the liver, this process promotes the APR, 
hepatoprotection and liver regeneration.  
ii. Ras/ERK/MAPK pathway 
As shown in Fig. 1.3, SHP2 is another mediator of IL-6 signalling, following its recruitment to 
phosphorylated gp130, and subsequent tyrosine phosphorylation by JAK1. Phosphorylated 
SHP2 associates with the adaptor protein, growth factor receptor-bound protein 2 (Grb2), 
which subsequently recruits and binds to son of sevenless (SOS). This series of interactions 
between these proteins lead to the activation of Ras, a monomeric small GTPase switch protein 
responsible for the activation of downstream signalling proteins such as extracellular 
signal-regulated kinases 1 or 2 (ERK1/2) and MAPK (Fig. 1.3) [69]. In addition, it has been 
shown that activation of the ERK/MAPK pathway can activate the transcription factor, 
C/EBP-β [70], via phosphorylation, whereafter it moves across the nuclear membrane to 
interact with its own cognate response elements (CAAT box) in the mammalian promotor 
regions of IL-6-responsive genes [71]. Overall, the Ras/ERK/MAPK pathway mediates diverse 
effects including cell growth, stimulation of APPs and immunoglobulin synthesis [69]. 
 
1.2.2.2. The role of IL-6 in insulin resistance 
Under normal physiological conditions, the expression of IL-6 is short-lived, contributing to 
tissue injury, and decreasing when tissue homeostasis is restored [36]. However, in the 
pathogenesis of diseases with an inflammatory background, including insulin resistance and 
T2D, the abnormal and chronic production of IL-6 plays a major role [49]. Several studies have 




resistance, and T2D in human subjects [11][13][72][73]. In particular studies have shown 
peripheral administration of IL-6 in rodents to induce insulin resistance [74][75]. The exact 
mechanism by which IL-6 induces insulin resistance appears to be complicated and versatile 
[76]–[82].  
 
In brief, IL-6 induces insulin resistance in muscle and adipose tissue via activation of the 
JAK/STAT3 pathway, leading to the reduction of the glucose transporter, GLUT4, and IRS-1 
expression [76]. Several studies in isolated hepatocytes and in the liver of experimental animals 
have linked the elevated levels of IL-6 to the inhibition of insulin signalling. In vivo studies in 
the liver, have shown that IL-6 blunted the ability of insulin to suppress gluconeogenesis and 
insulin-stimulated IRS-2 associated PI3K activity [77]. In vitro studies using both mouse 
hepatocytes and human hepatocarcinoma cells (HepG2) have demonstrated that IL-6 impairs 
insulin signalling by enhancing SOCS-3 expression, which impairs IRS-1 tyrosine 
phosphorylation [78][79]. In line with this, it has been proposed that mTOR plays an important 
role in IL-6-induced hepatic insulin resistance by regulating the activation of STAT3 [80]. 
Consequently, SOCS-3 expression increases leading to the impairment of insulin signalling 
[80]. In the liver tissue of obese mice, chronic exposure to IL-6 selectively induced insulin 
resistance, while systemic depletion of IL-6 improved hepatic insulin action [79][81]. 
Furthermore, evidence exists supporting the role of hepatic NF-κB activation in the 
development of insulin resistance. Mice models of obesity, with chronic activation of NF-κB, 
resulting in recurrent IKKβ activation, caused profound hepatic insulin resistance. However, 
injection of IL-6 neutralizing antibodies proved to be effective by improving hepatic insulin 
resistance in these mice [82]. Altogether these findings suggest a causative role for IL-6 in the 
development of insulin resistance, especially in the liver. 
1.3. Glucocorticoids: the hormone and its signalling pathway 
GCs are essential steroid hormones with potent anti-inflammatory capabilities that primarily 
function to modulate and suppress inflammation [83]. Naturally produced GCs such as cortisol 
and corticosterone are principally secreted by the human and rodent adrenal cortex, 
respectively. The effective anti-inflammatory activity of endogenous GCs are exploited by the 
pharmaceutical industry through the synthesis of synthetic GCs, such as dexamethasone (Dex) 
and prednisone [22]. These derivative steroid drugs are routinely prescribed in the management 
of many inflammatory disorders [84]. Endogenous GCs are mainly secreted in response to a 




internal or external stimulus’ [85]. The following section will review the current status of 
knowledge on the molecular sequence of events that unfolds when GCs reach its target organs 
and binds to its receptor. In addition, as GCs have been associated with insulin resistance and 
T2D, the section below will review the role it plays in the development thereof.  
 
1.3.1. Glucocorticoid signalling 
The stress response system, which also include the sympathetic nervous system (SNS), is 
essential for human survival and involves the activation of the HPA-axis, a multi-step hormonal 
process [86][87]. Upon exposure to stress (environmental or physiological) the hypothalamus 
is activated to release corticotropin-releasing hormone (CRH). In turn, CRH targets the anterior 
pituitary gland to secrete adrenocorticotropic hormone (ACTH). Next, ACTH acts on the 
cortex of the adrenal glands situated above each kidney to synthesize and release endogenous 
GCs such as cortisol into systemic circulation (Fig. 1.4). Once within the blood stream, cortisol 
will move to target organs in the periphery, such as the liver, where they will exert their tissue-
specific effects [87]. In the liver specifically, GCs stimulate gluconeogenesis, which provide 
systemic glucose needed to fuel the stress response [88]. In return, GCs control the regulation 
of basal HPA-axis activity, establishing a regulatory feedback loop [86]. It is important to note, 
that although a stress-induced increase in GCs is adaptive in the short term, anomalous GC 
secretion may result in health complications [83]. In addition, prolonged exposure to synthetic 


































Figure 1.4. Schematic illustration of the HPA-axis and glucocorticoid signalling pathways. Upon exposure 
to environmental and physiological stress the hypothalamus is stimulated to secrete CRH (1), which stimulates 
the release of ACTH by the anterior pituitary gland (2). In turn, ACTH targets the adrenal glands of the kidney to 
synthesize and secrete cortisol into the bloodstream (3). Cortisol can readily enter the cell, where this hormone 
binds to the GR in the cytoplasm (4). This induces a conformational change in the receptor, where it becomes 
hyperphosphorylated and dissociates from its chaperone molecules, such as heat shock proteins (HSPs) (4). The 
GR can signal in a non-genomic manner (5) or translocate into the nucleus where it exerts its actions through 
genomic mechanisms (6). In the nucleus, the GR can either dimerise (7) to transactivate anti-inflammatory genes 
or tether to pro-inflammatory transcription factors (TFs) as a monomer (8) to inhibit cytokine production, known 
as transrepression. Image was reproduced and adapted from Cruz-Topete & Cidlowski, 2015 [87]. Note: CRH = 
Corticotropin-releasing hormone, ACTH = Adrenocorticotropic hormone, AP-1 = Activator protein-1, Hsp90/70 
= Heat shock protein 90/70, FKBP = Immunophilins, MAPK = Mitogen-activated protein kinase, PI3K = 
Phosphoinositide 3-kinases, NF-κB = Nuclear factor kappa-light-chain-enhancer of activated B cells, GR = 
glucocorticoid receptor, sGRE = simple glucocorticoid response element 
 
GCs are lipophilic molecules which exert their physiological and pharmacological effects by 
diffusing across the cell membrane to bind to their cognate intracellular receptor, the 
glucocorticoid receptor (GR) [90]. Whilst synthetic GCs, such as Dex almost exclusively 
activate the GR, endogenous GCs can also activate the mineralocorticoid receptor (MR), which 
alongside the GR belongs to the nuclear receptor superfamily [24]. The GR is expressed in 
virtually all cell types, tissues and organs [87]. The ligand-bound GR functions as a 
transcription factor which can modulate the transcription of a large number of genes via well-
described genomic and less well understood non-genomic signalling mechanisms [91]. Human 




main protein isoforms, i.e., GRα and GRβ, which only differ in their C-terminal regions [92]. 
GRα is the classic receptor, which elicits most of the biological actions of GCs. Whereas, GRβ 
does not bind active GC agonists [87] and its biological relevance remains unclear. The 
expression of GRα is higher than GRβ in tissues [87].  
 
The GR consists of three major functional domains, each fulfilling a specific function (Fig. 1.5) 
[87]. Firstly, the N-terminal domain (NTD) contains a transcriptional activation function-1 
(AF-1) domain, which consists of residues that undergo several post-translational 
modifications. As a result, the NTD is important for the recruitment of basal transcriptional 
machinery [87]. Secondly, the central DNA-binding domain (DBD) is involved in GR 
dimerization, nuclear localization and binding of the GR to glucocorticoid response elements 
(GREs), within the promoter regions of GC-responsive genes [87]. Lastly, the C-terminal 
ligand-binding domain (LBD) contains an AF-2 domain which interacts with the chaperone 
protein, heat shock protein 90 (Hsp90), in a ligand-dependent manner and allows the GR to 











Figure 1.5. Schematic illustration of the human GR structure. Linear representation of the 777 amino acid GR 
showing the principal domains and regions involved in transactivation (AF-1 and AF-2), dimerization, nuclear 
localization and Hsp90 binding. Image was inspired by Cruz-Topete & Cidlowski, 2015 [87]. Note: NTD = N-




‘‘GC signalling is not merely a simplified signal transduction pathway but a 
complex homeostatic system that functions co-ordinately with other systems to 
help individuals cope with stressful stimuli’’ – Nicolaides et al., 2015 [91] 
 
Studies are surfacing, adding new layers of complexity to GR signalling [90][91]. To simplify 
this complex signalling system, only the general steps as illustrated in Fig. 1.4 will be 




predominantly retained in the cytoplasm complexed with Hsp90/70 chaperones, as well as 
other accessory proteins, such as the immunophilins (FKBP) [24][93]. This forms an inactive 
multi-protein complex, where the GR is considered to be functionless. A GC signalling cascade 
is triggered upon lipophilic GCs entering the cell and binding to the cytoplasmic GR via its 
LBD. This leads to conformational changes in the receptor which results in dissociation of the 
multi-protein complex and hyperphosphorylation of the GR [24]. Subsequently, allowing the 
receptor to either translocate along microtubules into the nucleus by virtue of a sequence in the 
DBD, or interfere with signal transduction components in the cytoplasm. Once within the 
nucleus, monomeric GR can assume different conformations and exert its actions via various 
genomic mechanisms as displayed in Fig. 1.6.    
 
The homodimeric GR can interact directly with GREs in the promoter (regulatory) regions of 
GC target genes, ultimately, influencing their transcription rate in a positive manner (referred 
to as transactivation). In addition, as a monomer, the ligand-activated GR can bind to negative 
GREs (nGREs) whereby transcription of the targeted genes are inhibited (referred to as 
transrepression) [24]. In addition, activated GR bound to GREs can interact with neighbouring 
DNA-bound transcription factors, commonly known as composite regulation. Alternatively, 
the activated GR can influence gene expression independently of GREs through protein-protein 



































Figure 1.6. Schematic illustration of the different GR genomic signalling mechanisms. The GR can repress 
or enhance the transcription of target genes by (1) directly binding to negative (nGRE) or simple (sGRE) 
glucocorticoid-response elements, respectively, (2) by tethering itself to other transcription factors (TFs), or (3)   
by directly binding to GREs and interacting with neighbouring TFs (known as composite regulation).  Image was 
adapted from Necela & Cidlowski, 2004 [94] using BioRender. 
 
Traditionally, transactivation is generally mediated by a GR homodimer directly binding to 
‘simple’ GRE sites (sGRE), thereby activating the gene transcription of multiple anti-
inflammatory genes, such as tristetraproline (TTP) (Fig. 1.4) [87]. On the other hand, 
transrepression is generally mediated via a tethering mechanism whereby the monomeric GR 
interacts with other transcription factors, thereby inhibiting their gene targets (Fig. 1.4) [94].  
 
During inflammation a signalling cascade is triggered, leading to the activation of pro-
inflammatory transcription factors, NF-κB and AP-1. As mentioned earlier, the former is 
composed of the p50 and p65 (RelA) subunits, whereas the latter is composed of the c-Jun and 
c-Fos subunits. However, the GR can inhibit the transcriptional activity of both NF-κB and 
AP-1 by binding to a GRE and simultaneously interacting with the p65 and c-Jun subunits, 
respectively (also known as composite regulation or negative tethering) [87]. Ultimately, 
leading to the repression of their capacity to induce pro-inflammatory gene transcription [91]. 
However, positive tethering by the GR via C/EBP [95][96], NF-κB [96] and STAT3 [94] has 




In addition to the GR’s genomic signalling, this steroid receptor can signal in a non-genomic 
manner, which is poorly understood. What is known to researchers thus far is that the non-
genomic effects of the GR involves its ability to directly modulate signal transduction 
pathways, including MAPK, P13K, and Akt pathways (Fig. 1.4) [87][97]. However, the 
detailed mechanism and biological implications have not been fully elucidated. Current 
knowledge suggests that GCs have inhibitory effects on the pro-inflammatory MAPK 
signalling pathway by inducing the expression of proteins, such as MAPK phosphatase-1 
(MPK-1), which inhibits p38. Thus preventing the induction of multiple pro-inflammatory 
genes encoding cytokines, which ultimately resolves the inflammatory process and restores 
homeostasis [87][97]. Whether the ligand activated GR directly interacts with any components 
of these signal transduction pathways remain unknown and requires further investigation.  
 
1.3.2. The role of glucocorticoids in insulin resistance 
As mentioned earlier, exogenous GCs, such as Dex, are routinely prescribed in the management 
of inflammatory disorders. However, long-term GC treatment can reportedly exaggerate 
insulin resistance [98]. In fact, the ligand-activated GR is responsible for the increase in the 
production of the gluconeogenic enzymes, glucose-6-phosphatase (G6PC) and 
phosphoenolpyruvate carboxykinase (PEPCK) [99][100], which upregulates gluconeogenesis, 
thereby increasing hepatic glucose production. However, studies have also demonstrated that 
the synthetic GC, Dex can interfere with insulin signalling more directly by decreasing IRS-1 
[101] and AKT protein expression [102] in mouse adipocytes, and decreasing tyrosine 
phosphorylation of the IR and IRS-1 in muscle and liver cells [103]. Altogether these findings 
suggest a causative role for exogenous GCs in the development of insulin resistance in all the 
major insulin target tissues.  
1.4. The acute phase response: current status of knowledge 
 
‘The maintenance of physiologic homeostasis during the ups and downs of daily 
living is assured by a number of physiological mechanisms. From time to time, 
however, perturbing events occur which represent a threat to the integrity of the 
organism’ – Kushner, Irving (1982) [104] 
 
Under normal circumstances, homeostatic maintenance is ensured by a number of 




imposing a serious threat to an individuals’ health. These homeostatic deviations can include 
any process leading to tissue damage including infection, inflammation, and stress, among 
others [104][105]. As a result, the body responds to these disturbances in a predetermined and 
well-coordinated manner, with a local inflammatory response accompanied by a large number 
of systemic responses [105]. These complex physiological events are collectively referred to 
as the APR, which involves the cardiovascular and central nervous system (CNS) systems as 
well as major organs like the liver [35].  
 
The APR is the cornerstone of the innate immune response [106], which is the body’s first line 
of defence against inflammatory stimuli. The activation of the APR is proportional to the 
severity of this inflammatory stimulus [107]. The APR occurs at the very beginning of the 
inflammatory process, showing a rapid response that peaks within the first 48 hours, but can 
continue up to three to five days [108][109]. Two main responses are generated by the APR, 
namely the local and systemic responses (Fig. 1.7). The local response is manifested as acute 
inflammation, with a prominent aspect being the dilation and leakage of blood vessels, resulting 
in tissue edema (swelling) and apparent redness [32]. Whereas the systemic response 
constitutes an array of changes, which are primarily expressed as fever, increased release of 
several hormones, leucocytosis and the drastic rearrangement of plasma protein synthesis 
[110]. Below a brief overview of the APR and the sequence of events it entails, is given. 
 
During the early part of the APR, at the local site of insult, cells of the innate immune system 
are activated. These cells primarily include white blood cells (leukocytes), such as blood 
monocytes and tissue macrophages, which are responsible for initiating the APR cascade [32]. 
Additionally, other events such as mast cell degranulation and aggregation-induced platelet 
activation can lead to the release of chemotactic mediators, such as transforming growth factor-
beta (TGF-β) [32]. TGF-β stimulates the migration and infiltration of more macrophages and 
monocytes to the site of insult [32]. Together, activated monocytes and macrophages secrete a 
number of pro-inflammatory cytokines, known as ‘alarm’ cytokines, into the bloodstream, 
most notable of which are TNF-α and IL-1 [32][111]. These cytokines stimulate the synthesis 
and release of a range of secondary cytokines from local stromal cells (fibroblasts), including, 
IL-6. IL-6 promotes the systemic effects of the APR in diverse tissues, ranging from the liver 





Thus, as the APR is initiated, pro-inflammatory cytokines are first produced and act locally in 
an autocrine manner. Additionally, these cytokines can act in a paracrine manner, by recruiting 
adjacent stromal cells, including fibroblasts and endothelial cells [113]. As a result, a second 
wave of pro-inflammatory cytokines are produced and released in larger quantities, further 
potentiating the cytokine-induced response. Ultimately, these early events of the APR, ensure 
that all cells of the body have the potential to be involved in the initiation and propagation of 


















Figure 1.7. Schematic illustration of the different phases that occur during the acute phase response. In 
response to various disturbances (infection, inflammation, stress), the acute phase response (APR) is activated 
and generates two responses: the local (1) and systemic (2) responses. The local response is known as acute 
inflammation, which results in the release of pro-inflammatory cytokines from sites of insult. Whereas the 
systemic response results in a number of physiological processes which, most importantly, includes increased 
production of acute phase proteins in the liver (pointed out with a grey circle). Ultimately, the APR functions to 
restore homeostasis. Image was reproduced and adapted from Heinrich et al. 1990 [112], Paltrinieri, 2008 [108] 
and Anglin et al., 2010 [114]. Note: IL = interleukin, TNF = tumour necrosis factor, IFN = interferon, TGF = 
tumour growth factor, CRH = corticotropin-releasing hormone, ACTH = adrenocorticotropic hormone 
 
 
As the APR progresses, pro-inflammatory cytokines leave the local site of insult and enter the 
bloodstream, where they act distally in a paracrine manner [113]. Ultimately, these signalling 
molecules are responsible for the induction of a wide range of systemic inflammatory effects, 




primary characteristic features of the systemic APR, including (i) generation of fever, (ii) 
increase in the release of several hormones, (iii) leucocytosis, and (iv) changes in the 
concentration of serum APPs, will be discussed below. Other prominent features of the APR 
include, an increase in the activation of the complement cascade and blood coagulation system 
[109] as well as increased gluconeogenesis [115][116], which will not be discussed in detail. 
The latter metabolic process is promoted by both IL-1 and TNF-α, in order to fuel obligated 
glucose-consuming cells during the course of the APR [33]. 
 
The induction of fever is one of the earliest recognised features of the APR in the body. This 
change in thermoregulation results from exogenous pyrogens, such as lipopolysaccharides 
(LPS), which activate monocytes and macrophages to release endogenous pyrogens, such as 
pro-inflammatory cytokines: IL-1, TNF-α, IL-6, and interferon-gamma (IFN-γ) [114]. As a 
result, these pro-inflammatory cytokines act on the CNS and anterior hypothalamus to locally 
produce intermediate molecules, such as prostaglandin E2 (PGE2) [32][109]. PGE2 stimulates 
the sympathetic nerve to activate the hypothalamic centres responsible for raising the 
temperature set point, ultimately increasing body temperature [114]. Additionally, pro-
inflammatory cytokines can stimulate adipocytes to release the leptin hormone, which can 
directly stimulate the thermoregulatory centres in the hypothalamus [114]. Fever can be seen 
as a beneficial outcome of the APR, since it can increase the rate of enzyme reactions, thus 
speeding up the body's metabolism [116]. However, a body temperature too high, may cause 
serious damage, including organ damage and failure. 
 
In addition to causing fever, pro-inflammatory cytokines, including IL-1, TNF-α, and IL-6, act 
on the HPA-axis to generate CRH and ACTH, which subsequently induces the production and 
release of the endogenous GC, cortisol [104][112]. Cortisol is regarded to locally play an anti-
inflammatory role by inhibiting cytokine-gene expression. Thus, providing a negative feedback 
loop, which may be one of the most important mechanisms in the termination of the APR. 
However, at a systemic level, cortisol can be involved in determining leucocytosis [108]. 
Increased cortisol levels have been found to be responsible for the rapid increase in circulating 
leukocytes such as neutrophils, by causing mature neutrophils to detach from the endothelium 
and enter the blood [108]. Additionally, the synthesis rate of a number of other hormones are 





Another important hallmark of the APR is increased leucocytosis [110]. This process is broadly 
defined as an increase in the white blood cell (leukocyte) concentration [116]. Briefly, IL-1 
and TNF-α, released in the local inflammatory response, stimulate the bone marrow competent 
cells to produce cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-
CSF). This cytokine is necessary for the growth and development of neutrophils [108], which 
are released from bone marrow storage pools, to further contribute to more pro-inflammatory 
cytokines being released into circulation. 
 
An integral part of the APR is the modification of more than 200 APPs in the liver [117]. APPs 
are defined as plasma proteins whose expression levels significantly changes during 
inflammation. Changes in the levels of APPs largely reflect altered production by hepatocytes, 
the parenchymal cells of the liver [32]. The hepatocytes respond to cytokines produced during 
the APR via their cell-surface receptors, as discussed in section 1.1. Although IL-1 and TNF-α 
can promote the synthesis of certain APPs in the liver, IL-6 is the major inducer of most APPs, 
as shown in studies involving hepatocytes [112]. IL-6 induces the synthesis of the full spectrum 
of APPs [33], which can be grouped as either positive, if they increase by at least 25% during 
inflammatory states, or negative, if they decrease [104]. Other metabolic changes as a result of 
the APR, include muscle (protein) catabolism, which leads to increased transfer of amino acids 
from the muscle to the liver [115]. Additionally, the decrease in negative APPs, such as 
albumin and transferrin, are suggested to allow for unused amino acids to instead be used to 
produce positive APPs [117]. Furthermore, the decrease of the negative APP, corticosteroid 
binding globulin (CBG), results in an increase in the bioavailability of GCs [118]. GCs, like 
pro-inflammatory cytokines, have been found to upregulate APP expression (discussed in the 
next section). 
 
Taken together, the APR is regulated in a highly complex manner, and it is this complexity that 
accounts for the diverse changes that occur during this response. The entire cycle of the APR 
is designed to re-establish homeostasis [115] by counteracting the underlying challenge and 
contributing to the resolution and activation of the tissue repair process [106][113]. Hence, why 
the APR represents a phenomenon of enormous biological importance. However, as with all 
inflammation-associated phenomena, the APR is not uniformly beneficial. Although short 
term-activated APR is generally understood to serve a homeostatic function, the systemic 
response of the APR can be prolonged by persistent stimulation or disruption of normal control 




have several disease implications, including metabolic syndrome X, atherosclerosis, 
cardiovascular disease, and T2D [26]. Interestingly, T2D has been suggested to be an ‘acute 
phase disease’ [119]. The development of T2D as a result of chronic APR is of special interest 
to this study. Therefore, an overview of APPs with a specific focus on, PAI-1 and CRP, will 
be discussed in the following section. 
1.5. Introduction to the acute phase proteins (APPs) 
As discussed in the previous section, hepatic protein synthesis is reprioritized with APPs being 
either downregulated (referred to as ‘negative APPs’) or upregulated (referred to as ‘positive 
APPs’) during the APR. Negative APPs include important metal-binding proteins (transferrin) 
or carrier proteins (albumin, CBG). Whereas positive APPs (SAA, CRP, PAI-1) constitute an 
important aspect of the systemic defence mechanism and APR. Positive APPs are further 
classified as minor, moderate or major, depending on the magnitude of their response. 
Traditionally, major proteins, including SAA and CRP, represent those that increase 10- to 
1000-fold. These proteins are normally present in plasma in only trace amounts but increase 
dramatically within the first 24to 48 hours after a triggering event. Moderate proteins, including 
PAI-1, represent those that increase 2- to 10-fold, while minor proteins represent those with 
only a modest increase [35]. This section will introduce the APPs of interest in our study, 
namely PAI-1 and CRP, by giving a broad overview of each (Table 1.1). Both are especially 
of interest, as increased PAI-1 [120]–[123] and CRP [11][122][124][125] levels are a common 
feature encountered among individuals with T2D. In addition, many studies exist which 
support the role of PAI-1 [14]–[17] and CRP [18]–[20] in the development of insulin resistance. 















 Table 1.1. Overview of the positive acute phase proteins, CRP and PAI-1. 
 








Cyclic homo-pentameric; each subunit 
consists of 2 β-sheets and 1 long α-helix 
 
Single chain glycoprotein consisting of 3 







Levels during APR 
 
 
Major (increase 10 to 1000-fold) 
 





Innate immune system: activation of 
complement, promotes apoptosis, 
induces phagocytosis and NO release. 
 
 
Inhibits the activation of plasminogen 
(inhibits plasma fibrinolytic activity) 
leading to blood clotting 
*Images: courtesy of the European Bioinformatics Institute 
Table created by the author of this study. 
 
1.5.1. Plasminogen activator inhibitor-1 (PAI-1)  
Plasminogen activator inhibitor-1 (PAI-1), also named Serpin E1, belongs to a superfamily of 
serine-protease inhibitors (SERPINs). It is produced and released into circulation by primarily 
endothelial cells but also by a variety of other cell types, including hepatocytes and adipocytes 
[126]. The latter explains why PAI-1 is a well-known adipocytokine, as its levels are markedly 
increased along with the accumulation of fat [17]. This possibly explains the correlation 
between elevated PAI-1 levels and obesity, a risk factor for T2D.  
 
PAI-1 is produced and secreted as a single chain glycoprotein consisting of three β-sheets and 
eight to nine α-helices (Table 1.1). It is composed of 379 amino acids with a molecular weight 
of 45 kDa. The main physiological role of PAI-1 is as key negative regulator of fibrinolysis 
through its role as the principle inhibitor of both urokinase- (u-PA) and tissue-plasminogen 
activator (t-PA) [127]. Under normal conditions, u-PA and t-PA are able to convert the inactive 
enzyme plasminogen to its active form, plasmin. As a result, plasmin can degrade many blood 
plasma proteins, including fibrin clots (Fig. 1.8). The process of fibrin degradation is known 
as fibrinolysis. PAI-1 is therefore capable of inhibiting intravascular fibrinolysis, which leads 
to blood clotting or coagulation (haemostasis). Therefore, if an individual is injured, the action 




blood vessels [126]. In addition to PAI-1’s role in haemostasis (normal blood coagulation), it 

















Figure 1.8. A schematic of the role PAI-1 plays in the fibrinolytic system. During the process of fibrinolysis, 
u-PA and t-PA, convert the inactive enzyme, plasminogen, to its active form, plasmin. Subsequently, plasmin 
degrades fibrin clots (blood plasma proteins) into fibrin degradation products. PAI-1 is the main inhibitor of both 
t-PA and u-PA, therefore inhibiting fibrinolysis, leading to blood clotting (haemostasis). Image was created by 
the author of this study, using BioRender. Note: t-PA = tissue-plasminogen activator, u-PA = urokinase-
plasminogen activator, PAI-1 = plasminogen activator inhibitor-1 
 
 
Circulating PAI-1 levels vary more than any other component of the fibrinolytic system. This 
could be due to PAI-1 production being stimulated by a wide variety of signalling molecules, 
including IL-1, TNF-α, and TGF-β [128]. In addition, PAI-1 has been indicated as a major 
stress-induced gene [129]. As previously explained, activation of the HPA-axis by stressors, 
lead to an increase in the secretion of GCs, which are able to induce PAI-1 expression in vivo 
[55][130]. In healthy individuals, normal active PAI-1 plasma concentration ranges from 5 to 
20 ng/ml [127]. This concentration range is suggested to be sufficient to control fibrinolysis 
[127]. However, under pathological conditions, several tissues produce substantial amounts of 
PAI-1 in response to inflammatory cytokines. As a result, elevated PAI-1 concentrations have 
been observed consistently in blood from patients suffering with T2D. Cho et al. reported basal 
plasma PAI-1 antigen concentration to be significantly higher in diabetic subjects (36 ng/ml) 




diabetic individuals had higher baseline levels of PAI-1 (15 to 37.5 ng/ml) compared to the 
control group (9 to 27 ng/ml) [122]. In addition, obese individuals, many of whom exhibit 
insulin resistance, were found to exhibit a three-fold elevation of PAI-1 in blood, compared 
with values in healthy lean individuals [131]. 
1.5.2. C-Reactive Protein (CRP) 
In 1930, Tillet and Francis were the first to discover C-reactive protein (CRP), while 
investigating the sera of patients infected with pneumococcal pneumonia. They reported that 
CRP reacted with the capsular (C)-polysaccharide of Streptococcus pneumoniae. Today much 
more is known of this molecule since its initial discovery. CRP, also named Pentraxin 1 
(PTX1), is a member of the highly conserved pentraxin family of proteins which include other 
structurally related molecules such as SAA. It is primarily synthesized in liver hepatocytes but 
also moderately by endothelial cells, macrophages, lymphocytes, smooth muscle cells, and 
adipocytes [132]. The CRP molecule is produced as a cyclic/ring-shaped homo-pentameric 
protein, which involves five identical non-covalently bound 23 kDa subunits arranged 
symmetrically around a central pole (Table 1.1) [133]. Each subunit is composed of 206 amino 
acids folded into two anti-parallel β-sheets with a flattened jelly-roll topology. In addition, a 
long α-helix folds against one of the β-sheets and the remainder of the secondary structure 
constitutes of random coils [133]. 
 
The main physiological role of CRP lies with the innate immune system, where it acts as an 
early defence system against foreign infectious pathogens. CRP exhibits anti-inflammatory 
activities including: (i) activation of the classical complement pathway [134], through binding 
to the C1q molecules, resulting in pathogens being opsonized and as a result cleared [133], (ii) 
promoting apoptosis or phagocytosis of damaged cells and lastly (iii) displaying an anti-
inflammatory effect by inhibiting neutrophil (leukocytes) action [132]. CRP participates in the 
systemic response to inflammation, increasing up to 1000-fold. Its levels start to rise after six 
to eight hours and peaks by 48 hours, after an inflammatory event [135]. Serum concentration 
of CRP increases dramatically during acute and chronic inflammation, in response to a variety 
of inflammatory cytokines, including TNF-α and IL-6 and in some non-inflammatory 
conditions such as stress [136]. Hence why the measurement of CRP levels is widely used to 
monitor various inflammatory states [136]. Highly variable plasma levels, ranging from 0.8 to 
3 µg/ml, are found in healthy individuals [132]. Factors such as polymorphisms in the CRP 




10 µg/ml are considered to indicate metabolic inflammation, which could lead to the 
development of insulin resistance [137]. This is supported by Festa and colleagues, which 
found a significant relation of CRP to the development of T2D, with diabetic individuals having 
higher baseline levels of CRP (1.3 to 5.9 µg/ml) compared to the control group (0.8 to 3.4 
µg/ml) [122]. 
 
The regulation of each APP is uniquely complex, with pro-inflammatory cytokines, GCs, and 
growth factors being some of its main mediators. Both in vitro and in vivo studies have reported 
the regulation of PAI-1 and CRP expression to be closely influenced by the pro-inflammatory 
cytokines, TNF-α and IL-6, and hormones such as GCs [126]. Identifying the possible 
regulatory binding sites via which these signalling molecules act to trigger a change in PAI-1 
and CRP levels, could lead to a better understanding of the molecular mechanism behind their 
action. A large variety of signalling pathways and transcriptional machinery exist which impact 
PAI-1 and CRP expression, and will be discussed below.  
 
1.5.3. The regulation of PAI-1 by glucocorticoids or pro-inflammatory 
cytokines 
Experimental in vivo studies performed in animal models, which include baboons [138][139], 
rodents [140][141], and human subjects [142], have shown that IL-6 and TNF-α are major 
contributors to the increase of PAI-1 (Addendum A: Table A1). In addition, experimental in 
vitro studies performed in endothelial cells [140][143]–[148], epithelial cells [149], vascular 
smooth muscle cells [150], adipocytes [151]–[154], and hepatocytes [155][156] have shown 
TNF-α to significantly upregulate PAI-1 expression (Addendum A: Table A1). This suggests 
that the regulation of PAI-1 by TNF-α is not dependent on cell type. Samad et al. showed that 
neutralisation of TNF-α or deletion of both TNFRs (p55 and p75) resulted in significantly 
reduced PAI-1 expression in adipose tissue of mice [157]. The mechanism by which TNF-α 
induces PAI-1 expression in endothelial cells was delineated by Gruber et al.; they identified 
the transcription factor, nuclear receptor-77 (Nur77) to be part of the TNF-α-induced PAI-1 
expression [146]. In addition, they reported that Nur77 drives the PAI-1 transcription via direct 
binding to a NGFI-B responsive element (NBRE), and that the human PAI-1 proximal 
promotor contains this functional binding motif from -261 to -254 bp. In addition, Hou et al. 
proposed that NF-κB was involved in TNF-α-induced PAI-1 expression in bovine aortic 
endothelial cells [147]. However, according to de Martin et al. the PAI-1 promotor lacks a 




(PKC) as a central mediator of TNF-α-mediated increase of PAI-1 levels in adipocytes, since 
the inhibition of the PKC pathway almost completely inhibited this response [154]. However, 
the mechanism of action whereby TNF-α increases PAI-1 levels in liver tissue is yet to be 
elucidated.  
 
In addition to TNF-α, experimental in vitro studies performed in a human hepatoma cell line 
(HepG2), murine and human primary hepatocytes [159][160], and human primary adipocytes 
[161] have shown IL-6 to significantly upregulate PAI-1 (Addendum A: Table A1). Dong et 
al., found that in HepG2 cells, IL-6-mediated PAI-1 promotor activity was mediated by the 
transcription factor, C/EBP-δ positioned between -226 to -213 bp in the human PAI-1 
(SERPIN1) promoter [160]. In addition, JAK/STAT signalling was also reported to be 
responsible for the IL-6-induced PAI-1 expression in HepG2 cells. However, whether IL-6 
induces C/EBP-δ via STAT3 is not clear. It should be mentioned, that studies do exist which 
have found IL-6 to have little to no effect on PAI-1 expression in primary human and murine 
hepatocytes [140][139][156] and HepG2 cells [155] [159][162] 
 
Like the pro-inflammatory cytokines, GCs have also been shown to influence PAI-1 levels 
(Addendum A: Table A1). GC-induced PAI-1 expression appears to not be cell type specific 
as a number of in vitro studies, using Dex as a representative GC, have reported it to occur in 
adipocytes [163]–[165], hepatocytes [130][166], fibrosarcoma cells [167]–[169], monocytes 
[170], trophoblasts [171], and epithelial cells [149]. PAI-1 induction by Dex is mediated by the 
GC-activated GR and its association with the GRE in the minimal promotor of the human PAI-
1 gene [166]–[168][172]. This has been proven by studies showing that Dex-induced PAI-1 
expression is completely dependent upon the GR pathway, by using RU-486, an inhibitor of 
the GR [149][169]. Riccio et al., found that the human PAI-1 gene contains a GRE motif in its 
promotor region at position -299 [168]. While van Zonneveld et al. identified the location of 
one-half of a putative GRE within -305 and +75 of the human PAI-1 gene, via which Dex 
induced PAI-1 promotor activity [173]. 
 
Collectively, the mechanism underlying IL-6 or Dex-induced PAI-1 regulation have been well 
defined, with the following transcription factors, respectively, being implicated: C/EBP-δ and 
the GR. In addition, studies have also mapped the binding site of each transcription factor in 
the minimal promotor of the human PAI-1 gene. However, contrasting findings exist on 




shown to be a major inducer of PAI-1 expression in a range of cell types, exactly how it controls 
PAI-1 expression in liver cells remain enigmatic.  
 
1.5.4. The regulation of CRP by glucocorticoids or pro-inflammatory 
cytokines 
Current knowledge of the regulation of CRP synthesis is mainly gained from studies in human 
hepatoma cells. In addition, there has been increasing evidence of a well-established 
relationship between CRP and IL-6, which is intimately involved in the hepatic regulation of 
the APR [174]. Therefore, CRP is well-known to be primarily synthesized by IL-6-dependent 
hepatic biosynthesis [11]. This has further been proven by Wendling et al. [175] and Bataille 
et al. [176] whom both demonstrated in vivo, that production of CRP in humans was blocked 
by anti-IL-6 treatment. IL-6 has been shown to significantly upregulate CRP levels in 
experimental in vitro studies performed in human hepatoma cells [177]–[186], primary 
hepatocytes [174][186][187], mouse hepatoma cells [88], adipocytes [188], and coronary 
smooth muscle cells [189], as summarised in Addendum A: Table A2, suggesting that the 
regulation of CRP by IL-6 is not dependent on cell type. In Hep3B cells, a human hepatoma 
cell line, IL-6 have been reported to induce CRP expression by activating transcription factors 
STAT3 and C/EBP-β. C/EBP-β binds to positions -52 and -219 on the CRP promoter [182], 
with STAT3 binding between these two positions, to a site at -108 on the promoter [183]. 
STAT3 has also been shown to act on the CRP promoter in a mouse hepatic cell line, 
confirming its role in driving CRP expression [190].  
 
Whilst IL-6-induced CRP regulation has been extensively studied, few studies have 
investigated the effect of TNF-α on CRP regulation (Addendum A: Table A2) Some studies 
have observed TNF-α to have no detectable effect on CRP protein synthesis [174][180], while 
others have observed a significant increase in CRP protein release and mRNA expression in 
response to TNF-α [189], depending on the in vitro cell system used. The molecular mechanism 
regarding which signalling pathway and transcriptions factors are involved in TNF-α-induced 
CRP regulation, remains to be elucidated. Similarly, although a few studies have demonstrated 
Dex-induced CRP expression as summarised in Addendum A: Table A2 [88][180], the 
molecular mechanism of action thereof is unclear. It is unknown whether functional GREs are 
present in the CRP promoter, which would facilitate direct DNA binding of the ligand-activated 




factors such as STAT3 [94], C/EBP [95][96], and NF-κB [87][96], which could possibly be 
the mechanism in which GCs increase CRP expression.  
 
Taken together, the mode of action governing IL-6-induced CRP expression has been well 
established, with studies finding C/EBP-β, STAT3, and NF-κB (p50/p65) to be involved. In 
addition, the binding sites for each transcription factor within the proximal promotor of the 
human CRP gene have also been identified. We are left with two unanswered questions; namely 
i) what is the underlying mechanism of Dex-induced CRP expression, especially in liver cells? 
and ii) does TNF-α have an effect on CRP expression in liver cells and if so, which 
transcriptional regulators are involved? 
1.6. Co-regulation of APPs by GCs and pro-inflammatory 
cytokines 
Despite the traditional knowledge that many pro-inflammatory cytokine induced-genes are 
profoundly repressed by GCs, studies have shown no repression, partial repression or even 
enhancement by GCs of the expression of such genes [191]. In recent years it has been 
suggested that GCs selectively regulate gene expression. For example, it has now become clear 
that GC effects on innate immunity are not universally anti-inflammatory [192]. The APR, 
where the synthesis of several APPs is increased, is the cornerstone of the innate immune 
response (discussed in section 1.4). Interestingly, a small number of APPs have been identified 
to be co-regulated by the combination of GCs and pro-inflammatory cytokines. This 
demonstrates how these seemingly opposing signalling molecules can work cooperatively with 
one another to upregulate the expression of genes involved in the APR. This concept of APP 
co-regulation by GCs and pro-inflammatory cytokines, was first reported in the late 1980s 
when Baumann et al. reported the stimulating effect of GCs on IL-6-induced APP mRNA 
expression of haptoglobin and α1-antichymotrypsin (α1-ACT) [193]. Since this initial 
discovery, a considerable body of knowledge has accumulated over the years concerning the 
possible crosstalk between GCs and pro-inflammatory cytokines to induce APP expression, 
which will be discussed in the following paragraphs (Addendum A: Table A3).  
 
A study by Liu et al. reported that Dex (400 ng/ml) and IL-6 (10 ng/ml) induced the protein 
synthesis of the murine APP, SIP24/24p3, in mouse embryonic fibroblasts (Balb/c 3T3) and 




compound alone. They suggested that the signalling molecules exerted their effects through 
different pathways independently leading to the possible synergism observed. Furthermore, an 
additive effect on SIP24/24p3 protein synthesis was observed when Dex was combined with 
TNF-α (1000 ng/ml) in the BNL cells. This additive effect was speculated to be due to the 
respective pathways of the signalling molecules overlapping. Another study by Diitrich et al. 
reported that Dex (100 nM) further enhanced IL-6 (20 ng/ml)-induced γ-fibrinogen (FGG) and 
α1-ACT mRNA expression, in both primary murine hepatocytes and human hepatoma 
(HepG2) cells [195]. This group demonstrated how Dex interferes with IL-6-induced 
expression of the feedback inhibitor, SOCS3, thereby leading to enhanced FGG and α1-ACT 
expression. They suggested that the GC exerted a dual activity by further inducing IL-6-
induced APPs expression (pro-inflammatory) and by dampening IL-6-induced SOCS3 
expression (anti-inflammatory). Furthermore, a study by Lannan et al. reported that the mRNA 
and protein expression of SerpinA3 (also known as α-AACT) were significantly upregulated 
in lung (A549) cells by means of co-administration with TNF-α (1000 ng/ml) and either Dex 
(10 nM) or cortisol (100 nM). These effects were beyond that expected from treatment of either 
compound alone [27]. The authors also proposed that the synergistic co-regulation of SerpinA3 
expression was due to the GC- and TNF-α signalling pathways interacting in novel way(s). The 
study proceeded with an in vivo experiment in lung and liver tissue of adrenalectomized mice, 
where they observed an additive increase of SerpinA3 mRNA expression in response to co-
treatment with Dex (1 mg/kg) and TNF-α (60 µg/kg). In addition, chromatin 
immunoprecipitation (ChIP) assays indicated that GR binding at the SerpinA3 transcription 
starting site was more robust when cells were co-treated with Dex and TNF-α.   
 
The possible co-regulation by GCs and pro-inflammatory cytokines of the APPs, SAA, PAI-1, 
and CRP, have been investigated by a number of research groups [27][88][149]. 
[180][181][195]–[201]. Although, it seems that most studies have focused on the co-regulation 
of SAA by GCs and pro-inflammatory cytokines, based on the amount of literature available 
on this subject.  
 
SAA expression by various pro-inflammatory cytokines in the presence of a GC is enhanced 
in vitro as well as in vivo, which appears not to be dependent on cell type or concentrations of 
either pro-inflammatory cytokine or GC. For example, Castell et al. reported that Dex (100 
nM) and IL-6 (10 ng/ml) synergistically induced SAA protein synthesis and secretion, in 




SAA protein synthesis, and vice versa. In addition, a study by Ganapathi et al. reported that 
induction of SAA protein synthesis by the combination of IL-1α (40 ng/ml) plus IL-6 (10 
ng/ml) was potentiated by Dex (1 µM), in Hep3B cells [180]. Another group, Meek et al. 
reported that SAA1, SAA2, and SAA4 mRNA expression was effectively induced by IL-1β or 
IL-6 (10 ng/ml), but only in the presence of Dex (1 µM), in human adult aortic smooth muscle 
cells [197]. In addition, Ito and colleagues, reported that only the combination of Dex (1 mg/kg) 
plus IL-6 (2 µg/mouse) increased SAA protein production in mice, compared to each treatment 
on its own. Interestingly, the SAA protein production was markedly elevated when the 
combination treatment with Dex and IL-6 was followed by an additional treatment with IL-1β 
(2 µg/mouse) [198]. Furthermore, a study by Thorn et al. [199] reported that Dex (50 nM) 
enhanced TNF-α or IL-6 (10 ng/ml) driven induction of the SAA1 promotor, in HepG2 cells. 
A similar study by Lannan et al. [27], reported that Dex (10 nM) cooperatively upregulated 
SAA1/2 mRNA expression in concert with TNF-α (1000 ng/ml), in A549 lung cells. Dittrich 
et al. [195] have also reported that Dex (4 mg/kg) increased IL-6 (100 µg/kg)-induced hepatic 
SAA mRNA expression and serum protein of treated mice. The authors showed that this effect 
elicited by Dex was dependent on SOCS3 expression and the SOCS3 recruiting motif within 
the gp130 receptor. Visser et al. reported that the combination of Dex (10 nM) plus IL-6 (10 
ng/ml) significantly increased SAA mRNA expression, compared to IL-6 but not Dex alone, 
in BWTG3 cells, a mouse hepatocyte cell line [88]. Although a significant increase in both 
intra- and extracellular SAA protein levels were seen after co-treatment with both agents, it 
was not more than what was observed with either agent alone. The most recent study by Su & 
Weindl, reported that Dex (100 nM) further enhanced TNF-α (10 ng/ml)-induced SAA1/2 
mRNA expression and secretion in keratinocytes [200]. In addition, co-immunoprecipitation 
(co-IP) assays indicated that the transcription factors, GR, STAT3, and NF-κB, mediated this 
TNF-α and Dex-induced SAA1 mRNA expression.  
 
Whilst cooperative regulation of SAA by GCs and various pro-inflammatory cytokines have 
been extensively studied, fewer have studied this phenomenon in regard to PAI-1 and CRP. In 
addition, the array of pro-inflammatory cytokines used is limited with most either reporting on 
TNF-α or IL-6. To the best of our knowledge, only two research groups have investigated the 
possible co-regulation of PAI-1, with both studies focussing on co-regulation by Dex and 
TNF-α [149][201]. Both studies reported an augmented increase in PAI-1 expression in the 
presence of Dex and TNF-α compared to individual treatments, albeit not in liver cells. 




48 hours had an additive effect on PAI-1 mRNA expression in vascular endothelial cells 
(HUVECs) [201]. Similarly, Kimura et al. showed that Dex (100 nM) enhanced TNF-α 
(10 ng/ml)-stimulated PAI-1 mRNA expression but not protein production in human proximal 
renal tubular cells (HPTECs), by an additonal 4.8-fold, after 24 hours [149]. Unfortunately it 
is still unknown how PAI-1 expression is affected by GCs and other pro-inflammatory 
cytokines, such as IL-6 and IL-1β. In addition, as PAI-1 is primarily produced in the liver- and 
adipose cells [55], it remains undetermined whether cooperative regulation by GCs and pro-
inflammatory cytokines occur in these cell types. This is especially important and requires to 
be investigated considering that PAI-1 levels are chronically high in a diabetic state [121][122] 
and has also been implicated in insulin resistance [131]. 
 
To the best of our knowledge, only three research groups have investigated the possible co-
regulation of CRP expression by GCs and pro-inflammatory cytokines. Like PAI-1, the 
primary source of CRP, which is also elevated in a diabetic state [124][202], is the liver. 
Presumably this is the reason why the few studies investigating co-regulation of CRP by GCs 
and a pro-inflammatory cytokine were all conducted in liver cell models. Unfortunately, only 
IL-6 was used as a representative pro-inflammatory cytokine in all three studies [88][181] 
[196]. Similar to the above-mentioned studies whereby SAA and PAI-1 expression are 
co-regulated by GCs and pro-inflammatory cytokines, IL-6-induced CRP expression was either 
augmented [181] or remained unchanged [88][196] in the presence of Dex. Specifically, Castell 
et al. discovered that human primary hepatocytes co-stimulated with Dex (100 nM) plus IL-6 
(10 ng/ml) for 20 hours, strongly induced extracellular CRP protein synthesis (23-fold), more 
than what was observed with Dex (1.7-fold) but not with IL-6 (22-fold) alone [196]. The lack 
of an amplified response observed by the authors in response to co-treatment with Dex and 
IL-6 when compared to IL-6 treatment alone, could possibly be attributed to maximal CRP 
protein synthesis being reached with 10 ng/ml IL-6 in primary hepatocytes. It would be 
interesting to examine how Dex affects IL6-mediated increase in CRP expression at a lower 
concentration of IL-6. Nonetheless, Depraetere et al. reported that HepG2 cells co-stimulated 
for 72 hours with IL-6 (10 ng/ml) and a higher Dex concentration (i.e., 1 µM) than used by 
Castell and colleagues, cooperatively increased (14-fold) the magnitude of extracellular CRP 
protein release significantly above what was seen with Dex (1.5-fold)- and IL-6 (9-fold) alone 
[181]. Whilst this does suggest that an augmented increase in CRP expression might be 
dependent on the concentration of test compounds used, the length of exposure to both 




treat significantly longer with the test compounds (20- versus 72 hours). Highlighting that 
cooperativity between GCs and pro-inflammatory cytokines might be dependent on both dose 
as well as duration of exposure. For example, Visser et al. found that extracellular CRP protein 
levels remained unchanged when BWTG3 cells, were co-stimulated with Dex (10 nM) for 24 
hours plus IL-6 (10 ng/ml) for 3 hours, compared to either agent alone [88]. Interestingly, the 
authors did observe Dex to significantly lower IL-6-induced intracellular CRP protein levels. 
While, both agents alone or combined did not significantly modulate each other effects at 
mRNA level.  
 
Taken together, it is clear, that in regard to APPs, GCs favour an increase in APP expression, 
sometimes under the right conditions enhancing cytokine-induced APP expression, as 
mentioned above for a number of APPs including ones associated with insulin resistance such 
as SAA, CRP, and PAI-1. Whether this cooperativity between GCs and pro-inflammatory 
cytokines is unique to APP regulation is unclear. Traditional dogma suggests that GCs and pro-
inflammatory cytokines primarily antagonise each other’s activity [23]. However, as discussed 
in section 1.3, GCs are not simply anti-inflammatory, since in recent years it has become 
abundantly clear that when GCs act in a pro-inflammatory manner by cooperatively enhancing 
cytokine-mediated APP expression, this reinforces the innate immune system and APR [203]. 
On the other hand, it is important to remember that neither hormonal nor cytokine networks 
function in isolation [34]. Thus, many more future contributions to our understanding of APP 
regulation by GCs and pro-inflammatory cytokines will be made by examining the complicated 
crosstalk between these signalling molecules.  
1.7. Concluding remarks 
Although it is well established that insulin resistance is central to the pathogenesis of T2D, how 
this abnormality arises at a molecular level remains to be elucidated. Inflammation, stress, and 
APPs, such as PAI-1 and CRP, have all been individually linked to the development of insulin 
resistance [14]–[20]. 
This study forms part of a larger project within the Verhoog research group. Ultimately, we 
wish to provide insight into whether stress (represented by GCs) and inflammation (represented 
by pro-inflammatory cytokines) affect hepatic insulin signalling via the production of APPs. 
We thus ask the question of whether GC- and pro-inflammatory cytokine-induced insulin 




question, our research group have previously shown the APPs, PAI-1 and CRP, disrupt hepatic 
insulin signalling at key nodes of the insulin signalling pathway (unpublished data) [25].  
 
In the current study these earlier observations are extended, by investigating the possible co-
regulation of the APPs, PAI-1, and CRP, by GCs and pro-inflammatory cytokines. Presently 
the extent of cooperative regulation by GCs and pro-inflammatory cytokines on PAI-1 and 
CRP expression remain largely unexplored in the literature. The ‘why’ behind the occurrence 
of co-regulation has become clear, but a knowledge gap still remains regarding the ‘how’ i.e., 
the molecular mechanism of action. No studies have yet been conducted, to the best of our 
knowledge, examining i) the possible cooperative regulation of PAI-1 expression by GCs and 
pro-inflammatory cytokines in liver cells, ii) the possible cooperative regulation of PAI-1 
expression by Dex and IL-6, iii) the possible cooperative regulation of CRP expression by Dex 
and TNF-α or importantly iv) the possible cooperative regulation of PAI-1 and CRP by GCs 
and pro-inflammatory cytokines in the same model system in addition to comparing different 
pro-inflammatory cytokines. Ultimately, the results obtained could provide further proof that 
GCs and pro-inflammatory cytokines crosstalk with one another to increase PAI-1 and CRP 
expression, as well as contribute to the existing literature available on this subject of 
cooperative regulation.  
1.8. Research question and Hypothesis 
Do GCs (representing stress) and pro-inflammatory cytokines (representing inflammation) co-
regulate APPs (PAI-1 and CRP) in hepatoma cells? Based on previous literature I hypothesise 
that in the liver, GCs and pro-inflammatory cytokines will cooperatively regulate PAI-1 and 
CRP expression, at both the mRNA and protein level. 
1.9. Research aims  
 
Aim 1: Determine whether the glucocorticoid, Dex, and/or pro-inflammatory cytokines, 
TNF-α and IL-6, affect PAI-1 and CRP mRNA expression in hepatoma cells? 
 
Aim 2: Determine if glucocorticoids (Dex, corticosterone, and cortisol) and/or pro-
inflammatory cytokines, TNF-α and IL-6, affect PAI-1 and CRP intracellular protein 





Aim 3: Investigate whether the molecular mechanism underlying the regulation of PAI-1 and 
CRP expression by the glucocorticoid, Dex, and/or pro-inflammatory cytokines, TNF-α and 


























2.1. Test compounds  
The test compounds used in this study, included a potent synthetic GRα agonist, 
Dexamethasone (Dex) [(11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-
3,20-dione], and the endogenous GCs, corticosterone (Cort) [11β,21-Dihydroxy-4-pregnene-
3,20-dione] and cortisol (F) [(11β)-17 α,21-Trihydroxypregn-4-ene-3,20-dione], which were 
purchased from Sigma-Aldrich. In addition, two pro-inflammatory cytokines were included in 
this study, namely tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which were 
both obtained from Thermo-Fisher. All glucocorticoids (GCs) were dissolved in 100% absolute 
ethanol (EtOH) (stock solution: 10-2 M), since this was recommended as suitable solvent for 
the hydrophobic GCs. Subsequently, serial dilution (10-3 M to 10-6 M) were prepared from the 
stock solution, and stored at -20 °C. For all experiments, GCs were diluted 1000 times in 
unsupplemented low glucose (1000 mg/L)-Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma-Aldrich). Final GC concentrations of 10 nM (10-8 M), 100 nM (10-7 M) and 1 µM 
(10-6 M) were used for treatment of cells. Lyophilised recombinant human TNF-α and IL-6 
powder were reconstituted in autoclaved distilled water and 100 mM acetic acid, respectively, 
to a stock concentration of 1 mg/ml. A working solution of 20 µg/ml each was prepared using 
low glucose-DMEM supplemented with 10% (v/v) FBS (Thermo-Fisher), and stored at -20 °C. 
For all experiments, TNF-α and IL-6 were diluted 1000 times to a final concentration of 20 
ng/ml using unsupplemented low glucose-DMEM. 
2.2. Mammalian cell culture   
 
2.2.1 Cell Growth and Maintenance 
Murine hepatoma (BWGT3) cells were obtained from the University of Gent, Belgium, and 
human hepatoma (HepG2) cells were purchased from Cellonex (refer to Table 2.1 & Fig. 2.1 
for more information). Both cell lines were cultured and maintained in 75 cm2 culture flasks 
(Bio-Smart Scientific) containing low glucose (1000 mg/L)-DMEM containing 1 mM sodium 
pyruvate and 17.9 mM sodium bicarbonate purchased from Sigma-Aldrich and supplemented 
with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin (Pen/Strep) (10 000 U/ml penicillin 
and 10 mg/mL streptomycin) (Sigma-Aldrich), hereafter referred to as complete DMEM. Cells 
were kept in an incubator set at 37 ⁰C in an atmosphere of 97% relative humidity and 5% CO2. 
Both cell cultures were passaged twice weekly with 1x trypsin-EDTA solution (Sigma-




cell lines employed were routinely monitored for Mycoplasma contamination using Hoechst 
staining, to ensure that only Mycoplasma-negative cells were used in experiments (Addendum 
B: Fig. B1).  
 
For mRNA experiments, BWGT3 cells were seeded in 6-well plates (Bio-Smart Scientific) at 
a density of 5 x 105 cells per well, as a better total RNA yield was observed compared to seeding 
the cells in 12-well plates. Whereas, for protein experiments BWGT3 and HepG2 cells were 
seeded in 12-well plates (Bio-Smart Scientific) at a density of 2 x 105 cells per well. For 
transfection experiments, BWTG3 cells were seeded in 10 cm2 dishes at a density of 5 x 105 
cells per dish and re-seeded in 96-well plates (Bio-Smart Scientific) at a density of 45 000 cells 
per well. 
 
 Table 2.1. Information on immortalized cell lines used in this study. 
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Figure 2.1. Morphology of immortalised cell lines used in this study. Since the liver is the main source of acute 
phase protein (APP) production, such as C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1), 
mouse (BWTG3) (left) and human (HepG2) (right) hepatoma cell lines were used as in vitro models. Images are 




2.2.2 Treatment conditions 
For time course experiments, to establish the time point at which the test compounds mentioned 
in section 2.1 maximally induces PAI-1 and CRP protein expression, BWGT3 and HepG2 cells 
were seeded in 12-well plates (Bio-Smart Scientific) at a density of 2 x 105 (BWTG3) and 
4 x 105 (HepG2) cells per well. Once the cells reached 70-80% confluency, complete medium 
was replaced with unsupplemented low glucose-DMEM for 24 hours. Subsequently, cells were 
treated with vehicle controls (0.1% EtOH or complete DMEM) and the test compounds. The 
final concentration of the test compounds Dex, Cort, and F were 10-8 M, 10-7 M, and 10-6 M, 
whilst for TNF-α and IL-6 it was 20 ng/ml. Cells were exposed to the test compounds for 24, 
48 and 72 hours. 
 
For PAI-1 and CRP and protein analysis, BWGT3 and HepG2 cells treated with increasing 
concentrations (10-8 M, 10-7 M, and 10-6 M) of Dex or Cort (BWTG3) or F (HepG2) with or 
without 20 ng/ml TNF-α or IL-6 for 48 hours. Both PAI-1 and CRP mRNA analysis and 
promoter-reporter experiments, cells were incubated for 24 hours with increasing 
concentrations of Dex (10-8 M, 10-7 M, 10-6 M) and/or TNF-α or IL-6 (20 ng/ml), for 24 hours.  
To allow for the same vehicle control (0.1% EtOH and 0.1% complete medium combined) to 
be used across all treatments including single treatments, it was ensured that EtOH was added 
to the wells containing cytokines to a final concentration of 0.1% and complete DMEM was 
added to the wells containing GCs to a final concentration of 0.1%.  
2.3. Total RNA Extraction  
For mRNA analysis, BWTG3 cells were treated as described in section 2.2.2. Total RNA from 
cultured cells was extracted using Tri-reagent as per the manufacturer’s protocol (Sigma-
Aldrich). Briefly, treatment medium was removed from each well and the cells lysed by the 
addition of 400 µl Tri-reagent per well, and placed at -20 °C overnight to promote cell lysis. 
The cell lysates were transferred into 1.5 ml microcentrifuge tubes after thawing, followed by 
the addition of 80 µl chloroform to extract total RNA (ribosomal, messenger, and transfer 
RNA). The cells were vortexed for 1 minute, followed by centrifugation at 14000 rpm for 20 
minutes at 4 °C to separate into three layers. Since RNA is confined in the clear aqueous phase, 
this phase was collected (100 µl) and transferred into a clean 1.5 ml microcentrifuge tube, 
followed by the addition of 100 µl isopropanol. Next, samples were vortexed for 1 minute and 




time (preferably more than two weeks) to enhance RNA precipitation. To pellet the RNA, 
samples were centrifuged at 14 000 rpm for 30 minutes at 4 °C. The supernatant was discarded, 
and the pellet was washed with 500 µl 70% DEPC-treated EtOH (EtOH was diluted in diethyl 
pyrocarbonate (DEPC) treated water) and vortexed for 1 minute followed by centrifugation at 
14000 rpm for 5 minutes at 4 °C. This wash step was repeated three times to ensure the removal 
of any contaminants. With the final wash step, the supernatant was removed, and the pellet air-
dried for 20 minutes to remove remaining traces of EtOH. The pellet was dissolved in 20 µl 
DEPC-treated water and incubated at 55 °C for 5 minutes on a heating block. RNA samples 
were stored at -80 °C. The RNA concentration and purity of the samples were assessed using 
a NanoDrop spectrophotometer (Central analytical facility (CAF), Stellenbosch). An A260/280 
ratio close to 2.0 was expected, since this indicates pure RNA. To confirm RNA integrity, the 
presence of intact 18S and 28S ribosomal RNA was determined. Total RNA (1 µg) was loaded 
on a 1% (w/v) agarose gel, containing biocide [204], which degrades any traces of RNases, and 
stained with Nancy-520 (Sigma-Aldrich). Subsequently after gel electrophoresis at 60V for 1 
hour, the agarose gel was immediately visualized under ultraviolet light using the Gel Doc™ 
XR+ Imaging System (Bio-Rad) with Image Lab™ Software (Addendum C1: Fig. C1).  
2.4. Reverse-Transcription (cDNA synthesis) 
Total RNA was reverse transcribed to complementary DNA (cDNA) using the ImProm-II 
Reverse Transcription System cDNA synthesis kit (Promega) as per manufacturer’s 
instructions. RNA is very easily degraded by RNases; therefore, it is more convenient to use 
the more stable cDNA for analysis of mRNA. Briefly, 2 µg RNA was added into a 0.5 ml thin-
walled PCR tube followed by the addition of 50 µg/ml oligoDT primers, which targets the 3’ 
end poly(A) tail of mRNA. Nuclease-free water was subsequently added to a final volume of 
5 µl. The reaction mixture was incubated at 70 °C for 5 minutes and immediately chilled on 
ice for 10 minutes. Thereafter, 15 µl of the second reaction mixture (master mix) was added to 
each sample. A master mix for a single sample, contains the following reagents: 4 µl ImProm-
II 5X reaction buffer, 0.9 µl MgCl2 (co-factor), 1 µl dNTP mix (extends the cDNA strand), 20 
U (0.5 µl) Recombinant RNasin® ribonuclease inhibitor and 1 µl ImProm-II reverse 
transcriptase (transcribes cDNA from mRNA), with the volume adjusted to 15 µl with 
nuclease-free water. Next, samples were incubated at 25 °C for 5 minutes to allow annealing 
of the oligoDT primers, followed by an incubation step at 45 °C for 60 minutes allowing the 




minutes to inactivate the reverse transcriptase. Finally, the cDNA samples were chilled on ice 
for 5 minutes and stored at -20 °C until analysis. 
2.5. Semi-quantitative real-time polymerase chain reaction (q) 
RT-PCR 
All qPCR reactions were carried out on a LightCycler 96 Real-Time PCR System (Roche 
Applied Science). For each cDNA sample, a master mix was prepared, containing the following 
reagents: 6.25 µl SYBR green (Kapa SYBR Fast qPCR master mix, containing the DNA 
polymerase enzyme and necessary reagents for the PCR reaction, Roche Applied Science), 0.5 
µl forward primer, 0.5 µl reverse primer (both 10 µM final concentration), and 1.75 µl DEPC-
treated water to a final volume of 9 µl. SYBR Green is a fluorescent dye that binds to the minor 
groove of double stranded DNA (dsDNA), emitting fluorescence when bound. This allows the 
levels of amplified product to be monitored. LightCycler multiwell plates were used (Celtic 
Molecular Diagnostics) for the qPCR reaction in which 9 µl of the master mix was added to 
each well and 1 µl of the cDNA sample (template) or nuclease-free H2O (non-template control). 
Each reaction was performed in duplicate. Predeveloped validated mouse PAI-1, CRP, and 18S 
primer sets were purchased from Integrated DNA Technologies (Whitehead Scientific). The 
details regarding these specific primer sets are shown in Table 2.2. The efficiency of each 
primer set was calculated by making a dilution curve from cDNA (untreated sample) 
(Addendum C2: Fig. C2). The efficiency is a measure of how much PCR product is amplified 
per cycle, 1 indicating no product and 2 indicating that every PCR product is amplified. 
LightCycler® 96 software (Roche Applied Science) was used to set the PCR thermal cycling 
conditions, which were as follows: 95 ⁰C for 3 seconds (pre-incubation or activation), followed 
by 45 cycles of amplification: 95 ⁰C for 3 seconds (denaturation), 55 ⁰C (mCRP) or 60 ⁰C 
(mPAI-1 & m18S) for 10 seconds (annealing), and 72 ⁰C for 3 seconds (elongation or 
extension). This was followed with a melting step at 95 °C for 10 seconds. Since the expression 
of 18S was not influenced by the treatment conditions (low variations in Ct values between 
different samples), it was used as an internal control against which samples were normalised. 
The melting curve analysis was performed to confirm the amplification of a single product in 
each sample (Addendum C3: Fig. C3). Relative quantification of the target genes was 
performed by using comparative 2-∆∆𝐶𝑇 method, with the vehicles arbitrarily set to 1. This 
was then normalized relative to the respective reference gene transcript levels. PCR products 




correct amplicon size of the amplified PAI-1, CRP, and 18S products and visualized under 
ultraviolet light using the Gel Doc™ XR+ Imaging System (Bio-Rad) with Image Lab™ 
Software. For determination of the correct amplicon size, samples were compared to the 100 
bp DNA ladder RTU (Celtic Molecular Diagnostic). 
 


























2.46 Reverse TGGTCCTCTCCCAGGTTACA 
PAI-1  





2.51 Reverse ACACTTTACTCCGAAGTCGGT 
18S  





2.33 Reverse CCATCCAATCGGTAGTAGCG 
2.5.1. Primer design  
The National Centre for Biotechnology Information (NCBI) provides a primer design tool, 
Primer-BLAST. Nucleotide mRNA sequences of PAI-1, CRP and 18S were found in the NCBI 
database. All the primers were designed to have the following: 
 
(i) GC-content less than 60%: high GC content will reduce PCR efficiency; GC 
bonds are stronger (require more energy to break) and less specific, because of the 
triple H-bond. Therefore, GC-rich regions are more prone to mispairing with other 
GC-rich regions.  
(ii) Yielding a product of less than 200 bp: this maximise the chance of amplifying 
with high PCR efficiency; the bigger the amplicon the faster the fluorescence level 
will be reached in earlier Ct cycles, thus masking the actual effect of the gene.  
(iii) Exon junction (intron spanning): exclusively targets cDNA and not genomic DNA 
which contains introns between exon-exon junctions.   
2.5.2. Primer preparation  
Primers were delivered as lyophilized powders in vials, and these were picofuged for a few 
seconds to collect the primers at the bottom of the vial. The primers were resuspended in TE 




solution (10 µM) of both forward and reverse primers were prepared. Primers were stored at -
20 °C. 
2.6. Western Blot Analysis 
2.6.1. Preparation of protein lysates 
For western blot analysis, BWTG3 and HepG2 cells were treated as described in section 2.2.2. 
Whole cell lysates were prepared: briefly, cells were washed with 1x PBS and lysed with 150 µl 
passive lysis buffer containing freshy added protease inhibitor tablet (Roche Applied Science) 
as well as phenylmethylsulphonyl fluoride (PMSF). The combination of protease inhibitors, 
which inhibits serine and cysteine proteases, are required for complete protection of proteins 
in cell lysates. In addition, cell lysis was promoted with an overnight freeze-thaw cycle and 
thereafter detached from plates using cell scrapers and transferred to clean microcentrifuge 
tubes to which 5x SDS-reducing buffer (Addendum D) was added.  Proteins in the lysates 
were denatured by boiling for 15 minutes at 95 °C , and stored at -20 °C until further analysis.  
2.6.2. SDS-PAGE and Western Blotting 
For gel electrophoresis, protein lysates were separated on a 10% polyacrylamide gel at a 
constant voltage of 75 V for 15 minutes, and 150 V for 1 hour, in 1x running buffer 
(Addendum D). A colour prestained protein standard broad range (245-25 kDa) protein ladder 
was used as a marker for protein size (Inqaba Biotechnology). Following electrophoresis, the 
proteins were transferred onto a Hybond™ ECL™ nitrocellulose membrane (AEC Amersham) 
for 2 hours at a constant current of 0.18 A in cold 1x transfer buffer (Addendum D). The 
membranes were subsequently blocked in 5% (w/v) fat-free milk powder prepared in 1x Tris 
buffered saline (TBS) containing Tween-20 (1x TBS-T) (Addendum D) for 90 minutes at 
room temperature. Membranes were subsequently rinsed with 1x TBS-T and incubated 
overnight (18-20 hours) at 4 ⁰C while agitating, in the appropriate antibody diluted in TBS-T 
(Table 2.3). Hsp90 was used as loading control to normalise for equal loading of protein across 
all wells, which was found not to be influenced by any of the test compounds (Addendum 
E1&E2). Membranes were washed with TBS-T for 10 minutes, followed by two 5-minute 
washes. Following the washing steps, the membranes were incubated for 90 minutes at room 
temperature with the appropriate secondary antibody diluted in 5% (w/v) fat-free milk powder 
in TBS-T (Table 2.3). Membranes were subsequently washed as previously described. Proteins 




chemiluminescence and visualized using the MyECL or iBright Imager (Thermo-Fisher). 
ImageJ software was used to quantify all western blot images.  
 





















































1Cell Signalling Company (CST)    
2Abcam     
3Santa Cruz Biotechnology     
4Sigma-Aldrich  
 
2.7. Plasmid DNA preparation  
2.7.1. Engineering of plasmid constructs  
The pGL4.10/PAI-1 (PAI-1-Luc) promoter-reporter plasmid was kindly provided by Dr Y. 
Kawarada (Nagoya City University, Japan). This plasmid was generated by ligating the human 
PAI-1 promoter region (−800/+71) with the luciferase reporter vector, pGL4.10, as described 
in Kawarada et al., 2016 [205]. The wild-type (WT) CRP reporter-promoter construct, 
5’∆10CAT3M or pCRP-luc (WT CRP -300), was kindly provided by Dr A. Agrawal (East 
Tennessee University, USA). WT CRP -300 was generated by ligating the human promoter 
region (-300/-1) with the luciferase reporter vector, pGL2 basic, as described in Kleemann et 
al., 2003 [206]. See Addendum F2, Fig. F1 for a schematic representation of the luciferase 




2.7.2. Transformation of bacterial cells  
E. coli DH5α competent cells were transformed by heat shock with the plasmids, PAI-1-Luc 
& WT CRP -300, respectively. Briefly, plasmid DNA (5 µl) was added to competent cells 
(100 µl) and the resulting mixture was incubated on ice for 30 minutes. This was followed by 
heat shock at 42 ⁰C for 30 seconds, followed by cooling the plasmid DNA-bacterial mix on ice 
for 5 minutes. Subsequently, room temperature Super Optimal Broth with Catabolite repression 
(SOC) medium (950 µl) was added to the mixture and vigorously shaken at 37 ⁰C for 1 hour. 
Finally, several dilutions of the bacterial suspension (undiluted, 20x, 50x, 100x) were prepared 
and spread onto LB (Lysogeny broth)-agar plates (Addendum D) containing 50 µg/ml 
ampicillin antibiotic (Addendum D). Plates were incubated at 37 ⁰C overnight. Ampicillin was 
chosen as suitable antibiotic, since both plasmid constructs contain an ampicillin resistant gene. 
Thus, if the bacterial cells are successfully transformed with the respective plasmid DNA, the 
cells will be able to grow in the presence of this antibiotic. In addition, a negative control was 
included, where no growth was expected.  
2.7.3. Plasmid DNA extraction 
Following transformation, a starter culture was prepared, where single E. coli colonies were 
picked from agar plates and inoculated into LB-medium (5 ml). This culture was vigorously 
shaken at 37 ⁰C for 6 hours. Subsequently, 1 ml of the starter culture was added to 250 ml LB-
medium containing ampicillin. This culture was vigorously shaken at 37 ⁰C overnight. The 
following day, the OD600 of the overnight culture was measured, to ensure that the culture was 
still in the exponential growth phase. Bacterial cells were centrifuged at 6000 x g for 10 
minutes at 4 °C to form a pellet. Plasmid DNA purifications were performed using the 
NucleoBond Xtra Maxi plasmid kit (Macherey-Nagel) according to the manufacturer’s 
instructions. Briefly, the supernatant was decanted, and the remaining pellet resuspended in a 
buffer containing RNase, to remove any excess RNA. The kit relies on the lysis of bacterial 
cells using an alkaline solution containing the detergent SDS. Proteins tagged with SDS, as 
well as chromosomal DNA, precipitate and aggregate upon neutralisation of the solution. 
Plasmid DNA, however, remains soluble and was subsequently exposed to a wash and elution 
step. Thereafter, the eluate containing the plasmid DNA was precipitated with isopropanol and 
underwent centrifugation (15000 x g, 30 minutes, 4 °C) to form a pellet. The supernatant was 
discarded, and the pellet retained and washed with 70% EtOH and centrifuged at 15000 x g for 




dried for 15 minutes to remove remaining traces of EtOH. DNA pellets were resuspended in 
Tris-EDTA (TE) buffer (1-1.5 ml) depending on the size of the pellet, and stored at -20 °C.  
2.7.4. Measurement of plasmid DNA concentration and A260/280 
ratio 
The concentration and purity of the isolated plasmid DNA was determined by measuring the 
absorbance at 260 nm and 280 nm (Addendum F3, Table F2). The concentration can be 
determined using the Beer-Lambert law, which predicts a linear change in absorbance with 
concentration. Quantification measurements were performed using a NanoDrop ND-1000 UV-
vis spectrophotometer (CAF, Stellenbosch). As a blank, TE buffer was used, since the plasmid 
DNA was resuspended in this solution. An A260/280 ratio of around 1.8 is expected [207], which 
is indicative of pure DNA free from contamination of organic solvents, salts and/or proteins. 
2.7.5. Restriction enzyme digestion 
A further plasmid DNA quality assurance was performed by restriction enzyme (RE) digestion. 
Single digests were performed in a 1.5 ml microcentrifuge tube, using 1 µg of plasmid DNA 
and 2000 U of the RE, SalI-HF (New England Biolabs). 2.5 µl 10x NE Buffer was added to 
this mixture, followed by the addition of Milli-Q water, to a final volume of 25 µl. In the case 
of undigested samples, no restriction enzyme was added. The digested and undigested plasmid 
samples were incubated at 37 ⁰C for 15 minutes. Digestion was terminated by adding 5 µl 
MgCl2. 
2.7.6. Agarose gel electrophoresis 
Following RE digestion, linearized (digested) and non-linearized (undigested) plasmid were 
separated on a 0.5% (w/v) agarose gel to confirm the quality and integrity of the plasmids i.e., 
if the isolated plasmid DNA is supercoiled and therefore suitable for transient transfection. 
Firstly, 6x gel loading dye (5 µl) was added to each sample. The dye serves three main 
functions: 1) provides colour to the samples to facilitate loading, 2) contains high glycerol 
content, which allows settling of the samples to the bottom of the well and 3) migrates 
independently from samples, allowing the user to estimate the migration of DNA. 
Subsequently, agarose in 1x TAE buffer (Addendum D) was prepared at a concentration of 
0.5% for plasmid DNA with a predicted size of >5000 bp. Agarose gels stained with Nancy-
520 (Sigma-Aldrich) were allowed to set at room temperature. Subsequently, after loading 20 




was visualized under UV light using the MyECL Imager (Pierce Thermo Scientific) 
(Addendum F4: Fig. F2). For determination of the plasmid DNA size, samples were compared 
to the O’GeneRuler 1 kB Plus DNA Ladder (Thermo-Fisher).  
2.8. Transient transfections  
Cells were plated into a 10 cm2 dish, to allow for equal transfection efficiency across the dish. 
When cells reached approximately 60 to 70% confluency, they were transiently transfected 
using the lipid-mediated transfection reagent, X-tremeGENE-HP DNA (Roche Applied 
Science), according to the manufacturer’s instructions. Briefly, the transfection reagent forms 
a lipid vesicle around the negatively charged exogenous plasmid DNA, allowing it to pass 
through the phospholipid membrane, into the cell cytoplasm. The cells were transfected with 
0.5 µg/µl of PAI-1-Luc (3:1) or 5 µg/µl WT CRP -300 (1:1). The transfection reagent and 
plasmid DNA mix were added to the cells in a drop wise manner. Following this, cells were 
incubated for 24 hours and subsequently re-plated into 96-well plates (Bio-Smart Scientific) at 
a density of 45 000 cells per well. 
2.9. Luciferase Promoter Reporter Assay  
For promoter reporter experiments, BWTG3 cells were transiently transfected and treated as 
described in sections 2.8 and 2.2.2, respectively. After treatment for 24 hours, cells were lysed 
with 35 µl passive lysis buffer (Addendum D). The cells were agitated for 10 minutes at room 
temperature to ensure the coverage of cells with buffer, and subsequently stored at -20 ⁰C 
overnight, to aid with cell lysis. Luciferase activity was determined using the luciferase assay 
kit (Promega) according to the manufacturer’s instructions. Briefly, once cells were thawed, 
10 μl of each lysate was transferred to a white 96-well clinical plate (Whitehead Scientific) and 
25 μl luciferase substrate was added to each well. The luciferase assay system generates light 
through a chemical reaction involving luciferin, which forms the product molecule 
oxyluciferin. As a result, light is produced which is measured using a Veritas™ microplate 
luminometer (Turner BioSystems). Therefore, promotor activity, expressed as relative light 
units (RLU), is quantitively measured as an end point experiment based on the amount of 
luciferase protein translated (light emitted). Luciferase promotor activity was normalized to 
total protein using the bicinchoninic acid assay (BCA) protein determination method (Thermo 
Scientific) described in section 2.10. Luciferase promotor activity was also compared relative 




2.10. Protein determination 
The bicinchoninic acid assay (BCA) protein determination method (Thermo-Fisher) was used 
to measure the total protein content of the cell lysates prepared for the promoter reporter assay 
described in section 2.9. The BCA assay is a colorimetric assay, based on the reduction of Cu2+ 
to Cu1+. The latter ion is chelated by two BCA molecules to form a tetradentate purple complex. 
Firstly, albumin (BSA) standards were prepared by performing eight serial dilutions of 1 ml 
albumin concentrate stock (2.0 mg/ml dissolved in a 0.9% aqueous NaCl solution containing 
sodium azide) in passive lysis buffer to concentrations ranging from 25-2000 µg/ml. Passive 
lysis buffer was used since the cell lysates used for the luciferase promoter reporter assay were 
lysed with this buffer. Next, the BCA working reagent was prepared as described by the 
manufacturer: for each cell lysate, 1 part of reagent B (containing 4% cupric sulphate) and 50 
parts of reagent A (containing sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1 M sodium hydroxide) were mixed (1:50, reagent B: A), referred to as the 
working reagent. For the reaction in the transparent 96-well microplate, 10 µl of cell lysate or 
the prepared standards in triplicate was added to each well. Hereafter, 200 µl of working 
reagent was added to each well. To protect the microplate from light, it was wrapped in foil 
and incubated at 37 °C for 30 minutes. The reaction forms a purple colour product and the 
BCA/Cu1+ complex exhibits a strong absorbance at 562 nm, hence why the absorbance was 
measured at 562 nm, using the Multiskan Sky UV/Vis plate reader (Thermo-Fisher Scientific). 
A standard curve was plotted using GraphPad Prism® version 5 software. The protein 
concentration of each cell lysate was measured by interpolating the absorbance readings of 
each cell lysate into the standard curve and using the equation of the linear region, taking the 
Beer-lambert law into account. 
2.11. Data and Statistical analysis  
Graphical representation and statistical analysis were conducted using the GraphPad Prism® 
version 5.0 software. Data is expressed as the mean ± standard deviation (SD) if two 
independent experiments (n=2) and mean ± standard error of mean (SEM) if three or more 
independent experiments (n=3<) were performed. One-way ANOVA with Dunnett’s 
Multiple Comparison’s post-test was used when comparing each treatment to the vehicle 
control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-way 
ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective 




symbol (*) was used. When comparing each co-treatment with its respective GC- or cytokine 
only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively 
(***/###/&&&: p<0.001, **/##/&&: p <0.01, */#/&: p<0.05). No statistical differences 
(p>0.05) are not shown in the figures. In addition, statistical analysis was not performed for 



































































It has been reported that an elevated APR occurs during insulin resistance [13]. The levels of 
APPs, such as PAI-1 and CRP, are significantly increased during this response, hence why they 
are commonly used as biological markers for T2D [21]. In addition, APPs are regulated by 
GCs and pro-inflammatory cytokines, which have also been implicated in the development of 
insulin resistance [10][11]. It thus begs the question whether GC- and pro-inflammatory 
cytokine-induced insulin resistance develops as a result of an increase in these APPs? In an 
attempt to answer this question, our research group previously showed that the APPs, PAI-1 
and CRP, were able to disrupt insulin signalling at key nodes of the insulin signalling pathway 
(unpublished data) [25]. This finding highlighted the role of APPs as possible causative agents 
in the development of insulin resistance. In the current study, we extend these earlier 
observations, by investigating the possible co-regulation of the expression of the APPs, PAI-1, 
and CRP, by GCs and pro-inflammatory cytokines. Although studies do exist investigating this 
possible co-regulation, our study sets out to further contribute to the knowlegde on this topic 
currently available in the literature.  
 
Both the synthetic GC, Dex, and natural occurring GCs, corticosterone and cortisol, in rodents 
and humans, respectively, were included in this study. Exogenous GC treatment is commonly 
prescribed to treat and combat chronic inflammation, which is associated with insulin 
resistance and diabetes [208]. It is for this reason; Dex was specifically included as a 
representative synthetic GC. Under normal conditions, the endogenous GC, cortisol, plays a 
fundamental role in the termination of the APR, as it functions as negative feedback system by 
downregulating pro-inflammatory cytokine production in humans [83]. The GCs were used at 
three physiologically relevant concentrations (10 nM, 100 nM, and 1 µM), based on the 
knowledge that under normal conditions, cortisol is secreted in a circadian manner with its 
levels peaking in the morning (138 to 635 nM) and decreasing in the afternoon (83 to 359 nM) 
[209].  
 
In addition, two well-studied, early-release pro-inflammatory cytokines, TNF-α and IL-6, were 
included, as both play an important role in the APR. The former indirectly promotes APP 
expression via orchestrating the production of cytokines, whereas the latter is understood to 
have a more direct effect on APP expression [112]. To the best of our knowledge, information 
regarding circulating cytokine levels in the body remain scarce and rather contradictory. Both 
healthy individuals and diabetic patients display inconsistent cytokine levels, which are far less 




(Addendum A: Tables A1&A2). As a result, a single concentration of 20 ng/ml was chosen 
for each pro-inflammatory cytokine, as based on the literature this concentration is commonly 
used to stimulate cytokine signalling in vitro [182][147]. Because the liver is the main source 
of APPs, both the murine (BWTG3) and human (HepG2) hepatoma (liver carcinoma) cell lines 
were chosen as suitable in vitro models for this investigation, allowing for the determination 
of any cell line specific effects. The cells were cultured in low glucose-DMEM (containing 
5.55 mM glucose) supplemented with FBS, which approximates normal blood sugar levels in 
vivo [211]. In addition, cells were serum starved with unsupplemented low glucose-DMEM for 
24 hours prior to treatment. Taking these steps limited the intereference of factors, other than 
our test compounds, on PAI-1 and CRP expression.  
 
The current study tested the hypothesis whether hepatoma cells co-treated with GCs and pro-
inflammatory cytokines, would cooperatively regulate PAI-1 and CRP expression, at both 
mRNA and protein level. For measuring mRNA and intracellular protein expression, real-time 
semi-quantitative (q)-PCR and western blotting were utilised, respectively. Firstly, the 
transcriptional regulation of PAI-1 and CRP in response to the synthetic GC, Dex, and/or either 
pro-inflammatory cytokine, TNF-α or IL-6 was determined. Next, the optimal time required to 
affect intracellular PAI-1 and CRP protein expression in response to either the endogenous- 
(cortisol or corticosterone) or synthetic (Dex) GC, or the pro-inflammatory cytokines (TNF-α 
or IL-6) in each hepatoma cell line was established. Subsequently, the results obtained from 
the time course experiments were used in choosing a suitable time point to investigate what 
effect GCs co-treated with either TNF-α or IL-6 would have on intracellular PAI-1- and CRP 
protein expression i.e., at translational level. Lastly, to elucidate the potential molecular 
mechanisms governing the action of these signalling molecules to affect the expression of both 
APPs were investigated. The following question was formulated: Is the predicted increase in 
APP expression as a result of an increase in promotor activity of the APPs? To answer this 
question, cells were transfected with luciferase reporter constructs containing either the human 
PAI-1 or CRP minimal promotor. The mRNA and promoter experiments were only conducted 







3.1  The effects of GC and/or pro-inflammatory cytokines on 
PAI-1 and CRP mRNA expression 
APP levels primarily increase during the APR in response to stress and inflammation aiding in 
restoring homeostasis. However, prolonged exposure to stress and inflammatory mediators 
such as GCs and pro-inflammatory cytokines can result in a prolonged APR and sustained APP 
production [113]. Chronic exposure to some APPs, like PAI-1 and CRP are associated with 
various disease states including T2D as previously mentioned [122]. PAI-1 and CRP mRNA 
expression in BWTG3 cells in response to Dex alone or in combination with the pro-
inflammatory cytokines, TNF-α and IL-6 was firstly determined (Figs 3.1&3.2). Due to 
difficulty experienced with the human PAI-1 and CRP primers mRNA expression was not 
investigated in the HepG2 cell line.  
 
3.1.1 TNF-α and IL-6 differentially regulate PAI-1 mRNA expression, 
whilst Dex did not affect either PAI-1 or CRP mRNA expression in the 
BWTG3 cell line 
Although stress and inflammatory mediators such as GCs and pro-inflammatory cytokines are 
associated with increased APP expression, they appear to influence PAI-1 and CRP mRNA 
expression differently. Dex at all three concentrations tested had no significant effect (p>0.05) 
on PAI-1- (Fig. 3.1) and CRP (Fig. 3.2) mRNA expression, relative to the vehicle control. 
Although both cytokines are categorised as pro-inflammatory mediators, it was observed that 
TNF-α and IL-6 differentially affected the mRNA levels of the two APPs. TNF-α had no 
significant effect (p>0.05) on PAI-1 mRNA expression compared to the vehicle control (Fig. 
3.1A), whereas IL-6 significantly (p<0.01) increased PAI-1 mRNA expression (Fig. 3.1B). In 
contrast, both TNF-α (Fig. 3.2A) and IL-6 (Fig. 3.2B) had no significant (p>0.05) effect 
compared to the vehicle control on CRP mRNA expression. However, caution should be 
exercised when interpreting the findings with the pro-inflammatory cytokines because of the 
high variability between the independent biological repeats as indicated by the error bars.  
 
In summary, the exogenous GC, Dex did not affect PAI-1 and CRP mRNA expression, whilst 






3.1.2 PAI-1 and CRP mRNA expression are affected similarly in response 
to Dex co-treated with TNF-α, but not IL-6 in the BWTG3 cell line 
Whilst single treatments with either 20 ng/ml TNF-α or Dex, at all three concentrations tested, 
had no significant effect on both PAI-1 and CRP mRNA expression, co-treatment with 10-8 M 
Dex, the lowest concentration used, plus TNF-α significantly (p<0.01) increased the mRNA 
levels of both APPs when compared to basal expression. Similarly, although not as pronounced 
as with 10-8 M Dex, TNF-α co-treated with the highest concentration of Dex used (10-6 M) 
significantly (p<0.05) increased PAI-1 and CRP mRNA expression compared to the vehicle 
control. Thus, an increase in PAI-1 and CRP mRNA expression was only observed when the 
BWTG3 cells were co-treated with TNF-α and either 10-8 M- or 10-6 M Dex. Furthermore, 
10-8 M Dex co-treated with TNF-α also lead to a significant (p<0.01) increase in mRNA 
expression of both APPs compared to 10-8 M Dex alone (Figs 3.1A & 3.2A), of which the latter 
was unable to induce PAI-1 and CRP mRNA expression.  
 
In contrast, PAI-1 mRNA levels remained unaffected when compared to vehicle control in 
response to Dex at all concentrations used when co-treated with IL-6 (Fig. 3.1B). Moreover, 
Dex appears to antagonise IL-6-induced PAI-1 mRNA expression by decreasing PAI-1 mRNA 
back to basal levels. However, significance was not established, possibly due to the variability 
observed between independent biological repeats for the IL-6 single treatment (Fig. 3.1B). A 
significant (p<0.05) increase in CRP mRNA levels compared to vehicle control was observed 
when BWTG3 cells were co-treated with IL-6 and the highest concentration (10-6 M) of Dex 
used (Fig. 3.2B). Surprisingly, CRP mRNA levels significantly (p<0.01) decreased when the 
cells were co-treated with IL-6 and a lower concentration (10-7 M) of Dex. Whereas CRP 
mRNA levels remained unaffected by the lowest concentration (10-8 M) of Dex used co-treated 
with IL-6 (Fig. 3.2B). In contrast, CRP mRNA levels were mostly upregulated when the 
BWTG3 cells were co-treated with TNF-α and various concentrations of Dex (Fig. 3.2A). 
 
In summary, both PAI-1- and CRP mRNA expression in BWTG3 cells were similarly affected 
by Dex when co-treated with TNF-α, but not IL-6. A significant (p<0.05) increase in both 
PAI-1- and CRP mRNA expression was observed in response to co-treatment with TNF-α and 
the highest and lowest concentrations of Dex used in the study (Figs 3.1A & 3.2A). In contrast, 
the effect co-treatment of IL-6 and Dex has on CRP mRNA levels, compared to the vehicle 




significantly (p<0.05) increased in response to IL-6 co-treated with Dex at the highest 
concentration used, significantly (p<0.01) decreased in response to IL-6 co-treated with a lower 
concentration of Dex used and remained unaffected in response to IL-6 and the lowest 
concentration of Dex used (Fig. 3.2B). Furthermore, the IL-6-mediated increase in PAI-1 
















Figure 3.1. PAI-1 mRNA expression in mouse hepatoma cells in response to co-treatment with Dex and 
either TNF-α or IL-6. BWTG3 cells were serum starved for 24 hours (h) followed by co-treatment with various 
concentrations (10-8 M, 10-7 M, 10-6 M) of the synthetic GC, dexamethasone (Dex) combined with either (A) TNF-
α or (B) IL-6 for 24 h. Hereafter, total RNA was isolated, cDNA synthesized, and analysed using qPCR with 
primers specific to PAI-1 and the internal control, 18S. The relative PAI-1 mRNA expression was normalised to 
the relative 18S mRNA expression. The data were plotted as fold change relative to the vehicle mRNA 
(combination of ethanol and supplemented DMEM), which was set to 1. Results displayed are representative of 
three to five independent biological repeats (± SEM), where each condition was performed in duplicate (two 
technical repeats). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing 
each treatment to the vehicle control, whereas two-way ANOVA with Bonferroni post-test was used to compare 
each co-treatment to the respective concentration of Dex on its own When comparing each co-treatment with its 
respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively (*: 





Figure 3.2. CRP mRNA expression in mouse hepatoma cells in response to co-treatment with Dex and either 
TNF-α or IL-6. BWTG3 cells were serum starved for 24 hours (h) followed by co-treatment with various 
concentrations (10-8 M, 10-7 M, 10-6 M) of the synthetic GC, dexamethasone (Dex) combined with either (A) TNF-
α or (B) IL-6 for 24 h. Hereafter, total RNA was isolated, cDNA synthesized, and analysed using qPCR with 
primers specific to PAI-1 and the internal control, 18S. The relative CRP mRNA expression was normalised to 
the relative 18S mRNA expression. The data were plotted as fold change relative to the vehicle mRNA 
(combination of ethanol and supplemented DMEM), which was set to 1. Results displayed are representative of 
three to five independent biological repeats (± SEM), where each condition was performed in duplicate (two 
technical repeats). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing 
each treatment to the vehicle control, whereas two-way ANOVA with Bonferroni post-test was used to compare 
each co-treatment to the respective concentration of Dex on its own When comparing each co-treatment with its 
respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively 




3.2    Time-dependent effects of GCs or pro-inflammatory 
cytokines on PAI-1 and CRP protein expression 
Establishing whether the effects of GCs and the pro-inflammatory cytokines on PAI-1 and CRP 
mRNA level are also reflected at the protein level was next established. Because some of the 
test compounds failed to affect PAI-1 and CRP expression at the transcriptional level at 24 
hours (Fig. 3.1), we first set out to investigate whether the length of exposure to the test 
compounds could affect intracellular PAI-1- and CRP protein expression. The normal APR in 
the liver is known to peak at 48 hours after a triggering event, but can proceed up to days [32]. 
In light of this, the time course study included three time points (24-, 48- and 72 hours) in order 
to determine the optimal treatment time with the selected test compounds. For the purpose of 
the time course study a single GC concentration of a 100 nM (10-7 M) was chosen, as the 
majority of studies in the literature which have investigated the regulation of APP expression 
by GCs, included this specific concentration (Addendum A: Tables A1&A2). The relative 
PAI-1- and CRP protein expression at each time point were normalised to time 0 (vehicle 
control), which was set to 1. For consideration of equal protein loading, Hsp90 was used as a 
loading control as it was shown to be not significantly regulated by the test compounds 
(Addendum E1&E2).  
Both the synthetic GC, Dex and the endogenous GC, corticosterone (Cort), lead to an increase 
in PAI-1 protein expression in the murine cell line (Fig. 3.3A&B).In the BWTG3 cells, a 
significant (p<0.05) increase in PAI-1 protein levels was observed in response to 24- and 48 
hours Dex treatment. In contrast, PAI-1 protein levels were unaffected when BWTG3 cells 
were treated with Dex for 72 hours (Fig. 3.3A). Furthermore, in the HepG2 cells, PAI-1 protein 
expression appeared to be unaffected by Dex although statistical analysis could not be done as 
only two biological independent repeats were performed (Fig. 3.4A). Like Dex, a significant 
increase in PAI-1 protein expression was found in the BWTG3 cells in response to the 
endogenous GC, Cort (Fig. 3.3B). However in contrast to Dex, a longer exposure to the 
endogenous GC, Cort was required before a significant (p<0.05) increase in PAI-1 protein 
expression was observed in the BWTG3 cells (Figs 3.3A&B). PAI-1 protein expression was 
only significantly (p<0.05) increased in response to 48 hours Cort treatment (Fig. 3.3B). 
Additionally, although statistical analysis could not be performed as only two biological 
independent repeats were done, in the HepG2 cells it does appear that a slight increase in PAI-1 




Like with the GCs, the effect of the pro-inflammatory cytokines on PAI-1 protein expression 
was also time dependent and varied between cell lines. No significant (p>0.05) effect on PAI-1 
protein expression was observed in response to TNF-α- and IL-6 exposure at all three 
timepoints in the BWTG3 cells. However, although not statistically significant (p>0.05), 
exposure to TNF-α for 48- and 72 hours and IL-6 for 48 hours appeared to increase PAI-1 
protein expression (Fig 3.3C&D). In the HepG2 cells however, TNF-α treatment for both 24- 
and 48 hours lead to a significant (p<0.01) increase in PAI-1 protein expression, which returned 
to basal levels when treated with TNF-α for 72 hours (Fig 3.4C). In contrast, HepG2 cells 
treated with IL-6 had no significant effect on PAI-1 protein levels although a slight decrease 



















Figure 3.3. Intracellular PAI-1 protein levels in a mouse hepatoma cell line over time in response to GCs, 
TNF-α, or IL-6. Total protein was extracted from BWTG3 cells treated with 10-7 M of (A) the synthetic GC, 
dexamethasone (Dex) or (B) endogenous GC, corticosterone (Cort), and 20 ng/ml of the pro-inflammatory 
cytokines, (C) TNF-α or (D) IL-6, for indicated time periods (0, 24, 48, 72 hours (h)). PAI-1 protein was identified 
as a single 45 kDa band using a monoclonal anti-rabbit PAI-1 antibody. Hsp90 was used as loading control. 
Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The relative 
PAI-1 protein expression levels at each time point were normalised to the loading control and compared with that 
at time 0, which was set to 1 (represented by the black dotted line). Results displayed are representative of three 
to four independent biological repeats (± SEM). Statistical analysis was performed using one-way ANOVA with 




























Figure 3.4. Intracellular PAI-1 protein levels in a human hepatoma cell line over time in response to GCs, 
TNF-α, or IL-6. Total protein was extracted from HepG2 cells treated with 10-7 M of (A) the synthetic GC, 
dexamethasone (Dex) or (B) endogenous GC, cortisol (F), and 20 ng/ml of the pro-inflammatory cytokines, (C) 
TNF-α or (D) IL-6, for indicated time periods (0, 24, 48, 72 hours (h)). PAI-1 protein was identified as a single 
45 kDa band using a monoclonal anti-rabbit PAI-1 antibody. Hsp90 was used as loading control. Densities of the 
western blot bands were measured by ImageJ software and illustrated as bar graphs. The relative PAI-1 protein 
expression levels at each time point were normalised to the loading control and compared with that at time 0, 
which was set to 1 (represented by the black dotted line). Results displayed are representative of two (± SD) to 
three independent biological repeats (± SEM). Statistical analysis was performed using one-way ANOVA with 
Dunnett’s Multiple Comparison’s post-test (**p<0.01, ***p<0.001). In addition, statistical analysis was not 





Both the synthetic GC, Dex and the endogenous GCs lead to an increase in CRP protein 
expression in both the murine and human hepatoma cell lines, albeit to different extents (Fig. 
3.5A vs Fig. 3.6A). Although an increase in CRP protein expression in response to Dex 
treatment was observed from 24 hours, significance was only established after 72 hours 
treatment in the BWTG3 cells (p<0.05) (Fig 3.5A). Similar to the BWTG3 cells, in HepG2 
cells Dex treatment resulted in an increase in CRP protein levels, with a significant increase 
(p<0.01) obtained at 24 and 48 hours (Fig 3.6A). Like Dex, the endogenous GCs also resulted 
in an increase in CRP protein levels albeit to different degrees. CRP protein levels only started 
to increase at 48 hours exposure to the endogenous murine GC, Cort, (Fig. 3.5B), whereas in 
the HepG2 cells, F the endogenous GC in humans at already 24 hours increased CRP protein 
levels (Fig. 3.6B). The highest fold increase in CRP protein expression for both endogenous 
GCs was shown at 48 hours (Figs 3.5B & 3.6B).  
 
The effect of each pro-inflammatory cytokine on CRP protein expression seems to differ 
between cell lines (possible species-specific differences). Although, a slight increase in CRP 
protein levels was detected after 48- and 72-hour exposure to TNF-α in BWTG3 cells, 
significance could not be established for either time points (p>0.05) (Fig. 3.5C). In contrast, a 
significant increase in CRP protein levels was already observed in HepG2 cells treated with 
TNF-α for 24 hours, which remained significantly (p<0.05) elevated up to 72 hours (Fig. 3.6C). 
Like TNF-α treatment, a slight but not significant (p>0.05) increase in CRP protein levels in 
response to IL-6 treatment for 48- and 72 hours was found in BWTG3 cells (Fig. 3.5D). CRP 
protein expression also appeared to increase in response to IL-6 at all the time points 
investigated in the HepG2 cells although significance could not be established due to large 
error between independent experiments (Fig. 3.6D).  
 
Taken together, both PAI-1- and CRP protein expression in both the BWTG3 and HepG2 cells 
were increased by the test compounds albeit to different extents. An increase in both PAI-1- 
and CRP protein levels were generally observed in response to the test compounds at 48 hours, 
which was chosen as the time point for subsequent combinatorial treatments. Treating the cells 
for a duration of 48 hours would allow us to examine how a combination of GCs plus pro-



































Figure 3.5. Intracellular CRP protein levels in a mouse hepatoma cell line over time in response to GCs, 
TNF-α, or IL-6. Total protein was extracted from BWTG3 cells treated with 10-7 M of (A) the synthetic GC, 
dexamethasone (Dex) or (B) endogenous GC, corticosterone (Cort), and 20 ng/ml of the pro-inflammatory 
cytokines, (C) TNF-α or (D) IL-6, for indicated time periods (0, 24, 48, 72 hours (h)). CRP protein was identified 
as a single 26 kDa band using a monoclonal anti-mouse CRP antibody. Hsp90 was used as loading control. 
Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs.  The relative 
CRP protein expression levels at each time point were normalised to the loading control and compared with that 
at time 0, which was set to 1 (represented by the black dotted line). Results displayed are representative of three 
to four independent biological repeats (± SEM). Statistical analysis was performed using one-way ANOVA with 


































Figure 3.6. Intracellular CRP protein levels in a human hepatoma cell line over time in response to GCs, 
TNF-α, or IL-6. Total protein was extracted from HepG2 cells treated with 10-7 M of (A) the synthetic GC, 
dexamethasone (Dex) or (B) endogenous GC, cortisol (F), and 20 ng/ml of the pro-inflammatory cytokines, (C) 
TNF-α or (D) IL-6, for indicated time periods (0, 24, 48, 72 hours (h)). CRP protein was identified as a single 26 
kDa band using a monoclonal anti-mouse CRP antibody. Hsp90 was used as loading control. Densities of the 
western blot bands were measured by ImageJ software and illustrated as bar graphs. The relative CRP protein 
expression levels at each time point were normalised to the loading control and compared with that at time 0, 
which was set to 1 (represented by the black dotted line). Results displayed are representative of three independent 
biological repeats (± SEM). Statistical analysis was performed using one-way ANOVA with Dunnett’s Multiple 




3.3 The effects of GCs and/or pro-inflammatory cytokines on 
PAI-1- and CRP expression at protein level 
Having determined the optimal treatment time with the selected test compound to induce 
intracellular PAI-1 and CRP protein expression, BWTG3 and HepG2 cells were treated for 
48 hours with increasing concentrations (10-8 M, 10-7 M, and 10-6 M) of Dex or endogenous 
GC in the absence and presence of 20 ng/ml of either, TNF-α or IL-6 (Figs 3.7-3.14). As 
previously mentioned, what occurs at the mRNA level of a protein does not necessarily reflect 
at its protein level. This could be due to complex and varied post-transcriptional modifications 
(microRNA regulation) which could occur between the transcript and protein product 
[212][213], or the export of proteins, which could affect the amount of protein present.  
 
Both pro-inflammatory cytokines in the absence of GCs resulted in a significant (p<0.01) 
increase in PAI-1- and CRP protein levels regardless of the cell line used (Figs 3.7-3.14), which 
was not observed for Dex.  
3.3.1. PAI-1 protein expression in response to GCs in the absence or 
presence of pro-inflammatory cytokines 
Differential regulation of PAI protein expression in response to Dex in the absence and 
presence of the pro-inflammatory cytokines was observed in the mouse and human hepatoma 
cell lines (Fig. 3.7 vs Fig. 3.8). Firstly, in the BWTG3 cells, Dex at all concentrations tested 
significantly (p<0.05) induced an increase in PAI-1 protein expression (Fig. 3.7). The addition 
of either TNF-α or IL-6, had no significant effect (p>0.05) on PAI-1 protein expression when 
compared to either the GC at the relevant concentration or to the appropriate pro-inflammatory 
cytokine alone (Fig. 3.7). In contrast to the results obtained in the BWTG3 cells, in the HepG2 
cells, Dex at all concentrations tested was unable to significantly affect PAI-1 protein levels 
(Fig. 3.8). Moreover, both TNF-α- and IL-6-induced increases in PAI-1 protein levels were 
significantly (p<0.05) antagonised by Dex, which was not observed in the murine hepatoma 
cell line (Fig. 3.8 vs Fig. 3.7). In addition, this antagonising effect by Dex appears to be dose-
dependent in the HepG2 cells.  
 
Similar to Dex, Cort the endogenous GC in rodents, significantly (p<0.05) increased PAI-1 
protein expression in BWTG3 cells, although 10-8 M Cort had no significant effect (p>0.05) 




combinatorial treatments, Cort had no significant (p>0.05) effect on the increase in PAI-1 
protein levels mediated by either TNF-α or IL-6 in the BWTG3 cells (Fig. 3.9). On the other 
hand, 10-8 M Cort co-treated with IL-6 significantly (p<0.01) increased PAI-1 protein 
expression when compared to 10-8 M Cort only treatment (Fig. 3.9B).  
 
In the HepG2 cells the endogenous GC, F only at 10-8 M and 10-6 M was able to increase PAI-1 
protein expression (Fig. 3.10), unlike Dex the synthetic GC which was unable to increase the 
protein levels of this APP at any of the concentrations used in the HepG2 cells (Fig. 3.8). 
Furthermore, whilst F generally had no significant effect on TNF-α-mediated increase in PAI-1 
protein expression, co-treatment of 10-7 M F with TNF-α resulted in a significant (p<0.001) 
increase in PAI-1 protein levels when compared to the 10-7 M F treatment alone (Fig. 3.10A). 
Moreover, whilst both 10-6 M F- and IL-6 only treatments resulted in a significant (p<0.05) 
increase in PAI-1 protein levels, surprisingly co-treatment of these two compounds resulted in 
PAI-1 levels similar to that observed with basal expression, suggesting that at this 
concentration of F the two compounds are antagonising each other (Fig. 3.10B). 
 
Thus, to summarise, whilst PAI-1 protein expression was upregulated by both TNF-α- and IL-6 
only treatments in both the murine and human liver cells, cell line specific effects in response 
to the GCs were observed. PAI-1 protein expression in the BWTG3 cells appeared to be more 
sensitive to GC treatment as both Dex (at all concentrations tested) and the endogenous GC, 
Cort (at the two highest concentrations tested) increased PAI-1 protein levels (Figs 3.7 & 3.9). 
Whilst in the HepG2 cells Dex (at all concentrations tested) had no effect on PAI-1 protein 
expression compared to vehicle control (Fig. 3.8). Despite this, F at concentrations of 
10-8 M and 10-6 M was able to induce a significant increase in PAI-1 protein expression 
(Fig. 3.10). However, although the PAI-1 protein regulation was less sensitive to GCs in 
HepG2 cells, TNF-α- and IL-6-mediated increase in PAI-1 protein expression was more 
affected by the GCs in the human hepatoma cell line. For example, both TNF-α- and IL-6-
mediated increase in PAI-1 protein expression was antagonised by Dex (Fig. 3.8), and 10-6 M F 
antagonised IL-6-induced PAI-1 protein expression (Fig. 3.10B) in the HepG2 cells. 
Furthermore, also in the HepG2 cells, 10-7 M F potentiated TNF-α-induced PAI-1 protein levels 
(Fig. 3.10A). These results suggest that PAI-1 regulation by GCs in the presence and absence 
































Figure 3.7. Intracellular PAI-1 protein levels in a mouse hepatoma cell line response to single- and co-
treatment with Dex and either TNF-α or IL-6. Total protein was extracted from BWTG3 cells after 48 hours 
(h) treatment with various concentrations of (A) the synthetic GC, dexamethasone (Dex), or 20 ng/ml of TNF-α 
(T) or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown 
in (D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative PAI-1 protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1 (represented by the black dotted line). Results displayed are representative of three to 
five independent biological repeats (± SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test 
was used when comparing each treatment to the vehicle control or each co-treatment to either pro-inflammatory 
cytokine alone treatment. Two-way ANOVA with Bonferroni post-test was used to compare each co-treatment to 
the respective concentration of Dex on its own. When comparing each treatment to the vehicle, an asterisk symbol 
(*) was used. When comparing each co-treatment with its respective Dex- or cytokine only treatment, a hashtag- 





































Figure 3.8. Intracellular PAI-1 protein levels in a human hepatoma cell line response to single- and co-
treatment with Dex and either TNF-α or IL-6. Total protein was extracted from HepG2 cells after 48 hours (h) 
treatment with various concentrations of (A) the synthetic GC, dexamethasone (Dex), or 20 ng/ml of TNF-α (T) 
or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown in 
(D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative PAI-1 protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1. Results displayed are representative of three to five independent biological repeats (± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each 
treatment to the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-
way ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective concentration of 
Dex on its own. When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing 
each co-treatment with its respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) 


































Figure 3.9. Intracellular PAI-1 protein levels in a mouse hepatoma cell line response to single- and co-
treatment with Cort and either TNF-α or IL-6. Total protein was extracted from BWTG3 cells after 48 hours 
(h) treatment with various concentrations of (A) the endogenous GC, corticosterone (Cort), or 20 ng/ml of TNF-
α (T) or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown 
in (D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative PAI-1 protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1. Results displayed are representative of three to five independent biological repeats (± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each 
treatment to the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-
way ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective concentration of 
Cort on its own. When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing 
each co-treatment with its respective Cort- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) 
































Figure 3.10. Intracellular PAI-1 protein levels in a human hepatoma cell line response to single- and co-
treatment with F and either TNF-α or IL-6. Total protein was extracted from HepG2 cells after 48 hours (h) 
treatment with various concentrations of (A) the endogenous GC, cortisol (F), or 20 ng/ml of TNF-α (T) or IL-6 
(I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown in (D). 
Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The relative 
PAI-1 protein expression was normalised to the loading control (Hsp90) and compared with the vehicle control, 
which was set to 1. Results displayed are representative of three to five independent biological repeats (± SEM). 
One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each treatment to 
the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-way ANOVA 
with Bonferroni post-test was used to compare each co-treatment to the respective concentration of F on its own. 
When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing each co-
treatment with its respective F- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, 




3.3.2. CRP protein expression in response to GCs in the absence or 
presence of pro-inflammatory cytokines  
CRP protein expression had a similar response to Dex in the absence and presence of the pro-
inflammatory cytokines in the murine and human hepatoma cell lines (Fig. 3.11 vs Fig. 3.12). 
Firstly, in the BWTG3 cells, Dex at all concentrations tested significantly (p<0.05) induced an 
increase in CRP protein expression compared to the vehicle control (Fig. 3.11). The addition 
of either TNF-α (Fig. 3.11A) or IL-6 (Fig. 3.11B), had no significant effect (p>0.05) on CRP 
protein expression when compared to either the GC at the relevant concentration or the 
appropriate pro-inflammatory cytokine.  
 
Similar to the results obtained in the BWTG3 cells, in the HepG2 cells, Dex at all 
concentrations tested significantly (p<0.01) increased CRP protein expression compared to the 
vehicle control (Fig. 3.12). Like observed in the BWTG3 cells, CRP protein expression 
remained significantly (p<0.01) elevated when HepG2 cells were co-treated with Dex in the 
presence of either pro-inflammatory cytokine. Overall, the addition of either TNF-α (Fig. 
3.12A) or IL-6 (Fig. 3.12B), had no significant effect (p>0.05) on CRP protein expression 
when compared to either the GC at the relevant concentration or the appropriate pro-
inflammatory cytokine. The exception to this was 10-7 M Dex co-treated with IL-6, which 
potentiated (p<0.05) both Dex- and IL-6-induced CRP protein expression, more than what was 
observed for either test compound alone (Fig. 3.12B). 
 
Similar to Dex treatment in the BWTG3 cells, Cort significantly (p<0.01) increased CRP 
protein expression compared to the vehicle control (Fig. 3.11 vs Fig. 3.13). In regard to the 
combinatorial treatments, CRP protein levels remained significantly (p<0.05) elevated 
although not significantly (p>0.05) more than what was observed for either test compound 
alone (Fig. 3.13). Similar to Dex treatment in the HepG2 cells, F significantly (p<0.01) 
increased CRP protein expression relative to the vehicle control (Fig. 3.12 vs Fig. 3.14). In 
regard to the combinatorial treatments, CRP protein levels appear to remain elevated although 
not significantly (p>0.05) more than what was observed for either test compound alone (Fig. 
3.14). However, co-treatment with the lowest concentration of F used (10-8 M) and either 
TNF-α (Fig. 3.14A) or IL-6 (Fig. 3.14B) did appear to slightly decrease CRP protein levels, 
which is not statistically different to basal levels (p>0.05). This suggests that at a concentration 




Thus, to summarise, both the murine and human liver cells were equally responsive to single 
treatment with GCs or either pro-inflammatory cytokine to increase CRP protein expression. 
In addition, when Dex (Figs 3.11 & 3.12) or Cort (Fig. 3.13) were in the presence of either 
pro-inflammatory cytokine, CRP protein levels remained significantly (p<0.05) elevated, but 
not more than what was observed for each test compound on its own. This occurred with the 
exception of 10-7 M Dex co-treated with IL-6, which did in fact exhibit cooperativity, as CRP 
protein levels were more pronounced compared to treatment with either test compound alone 
(Fig. 3.12B). In contrast to the above-mentioned results, the lowest concentration of F used 
combined with either TNF-α (Fig. 3.14A) or IL-6 (Fig. 3.14B) appear to repress CRP protein 
expression back to basal expression. However, at higher concentrations of the GC this apparent 



















































Figure 3.11. Intracellular CRP protein levels in a mouse hepatoma cell line response to single- and co-
treatment with Dex and either TNF-α or IL-6. Total protein was extracted from BWTG3 cells after 48 hours 
(h) treatment with various concentrations of (A) the synthetic GC, dexamethasone (Dex), or 20 ng/ml of TNF-α 
(T) or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown 
in (D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative CRP protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1. Results displayed are representative of three to four independent biological repeats (± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each 
treatment to the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-
way ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective concentration of 
Dex on its own. When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing 
each co-treatment with its respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) 



























Figure 3.12. Intracellular CRP protein levels in a human hepatoma cell line response to single- and co-
treatment with Dex and either TNF-α or IL-6. Total protein was extracted from HepG2 cells after 48 hours (h) 
treatment with various concentrations of (A) the synthetic GC, dexamethasone (Dex), or 20 ng/ml of TNF-α (T) 
or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown in 
(D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative CRP protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1. Results displayed are representative of three to four independent biological repeats (± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each 
treatment to the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-
way ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective concentration of 
Dex on its own. When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing 
each co-treatment with its respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) 































Figure 3.13. Intracellular CRP protein levels in a mouse hepatoma cell line response to single- and co-
treatment with Cort and either TNF-α or IL-6. Total protein was extracted from BWTG3 cells after 48 hours 
(h) treatment with various concentrations of (A) the endogenous GC, corticosterone (Cort), or 20 ng/ml of TNF-
α (T) or IL-6 (I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown 
in (D). Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The 
relative CRP protein expression was normalised to the loading control (Hsp90) and compared with the vehicle 
control, which was set to 1. Results displayed are representative of three to four independent biological repeats (± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each 
treatment to the vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-
way ANOVA with Bonferroni post-test was used to compare each co-treatment to the respective concentration of 
Cort on its own. When comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing 
each co-treatment with its respective Cort- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) 































Figure 3.14. Intracellular CRP protein levels in a human hepatoma cell line response to single- and co-
treatment with F and either TNF-α or IL-6. Total protein was extracted from HepG2 cells after 48 hours (h) 
treatment with various concentrations of (A) the endogenous GC, cortisol (F), or 20 ng/ml of TNF-α (T) or IL-6 
(I), in addition to the GC co-treated with either (B) TNF-α or (C) IL-6. A representative blot is shown in (D). 
Densities of the western blot bands were measured by ImageJ software and illustrated as bar graphs. The relative 
CRP protein expression was normalised to the loading control (Hsp90) and compared with the vehicle control, 
which was set to 1. Results displayed are representative of three independent biological repeats (± SEM). One-
way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each treatment to the 
vehicle control or each co-treatment to either pro-inflammatory cytokine alone treatment. Two-way ANOVA with 
Bonferroni post-test was used to compare each co-treatment to the respective concentration of F on its own. When 
comparing each treatment to the vehicle, an asterisk symbol (*) was used. When comparing each co-treatment 
with its respective F- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively 




3.4 The effects of GCs and/or pro-inflammatory cytokines on 
PAI-1- and CRP promotor activity 
Next, to better understand at the molecular level how GCs and the pro-inflammatory cytokines, 
TNF-α and IL-6, affect PAI-1 and CRP levels, the promoter activities of each of the APP was 
measured. BWTG3 cells were transiently transfected with plasmid DNA containing the 
endogenous human PAI-1 or CRP minimal promoter, each linked to a luciferase (Luc)-reporter. 
As a result, the Luc gene was placed under control of either the PAI-1 or CRP minimal 
promotors. Promotor activity, expressed as relative light units (RLU), was quantitively 
measured based on the amount of luciferase protein translated (light emitted), as described in 
detail in Chapter 2 (Materials and Methods). Results were normalized to total protein in each 
well, determined by the BCA protein determination assay. To ensure the successful transfection 
of cells with either PAI-1 Luc or WT CRP -300 plasmids, wells containing untransfected cells 
were included as a negative control. Little to no light was emitted from these wells, which 
confirmed successful transfection. Furthermore, the experimental design for this investigation, 
mimicked the treatment regime used for mRNA experiments, which allowed for direct 
comparisons between what was observed at mRNA level versus promotor level. Due to 
difficulty experienced transfecting the HepG2 cells with our plasmid constructs, promotor 
activity for both APPs were not investigated in the HepG2 cell line. 
3.4.1. PAI-1 promotor activity is increased in response to Dex in the 
absence or presence of either TNF-α or IL-6 
PAI-1 promoter activity was significantly (p<0.05) increased by Dex at all the concentrations 
tested by ~2-fold, relative to the vehicle control (Fig. 3.15). Similarly, both pro-inflammatory 
cytokines, TNF-α (Fig. 3.15A) and IL-6 (Fig. 3.15B), significantly (p<0.001) increased PAI-1 
promoter activity, also by ~2-fold. Generally, the ability of Dex to induce PAI-1 promotor 
activity was not significantly (p>0.05) influenced by the presence of either TNF-α (Fig. 3.15A) 
or IL-6 (Fig. 3.15B). Additionally, a slight but not significant decrease (p>0.05) in PAI-1 
promoter activity was observed in response to 10-6 M Dex co-treated with TNF-α (Fig 3.15A) 




3.4.2. Dex in the absence and presence of either TNF-α or IL-6 induces 
CRP promotor activity 
Similar to what was observed with the PAI-1 promoter activity, all concentrations of Dex tested 
was able to significantly (p<0.001) increase CRP promoter activity, relative to the vehicle 
control (Fig. 3.16). Like Dex, TNF-α (Fig. 3.16A) and IL-6 (Fig. 3.16B) each also significantly 
(p<0.001) increased CRP promoter activity. On the whole, Dex-mediated increase in CRP 
promoter activity was not significantly (p>0.05) affected by co-treating with either TNF-α 
(Fig. 3.16A) or IL-6 (Fig. 3.16B). However, 10-8 M Dex co-treated with TNF-α potentiated 
both Dex- and TNF-α only induced CRP promoter activity (p<0.001) (Fig. 3.16A), and 10-6 M 
Dex co-treated with IL-6 augmented both Dex- and IL-6 only induced CRP promoter activity 
(p<0.01) (Fig. 3.16B).  
 
Taken together, Dex as well as the pro-inflammatory cytokines, TNF-α and IL-6, increased 
PAI-1- and CRP promotor activity, which remained unaffected when Dex was co-treated with 
either of the pro-inflammatory cytokines (Fig. 3.15 & 3.16). This was with the exception of 
10-8 M Dex co-treated with TNF-α and 10-6 M Dex co-treated with IL-6, which further 
increased CRP promoter activity, more than what was observed with either test compound on 









Figure 3.15. PAI-1 promotor activity in mouse hepatoma cells in response to co-treatment with Dex and 
either TNF-α or IL-6. BWTG3 cells were transiently transfected with PAI-1-Luc promoter-reporter construct. 
Cells were co-treated with various concentrations (10-8 M, 10-7 M, 10-6 M) of dexamethasone (Dex) in the absence 
and presence of 20 ng/ml of either (A) TNF-α or (B) IL-6 for 24 hours (h). Luciferase activity was measured in 
relative light units (RLU) and normalised to protein concentration. The response of each treatment was plotted 
relative to the vehicle, which was set to 1. Results displayed are the averages (± SEM) of five to seven independent 
biological repeats with each condition performed in triplicate (three technical repeats). One-way ANOVA with 
Dunnett’s Multiple Comparison’s post-test was used when comparing each co-treatment to either pro-
inflammatory cytokine alone treatment. Two-way ANOVA with Bonferroni post-test was used to compare each 
co-treatment to the respective concentration of Dex on its own. When comparing each co-treatment with its 
respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively (*: 






Figure 3.16. CRP promotor activity in mouse hepatoma cells in response to co-treatment with Dex and 
either TNF-α or IL-6. BWTG3 cells were transiently transfected with WT CRP -300 promoter-reporter construct. 
Cells were co-treated with various concentrations (10-8 M, 10-7 M, 10-6 M) of dexamethasone (Dex) in the absence 
and presence of 20 ng/ml of either (A) TNF-α or (B) IL-6 for 24 hours (h). Luciferase activity was measured in 
relative light units (RLU) and normalised to protein concentration. The response of each treatment was plotted 
relative to the vehicle, which was set to 1. Results displayed are the averages (± SEM) of four to seven 
independent biological repeats with each condition performed in triplicate (three technical repeats). One-way 
ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing each co-treatment to either 
pro-inflammatory cytokine alone treatment. Two-way ANOVA with Bonferroni post-test was used to compare 
each co-treatment to the respective concentration of Dex on its own. When comparing each co-treatment with its 
respective Dex- or cytokine only treatment, a hashtag- (#) and ampersand symbol (&) were used, respectively 



















CHAPTER FOUR: DISCUSSION, CONCLUSION 


















4.1    Introduction 
T2D, the most common form of DM, is an escalating public health crisis not only in South 
Africa but worldwide. Although it is well established that insulin resistance is the main risk 
factor for T2D, it remains unsolved what the principal molecular defects are which lead to this 
pathogenesis. A common theme throughout literature portrays inflammation (represented by 
pro-inflammatory cytokines) and stress (represented by GCs) as key role players in the 
development of insulin resistance [21][98]. Generally, pro-inflammatory cytokines, such as 
TNF-α and IL-6, are understood to play a causative role in the development of insulin 
resistance, by interfering with insulin signalling (refer to Chapter 1, sections 1.2.1.2 & 
1.2.2.2) Similarly, GCs have also been demonstrated to directly interfere with insulin signalling 
in vitro and in vivo [103][214]–[216]. Furthermore, it has been reported that an elevated APR 
occurs during insulin resistance [119].  
 
APPs, such as PAI-1, CRP, and SAA, are upregulated during the diabetic state, hence why they 
are commonly used as biological markers for T2D [21]. The APR is regulated in a highly 
complex manner by many factors of which pro-inflammatory cytokines and the endogenous 
GCs are most important. Although short term-activated APR is understood to serve a 
homeostatic function, the systemic response of the APR can be prolonged by persistent 
stimulation or disruption of normal control mechanisms, converting to a recurrent chronic state 
of inflammation [113]. Traditional knowledge would suggest that under normal circumstances, 
GCs function as negative feedback system of the APR by downregulating pro-inflammatory 
cytokine production, thereby bringing the inflammatory response to a halt. Interestingly, 
several studies have also shown the synthetic GC, Dex, to enhance pro-inflammatory cytokine-
induced APP expression, thereby reinforcing the innate immune system and APR 
[149][180][193][195][199][200].  
 
In the current study we extended on these earlier observations, by investigating the possible 
co-regulation of the APPs, PAI-1, and CRP, by GCs and pro-inflammatory cytokines, both at 
the mRNA and protein level. Whilst cooperative regulation of SAA by GCs and various pro-
inflammatory cytokines have been extensively studied [27], fewer have studied this 
phenomenon in regards to PAI-1 and CRP. In this study, the effect the presence of either pro-




is important to examine regulation from both perspectives, as it has become abundantly clear 
that both the stress and immune system have bidirectional effects on each other [26].  
 
Therefore, based on the literature, it was hypothesized that GCs and pro-inflammatory 
cytokines would cooperatively regulate PAI-1 and CRP expression, at both mRNA and protein 
level. To test this hypothesis, the effect of GCs (synthetic and endogenous) in the presence of 
either pro-inflammatory cytokine (TNF-α or IL-6) on the expression of APPs (PAI-1 and CRP) 
in hepatoma cells (BWTG3 and HepG2) was investigated. Liver cells were used as it is a major 
source of APPs, such as PAI-1 and CRP. Both cell lines proved to be generally responsive to 
single treatment with either of the selected signalling molecules, and therefore allowed us to 
examine how a combination thereof would affect the expression levels of the APPs 
investigated.  
 
In this chapter the findings of this thesis will be discussed in context with the literature. The 
chapter has been divided into two sections: Firstly, the effects of GCs and/or pro-inflammatory 
cytokines on PAI-1- and CRP expression at both transcriptional (mRNA) and translational 
(intracellular protein) level will be discussed, in sub-sections 4.2.1 and 4.2.2, respectively. 
Subsequently, to elucidate the molecular mechanism underlying the regulation of PAI-1 and 
CRP expression by GCs and/or pro-inflammatory cytokines, the affect at the promoter level is 
reviewed in sub-sections 4.3.1 and 4.3.2, respectively. Finally, to conclude the findings of this 
MSc thesis, the latter, will be placed in a broader context with the literature, followed by future 
prospectives. 
4.2 Effects of glucocorticoids and pro-inflammatory mediators 
on APPs expression 
4.2.1. PAI-1 regulation by stress and inflammatory mediators 
4.2.1.1. PAI-1 regulation in response to individual treatments 
PAI-1 protein levels were increased by both GCs and pro-inflammatory cytokines in the liver 
cell lines used except for Dex, which only increased PAI-1 protein expression in the BWTG3 
cells. The increase in PAI-1 protein levels was not necessarily reflected at mRNA level 
(Addendum G: Table G1) in the BWTG3 cells, with neither Dex nor TNF-α influencing 




Conflicting results exist regarding Dex-mediated regulation of PAI-1 mRNA expression in the 
literature. Some studies have reported Dex to have no effect on mRNA expression [156][159] 
in liver cells, whilst others have observed Dex-induced increase in PAI-1 mRNA expression in 
various cell types including those derived from the liver [149][163][165]–[167][169]. Thus, 
the lack of Dex-mediated PAI-1 mRNA regulation does somewhat agree with the literature, 
although an increase in PAI-1 protein expression was observed, suggesting that the lack of 
mRNA regulation observed in response to Dex could be attributed to length of treatment. From 
the protein time course data (Fig. 3.3A), a significant increase in PAI-1 protein levels were 
already observed at 24 hours Dex exposure, suggesting that Dex-induced PAI-1 mRNA 
expression could possibly have been observed if treated with Dex for less than 24 hours, as 
mRNA precedes protein synthesis.  
 
Several studies have shown enhanced intra- and extracellular PAI-1 protein expression in 
response to Dex in various cell types, including rat hepatoma cells [166], human and mouse 
adipocytes [164][165], human adipose tissue [163], human fibrosarcoma cells [167][169], 
human trophoblast cells [171], human epithelial cells [163], and human monocytes [170]. To 
the best of our knowledge, no studies have investigated the effect of Dex or the endogenous 
GCs, corticosterone and cortisol, on PAI-1 protein expression in human or murine liver cells. 
Therefore, the current study is the first to report GC-induced increase in intracellular PAI-1 
protein expression in the murine and human hepatoma cell lines. Dex-mediated PAI-1 protein 
expression was not observed in the HepG2 cells, whereas already at 24 hours significant 
increase in PAI-1 protein expression was observed in the BWTG3 cells. In contrast, an increase 
in PAI-1 protein expression in response to both corticosterone and cortisol was observed at 48 
hours treatment in BWTG3 and HepG2 cells, respectively. This would suggest that the rate of 
PAI-1 protein synthesis in response to the GCs differ, with the potent GR agonist Dex possibly 
inducing PAI-1 synthesis at a faster rate in murine liver cells and might explain why no PAI-1 
protein expression was observed in the HepG2 cells in response to Dex. However definitive 
conclusions regarding the rate of PAI-1 protein synthesis comparing Dex versus the 
endogenous GCs cannot be made without determining the t1/2 for PAI-1 protein synthesis, 
which should include treatment times earlier than 24 hours. In addition, the differences in 
PAI-1 protein expression in response to the GCs in HepG2 cells could also be compounded by 
the rate of PAI-1 export, which might differ between the two cell lines. Unfortunately, there 
are no data available on the rate of PAI-1 export in either the BWTG3 or HepG2 cells to 




fibrosarcoma cells reported that Dex (1 µM) increased intracellular PAI-1 protein levels within 
4 hours, which levelled off after 20 hours, whilst extracellular PAI-1 levels were significantly 
increased after 16 hours and continued to increase during the 48-hour incubation. Therefore, it 
would have been interesting to have also measured the extracellular PAI-1 protein levels in the 
current study and is something that should be considered in future studies (refer to section 
5.5).  
 
Similar to Dex, TNF-α had no effect on PAI-1 mRNA as previously mentioned, which is in 
stark contrast to several lines of evidence from the literature, which found concentrations of 
TNF-α ranging between 5 to 50 ng/ml, to be potent enough to induce PAI-1 mRNA expression 
[141][144]–[146][148]–[150][153][154][165]. However, these studies were not performed in 
liver cells, and exposure to TNF-α was much shorter compared to the current study. To the best 
of our knowledge, only Seki & Gelehrter used liver cells in their study [156]. They found that 
1 hour exposure to TNF-α (50 ng/ml) increased PAI-1 mRNA by 4-fold, returning to basal 
levels after 4 hours in murine primary hepatocytes. This could explain the lack of TNF-α-
induced PAI-1 mRNA expression in the current study as both the concentration of TNF-α used 
as well as exposure time differs to that of Seki & Gelehrter. In addition, although primary 
hepatocytes and hepatoma cells are both of hepatic origin, they appear to show considerable 
differences in growth behaviour and expression of acute phase genes [217].  
 
Whilst, 24 hours exposure to TNF-α had no effect on PAI-1 mRNA expression in the BWTG3 
cells, increase in protein expression was observed in both the BWTG3- and HepG2 cells in 
response to 48 hours TNF-α treatment (Addendum G: Table G1). Others using a higher 
concentration of TNF-α (50 ng/ml) have also shown it to be a potent inducer of PAI-1 protein 
synthesis in HepG2 cells [155] and human and rat hepatocytes [140], after 24 hours. Similarly, 
lower concentrations of TNF-α ranging from 5 to 10 ng/ml were reported to markedly induce 
PAI-1 protein accumulation in human and mouse adipocytes after 24 hours [141][153]. TNF-α-
mediated increase in PAI-1 protein appears not to be cell type dependent, albeit dependent on 
the TNF-α concentration. Several research groups have shown PAI-1 protein synthesis to be 
induced by TNF-α in a number of different cell types, including human smooth muscle cells 
[150], human and bovine endothelial cells [143][145], and human epithelial cells [145].  
While neither Dex nor TNF-α induced PAI-1 mRNA expression, BWTG3 cells treated with 
20 ng/ml IL-6 for 24 hours resulted in an approximately 3.9-fold increase in PAI-1 mRNA 




hepatoma (HepG2) cells, murine, and human primary hepatocytes, and human adipocytes 
[159]–[161]. Dong et al. reported that IL-6 at a lower concentration of 1 ng/ml significantly 
increased PAI-1 mRNA expression by 2-fold in both HepG2 cells and mouse primary 
hepatocytes after 4 hours treatment [160]. Similarly, Healy & Gelehrter reported that IL-6 at a 
much higher concentration of 40 ng/ml had a significant effect on PAI-1 mRNA expression, 
increasing its levels by up to 2.5-fold, in HepG2 cells after 4 hours [159]. IL-6-induced PAI-1 
mRNA expression is not limited to the liver, as Rega et al. reported that IL-6 at an even higher 
concentration of 100 ng/ml significantly increased PAI-1 mRNA expression by 10-fold, in 
human adipocytes after 24 hours [161].  
 
Surprisingly, although IL-6-induced PAI-1 mRNA expression have been reported in HepG2 
cells, other studies using the same cell line [155][159][162] as well as human and murine 
hepatocytes [139] have found IL-6 to have no detectable effect on extracellular PAI-1 protein 
synthesis after 24 hours. Our time course data support these findings, as IL-6 had no effect on 
intracellular PAI-1 protein expression in both murine and human hepatoma cell lines after 
24 hours treatment (Figs 3.3D & 3.4D). However, IL-6 was capable of increasing intracellular 
PAI-1 protein levels after 48 hours, suggesting that the rate of protein synthesis and export here 
too plays a role and highlights the importance of measuring both intra- and extracellular APP 
expression as well as at different time points.  
4.2.1.2. PAI-1 regulation in response to combinatorial treatments 
Although both Dex, at all concentrations tested, and TNF-α only treatment had no effect on 
PAI-1 mRNA expression, co-treatment of 10-8 M- and 10-6 M Dex with TNF-α led to a 
significant increase of PAI-1 mRNA expression in the BWTG3 cells (Fig. 3.1A). Interestingly, 
while no studies exist, to the best of our knowledge, investigating possible co-regulation of 
PAI-1 mRNA expression by Dex and TNF-α in liver cells, studies performed in human 
endothelial [201] and epithelial cells [149], have reported their cooperative effect on PAI-1 
mRNA expression, beyond that observed from either signalling molecule alone. These studies 
are in agreement with the results obtained in the current study in regard to combinatorial 
treatment with Dex and TNF-α.  
 
This cooperative effect observed suggests cross talk between GC- and TNF-α signalling, which 
has been reported for other APP such as SerpinA3 [163]. Lannan et al. in fact demonstrated 




start site was more robust when cells were exposed to Dex (10-8 M) plus TNF-α [27]. The 
authors of this particular study also suggested that the GR is allowed to bind and mediate the 
effects of its ligand, Dex, because of TNF-α possibly promoting local unwinding of chromatin, 
although this still needs to be confirmed experimentally.  
 
Interestingly, this cooperative effect of 10-8 M Dex and TNF-α was not reflected at protein 
level in the BWTG3 cells. The increase in PAI-1 protein levels in response to either Dex or 
TNF-α remained unaffected when the murine cells were co-treated with Dex and TNF-α, 
although slight but not significant (p>0.05) increases were observed when TNF-α was 
co-treated with 10-8- and 10-7 M Dex. Similarly, TNF-α co-treated with corticosterone had little 
effect on the already increased PAI-1 protein expression of TNF-α- and corticosterone 
(10-7- & 10-6 M) only treatment in the BWTG3 cells (Fig. 3.9A). In addition, GCs co-treated 
with IL-6 also lead to a slight, but not significant (p>0.05) increase compared to either 
treatment alone, which could suggest some co-operativity between the GCs and IL-6 in the 
BWTG3 cells. However due to variability between independent biological repeats causing 
large error this needs to be confirmed for co-treatments of GCs with the pro-inflammatory 
cytokines.  
 
Meanwhile, whilst the presence of Dex had no effect on either cytokine-induced PAI-1 protein 
levels in the murine liver cell line, a different regulatory pattern emerged in the human liver 
cell line. In the HepG2 cells, the presence of various concentrations of Dex significantly 
(p<0.05) antagonised both TNF-α- and IL-6-induced intracellular PAI-1 protein expression 
(Fig. 3.8). This antagonism by Dex of either pro-inflammatory cytokine-induced PAI-1 protein 
expression was most noticeable with the highest concentration (10-6 M) of Dex used. These 
cell type specific effects could be attributed to different expression levels of key proteins in 
GC- and cytokine signalling pathways such as different levels of the GR, NF-κB, or STAT3 
proteins and requires further investigation. Also, to confirm antagonism in the HepG2 cells, 
measuring extracellular PAI-1 protein levels should be considered in future studies as the 
decrease in cytokine-induced intracellular PAI-1 in response to Dex treatment could be 
attributed to a faster rate of export from the cells as mentioned earlier. This is however merely 
speculative especially since PAI-1 mRNA levels were not examined in the HepG2 cells.  
 
Co-regulation of PAI 1 protein levels by Dex and TNF-α have been reported in cell types other 




(10-7 M) significantly modulated TNF-α (10 ng/ml)-induced extracellular PAI 1 protein 
production by an additional 2.3-fold, after 24 hours [13]. Thus, emphasising the need to also 
investigate extracellular PAI 1 protein expression and to consider the rate of protein synthesis 
as well as export. 
 
Unlike Dex, co-treatment of cortisol with the pro-inflammatory cytokines had little effect on 
either TNF-α or IL-6-induced PAI-1 protein expression in the HepG2 cells. However, 10-6 M 
cortisol did antagonise IL-6-mediated increase in PAI-1 expression. This different effect 
between cortisol and the synthetic GC could be attributed to the fact that Dex is a more potent 
GR agonist due to its higher binding affinity for the GR [218], suggested by cortisol only able 
to antagonise IL-6-induced PAI-1 protein expression at the highest concentration tested i.e., 
10-6 M. It should also be noted that cortisol and corticosterone can bind to other receptors such 
as the mineralocorticoid receptor (MR) [83], which could also explain these differences 
observed between the synthetic- and endogenous GC.  
 
Taken together, cooperative regulation of PAI-1 by the GCs and the pro-inflammatory 
cytokines was only really observed at the mRNA level and only with the lowest concentration 
of Dex tested in the presence of TNF-α. Very little cooperative effects by the GCs and the pro-
inflammatory cytokines were observed at the protein level, mainly due to huge error between 
independent biological repeats. In fact, various concentrations of Dex were able to significantly 
(p<0.05) antagonise both TNF-α- and IL-6-induced intracellular PAI-1 protein expression in 
the human liver cell line, most notably with the highest concentration of Dex used. Nonetheless, 
co-treatments mainly resulted in little to no changes to the individual treatments on their own 
in the murine liver cell line. This emphasises again that GCs cannot always only be considered 
anti-inflammatory.  
4.2.2. CRP regulation by stress and inflammatory mediators 
4.2.2.1. CRP regulation in response to individual treatments 
CRP protein levels were increased by both GCs and pro-inflammatory cytokines in the liver 
cell lines. The increase in CRP protein levels was not reflected at the mRNA level (Addendum 
G: Table G1). in the BWTG3 cells, with none of the cell signalling mediators able to 





As previously mentioned, Dex at concentrations of 10-8M to 10-6 M had no effect on CRP 
mRNA, which is in agreement with results from a previous study also performed in BWTG3 
cells. Visser et al. reported that Dex at a concentration of 10-8 M had no effect on CRP mRNA 
expression after 24 hours [88]. The lack of mRNA regulation observed in response to Dex 
could be attributed to length of treatment. From the protein time course data (Fig. 3.5A), an 
increase in CRP protein levels were already observed at 24- and 48 hours Dex exposure, 
suggesting that Dex-induced CRP mRNA expression could possibly have been observed if 
treated with Dex for less than 24 hours, as mRNA precedes protein synthesis. To the best of 
our knowledge, no studies have investigated the effect of the endogenous GCs, on CRP protein 
expression in human or murine liver cells. Therefore, this is the first study to report 
corticosterone- and cortisol-induced increase in intracellular CRP protein expression in murine 
and human hepatoma cell lines.  
 
Although endogenous- and synthetic GCs produce different metabolites, both elicited a similar 
biological response in regards to intracellular CRP protein expression. Conflicting data exists 
regarding the effects of Dex on intra- and extracellular CRP protein expression, as both an 
increase [88][180] as well as no effect [181] in response to Dex have been reported. In 
agreement with the current study, Visser et al. reported that Dex, at a concentration of 10-8 M, 
significantly increased intra- and extracellular CRP protein expression in BWTG3 cells after 
24 hours [88]. In addition, Ganapathi et al. reported that Dex (10-7 M) increased extracellular 
CRP protein synthesis by 2.2-fold in human hepatoma (Hep3B) cells after 24 hours [180]. The 
findings of both groups are consistent with the time course results from the current study, where 
an increase in intracellular CRP protein levels in response to Dex were observed in the 
BWTG3- (Fig. 3.5A) and HepG2 cells (Fig. 3.6A). In contrast, Depraetere et al. found that 
Dex (10-6 M) had no effect on extracellular CRP protein secretion in HepG2 cells after 72 to 
96 hours [181]. It is possible that they lost the effect of Dex on CRP protein expression due to 
stimulating the cells for too long a period, as in the current study and previous groups observed 
a response after 24- or 48 hours.  
 
Similar to Dex, IL-6 had no effect on CRP mRNA expression as earlier mentioned, which is 
consistent with results from a previous study also performed in the BWTG3 liver cell line [88]. 
In contrast, studies performed in human hepatoma (PLC/PTF/5) cells [179] and human- and 
mouse primary hepatocytes [174][187], have shown treatments between 9- to 24 hours with 




to 9-fold. Thus, the lack of IL-6-mediated CRP mRNA regulation observed in the current study 
could be attributed to length of treatment, and IL-6-induced CRP mRNA expression could 
possibly have been observed if treated with IL-6 for less than 24 hours.  
 
Whilst, 24 hours exposure to IL-6 elicited no effect on CRP mRNA expression in the BWTG3 
cells in the current study, an increase in protein expression was observed in both the BWTG3- 
and HepG2 cells in response to 48 hours IL-6 treatment (Addendum G: Table G1). Others 
using a two times lower concentration of IL-6 (10 ng/ml) compared to the current study, have 
also observed an increase in both intra- and extracellular CRP protein expression in BWTG3 
cells [181] and extracellular CRP protein secretion in Hep3B cells [177]. The latter study also 
found IL-6 at a lower concentration of 5 ng/ml to induce extracellular CRP protein synthesis 
in NPLC/PRF/5 cells [180]. Interestingly, IL-6 (10 ng/ml) have also been shown to increase 
extracellular CRP protein synthesis by 22.5-fold in human primary hepatocytes [174]. As 
previously mentioned, heterogeneity does exist between hepatic primary and established cell 
lines [217]. Thus, possibly explaining the considerable difference in fold-induction observed 
for CRP protein expression in the primary cell culture as opposed to that in carcinoma cells. 
Furthermore, studies have shown IL-6 to induce extracellular CRP protein production in other 
cell types, including human primary adipocytes [188] and human coronary smooth muscle cells 
[189]. 
 
TNF-α had no significant effect on CRP mRNA expression as earlier mentioned. However, 
due to variability between independent biological repeats causing large error, the exact effect 
20 ng/ml TNF-α has on CRP mRNA expression in the BWTG3 cells remain inconclusive. To 
the best of our knowledge, only one study has investigated the effect of TNF-α on CRP mRNA 
expression. Calabro et al. found TNF-α (50 ng/ml) to significantly induce CRP mRNA 
expression by 2.5-fold, after 48 hours [189]. However, this study was performed in human 
coronary artery smooth muscle cells, and the authors used a higher concentration of TNF-α, 
and also exposed the cells to TNF-α for much longer compared to the current study.  
 
Whilst, 24 hours exposure to TNF-α had no effect on CRP mRNA expression in the BWTG3 
cells, a significant increase in protein expression was observed in both the BWTG3- and HepG2 
cells in response to 48-hour TNF-α treatment (Addendum G: Table G1). This finding is in 
disagreement with results from previous studies, where TNF-α concentrations ranging from 




hepatocytes [174] and Hep3B cells [180], after 24 hours. However, from the time course data 
(Fig. 3.6C), a significant increase in intracellular CRP protein levels were already observed at 
24 hours TNF-α exposure in the HepG2 cells. This would suggest that the rate at which 
intracellular CRP protein is exported from the human liver cell into the extracellular 
environment could be much slower, and might explain why the above-mentioned studies 
detected an insignificant amount of extracellular CRP protein in response to TNF-α after 24 
hours. Unfortunately, there are no data available on the rate of CRP export in liver cells to 
confirm this argument.  
4.2.2.2. CRP regulation in response to combinatorial treatments 
Although both Dex, at all concentrations tested, and either pro-inflammatory cytokine only 
treatment had no effect on CRP mRNA expression, co-treatment of 10-8 M and 10-6 M Dex 
with TNF-α (Fig. 3.2A), and co-treatment of 10-6 M Dex and IL-6 (Fig. 3.2B) led to a 
significant (p<0.05) increase of CRP mRNA expression in the BWTG3 cells after 24 hours. 
The increase in CRP mRNA does appear to be dependent on the concentration of Dex. To the 
best of our knowledge, only one group has investigated the possible co-regulation of CRP 
mRNA expression by GCs and pro-inflammatory cytokines [88]. Visser et al. found that Dex 
(10-8 M) and IL-6 (10 ng/ml) alone and combined had no effect on CRP mRNA expression in 
BWTG3 cells. Their findings do, however, somewhat differ from that found in the current 
study, as Dex (10-8 M) appeared to decrease CRP mRNA expression in the BWTG3 cells, and 
with the addition of IL-6 (20 ng/ml) this effect was significantly attenuated (Fig. 3.2B). It is 
likely that these disparate findings are due to different treatment regimens used between the 
Visser et al. versus the current study. They sequentially treated cells with Dex for 24 hours 
followed by treatment with a two times lower concentration of IL-6 for 3 hours. Whereas, in 
the current study Dex and IL-6 were introduced to the cells concurrently. In a recent review by 
Desmet et al., it was suggested that pro-inflammatory genes are synergistically increased when 
GCs and pro-inflammatory cytokines are administrated simultaneously [203], which is 
supported by our findings. Therefore, it would be interesting to examine how treatment with 
GCs prior to addition of the pro-inflammatory cytokine (known as GC priming), as applied by 
Visser et al., would affect the regulation CRP.  
 
In the current study, intracellular CRP protein levels remained significantly (p<0.05) increased 
after BWTG3- and HepG2 cells were co-treated with either pro-inflammatory cytokine and 




than what was observed with either GC or cytokine on its own (Figs. 3.11-3.13). Interestingly, 
only cortisol at the lowest concentration used, deviated from this pattern of regulation, as in 
combination with either cytokine, CRP protein levels were no different to that of basal levels 
(Fig. 3.14). To the best of our knowledge, only three research groups have investigated the 
possible co-regulation of CRP protein expression by GCs and pro-inflammatory cytokines, in 
liver cells (human primary hepatocytes [196], HepG2 cells [181] & BWTG3 cells [88]). 
Unfortunately, in all three studies only IL-6 was used as a representative pro-inflammatory 
cytokine, at a concentration of 10 ng/ml. Firstly, Depraetere et al. found that HepG2 cells co-
treated with Dex (10-6 M) and IL-6 for 48 hours cooperatively increased extracellular CRP 
protein expression more than what was observed with either test compound alone [181]. This 
is analogous to the finding in the current study, where co-treatment with Dex, although at a 
lower concentration of 10-7 M, and IL-6 significantly induced intracellular CRP protein 
expression in the HepG2 cells, more than what was observed for either test compound alone 
(Fig. 3.12B). Furthermore, Castell et al. found that human primary hepatocytes co-treated with 
Dex (10-7 M) and IL-6 for 20 hours, potentiated extracellular CRP protein expression more 
than what was observed with Dex, but not IL-6 alone [196]. Lastly, Visser et al. found that 
BWTG3 cells co-treated with Dex (10-8 M), and IL-6 increased extracellular CRP protein 
expression, although not more than what was observed with either test compound alone. In 
addition, they found that the presence of Dex was able to significantly decrease the IL-6-
induced intracellular CRP protein expression back to basal expression [88]. This in stark 
contrast to what was observed in the current study, as it was found that in the same murine cell 
line, the presence of Dex (10-8 M) appeared to strengthen IL-6-induced intracellular CRP 
protein expression (Fig. 3.11B). However, Visser et al. mentioned that optimisation for their 
study was only performed at the level of GR protein expression, unlike the current study, which 
optimised CRP protein expression in both liver cell lines in response to each test compound 
via performing a time course.  
 
Taken together, similar to PAI-1, cooperative regulation of CRP by the GCs and the pro-
inflammatory cytokines was only really observed at the mRNA level and only with the lowest 
concentration of Dex tested in the presence of TNF-α and the highest concentration of Dex 
tested in the presence of IL-6. Very little cooperative effects by the GCs and the pro-
inflammatory cytokines were observed at the protein level, mainly due to huge error between 
independent biological repeats. Overall CRP protein levels remained significantly elevated in 




treatments on their own. This nonetheless emphasises again that GC-mediated effects are not 
simply anti-inflammatory and at least in regard to APPs, co-regulation between pro-
inflammatory cytokines and GCs occurs, which might be related to the initial response to stress 
[203]. In addition, as observed for PAI-1, there appears to be a poor correlation between what 
was observed for all treatments (single and combined) on CRP mRNA versus protein level. 
This discrepancy could be attributed to (i) different treatment times (24- versus 48 hours) used 
in each experiment and, (ii) the involvement of other levels of regulation (post-transcriptional 
modifications) between the transcript and protein product. 
4.3 Involvement of the proximal promoter in PAI-1 and CRP 
gene regulation  
The regulation of PAI-1 and CRP by the GCs in the absence and presence of TNF-α and IL-6 
shown at mRNA and protein level could be attributed to gene transcription activation. Studies 
have identified many cis-acting sequences and trans-activating transcription factors involved 
in the transcriptional induction of PAI-1 and CRP by pro-inflammatory cytokines, such as 
TNF-α and IL-6, or the synthetic GC, Dex. The proximal promoter region of both PAI-1 and 
CRP contain recognition sites for transcription factors involved in GC-, TNF-α- and IL-6 
signalling as shown in Fig. 4.1. The current study shows that both Dex and the pro-
inflammatory cytokines induce PAI-1- and CRP promoter activity, which remains generally 










Figure 4.1. Schematic representation of the proximal promotor region for the (A) PAI-1 and (B) CRP gene 
used in the current study. The relative positions of transcription factor recognition sites identified in each 
promoter are shown. The known response elements (RE) contained in each promoter are indicated in either black 
(obtained from the research paper of the respective authors which kindly gifted each plasmid) or grey (obtained 
from the literature). Diagrams were created by the author of this study. Note: GRE = glucocorticoid responsive 
element; p50-NF-κB-RE = p50 nuclear factor kappa B responsive element; C/EBP-RE = CCAAT-enhancer-
binding protein response element; NBRE = NGFI-B response element; SBE = smad binding element; STAT3 = 




4.3.1. PAI-1 promotor regulation by stress and inflammatory 
mediators 
There is good evidence that GC-induced PAI-1 expression is mediated by the GC-activated GR 
and its association with the GRE in the proximal promotor of the human PAI-1 gene [166]–
[168][172][173]. Riccio et al. not only found Dex to induce PAI-1 mRNA expression in human 
fibrosarcoma cells, but also identified that the most conserved hexanucleotide (TGT(T/C)CT) 
of the GRE was present at -299 in the anti-sense orientation, in the regulatory region of the 
human PAI-1 gene [168]. In addition, Dex-induced PAI-1 promotor activity was shown by Van 
Zonneveld et al. to be mediated via the Dex-bound GR directly interacting with one-half of a 
presumable GRE with enhancer-like properties located within the region between nucleotides 
-305 and +75 of the human PAI-1 promoter, transfected into rat hepatoma (FTO-2B) cells 
[173]. The PAI-1-Luc construct used in the current study should encompass at least one GRE, 
as the construct includes this specific regulatory region explaining the Dex-induced PAI-1 
promotor activity shown (Fig. 3.15). The presence of GREs within the promoter region of the 
PAI-1 promoter also suggest the molecular mechanism of action whereby PAI-1 levels are 
increased in response to GCs.  
 
TNF-α increased PAI-1 promotor activity in BWTG3 cells, by 2-fold (Fig. 3.15A). However, 
the mechanism of action whereby TNF-α increases PAI-1 expression in liver cells remain 
unclear. However, some studies do provide a possible mechanism of action whereby TNF-α 
induces PAI-1 expression in endothelial cells. For example, Hou et al. identified a distal TNF-α 
responsive enhancer of the PAI-1 gene, which contained a NF-κB-binding site (5´-
TGGAATTTCT-3´) at –14889/-14880, able to bind NF-κB (p50 and p65), as well as mediate 
the response to TNF-α [147]. However, according to de Martin et al. the human PAI-1 
promotor lacks a consensus sequence for NF-κB [158]. More recently, Gruber et al. delineated 
the mechanism by which TNF-α induces PAI-1 mRNA expression in endothelial cells 
(HUVECs); they identified that the transcription factor, Nur77 to be part of TNF-α-induced 
PAI-1 expression [146]. In addition, they reported that Nur77 drives the PAI-1 transcription 
via direct binding to a NBRE. The human PAI-1 proximal promotor in fact contains a 
functional binding motif for Nur77 from -261 to -254 bp. Therefore, it is possible that this 
Nur77-NRBE complex contributes to the TNF-α-induced PAI-1 promotor activity observed in 





IL-6-mediated PAI-1 promoter activity was shown by Dong et al. to be mediated by a C/EBP-δ 
motif positioned between -226 to -213 bp in the human PAI-1 promotor [160]. They reported 
that IL-6 (1 ng/ml) increased PAI-1 promotor activity in HepG2 cells transfected with the 
human PAI-1 promoter (-829 to +36 bp), by 2.4-fold. Similarly, the current study observed a 
2-fold induction in PAI-1 promotor activity in response to IL-6 (Fig. 3.15B), which could 
possibly also be mediated via C/EBP-δ.  
 
Co-treatment of Dex with either pro-inflammatory cytokine did not influence the increase in 
PAI-1 promoter activity observed with either test compounds on their own.  Overall, the results 
on a synthetic promotor-reporter differ from what was observed for the endogenous PAI-1 
gene, which suggest that the molecular mechanism of action whereby GCs and the pro-
inflammatory cytokines, TNF-α and IL-6, increase PAI-1 levels is at the promoter level. 
Whether only the proximal promotor is involved remains to be elucidated. It is possible that 
promotor-reporters may not reflect the regulation on full-length endogenous regulatory region 
of the gene as it would be in the native chromatin structure. 
 
4.3.2. CRP promotor regulation by stress and inflammatory 
mediators 
Although in the current study Dex at the various concentrations tested, increased CRP promotor 
activity (Fig. 3.16), functional GREs have yet to be identified. Thereby the exact molecular 
mechanism whereby GCs induce CRP promoter activity remains to be elucidated. It is 
traditionally understood, that GCs exert their effects via binding to the GR, which following 
translocation to the nucleus, binds to GRE(s) in the promotors of GC-responsive genes. The 
lack of GR binding sites in the CRP promoter suggests GC-activated GR positively regulate 
the CRP levels via possible positive tethering to other transcription factors (Chapter 1, 
Fig. 1.6). Positive gene regulation of ligand-activated GR via interacting with other 
transcription factors have been described [87][94]. It has been reported that the GR can tether 
to C/EBP [96][219], STAT3 [94], or NF-κB [87][96], to promote positive regulation of genes. 
Therefore, a tethering mechanism could possibly be involved in which GCs, such as Dex 
increase CRP expression.  
 
Similarly, regulatory elements within the CRP promoter activated by TNF-α have not been 
identified, thus the increase in CRP promoter activity in response to TNF-α (Fig. 3.16A) 




activity (Fig. 3.16B) could be attributed to the presence of both C/EBP and STAT3 as these 
transcription factor recognition sequences have been shown to be present [185][190]. The WT 
CRP -300 construct has two sites to which C/EBP can bind, namely -52 and -219 [182], with 
STAT3 binding between these two positions to a site at -108 on the promotor [183]. IL-6-
induced CRP promoter activity shown in the current study is in agreement with other studies 
performed in human liver cell lines [178][182][185].  
 
When various concentrations of Dex were combined with either TNF-α or IL-6, CRP promotor 
activity remained significantly (p<0.001) elevated. In addition, cooperative regulation of CRP 
promotor activity, more than what was observed with either signalling molecule alone, was 
observed for: (i) the lowest concentration of Dex (10-8 M) plus TNF-α (Fig. 3.16A) and (ii) the 
highest concentration of Dex (10-6 M) plus IL-6 (Fig. 3.16B). This cooperativity displayed was 
also observed at mRNA level, and could be due to a positive tethering mechanism, where 
crosstalk occurs between the transcription factors involved in Dex-, TNF-α-, and IL-6 
signalling, and the promotor of the CRP gene. For example, the GR along with other 
transcription factors (C/EBP, STAT3, NF-κB) could be co-recruited, to simultaneously occupy 
the promotor of the CRP gene to induce its expression. However, as mentioned earlier, the 
luciferase promotor-reporter assay used is an artificial system, in which the plasmids involved 
contain only the minimal promotor and not the fully endogenous gene of our proteins of 
interest.   
 
Taken together, an increase in both PAI-1 and CRP levels could be attributed to the activation 
of the gene promoters of PAI-1 and CRP, respectively.  
4.4 Conclusions  
The hypothesis of the current study is partially accepted, as cooperative regulation of PAI-1 
and CRP by GCs in the presence of either pro-inflammatory cytokine, were observed under 
some but not all experimental conditions. Generally, PAI-1 and CRP levels remained 
significantly elevated in response to combinatorial treatments, which occurred predominantly 
at the promotor- and protein level. However, the GCs were also able to antagonise the cytokine-
induced PAI-1 and CRP expression under certain conditions, which is in line with their well-
known anti-inflammatory role. Nonetheless, it has become abundantly clear, that GCs-
mediated effects go beyond just that of being anti-inflammatory, by surprisingly promoting 




either pro-inflammatory cytokine, under certain conditions, it cooperatively induced an 
increase in PAI-1 and CRP expression, more than what was observed with either test compound 
alone.  
 
Conclusively, the findings of the current study in itself highlight the layered complexity of APP 
regulation by GCs and pro-inflammatory cytokines. It is difficult to identify a uniform pattern 
of regulation across all the components forming part of this study, as the crosstalk between 
GCs and pro-inflammatory cytokines appear to be rather complex. In addition, the current study 
only reflected a snapshot of parameters, and not the complete cytokine nor hormonal networks. 
Despite this limitation, our findings do highlight the importance of investigating the regulation 
of various APPs by GCs and pro-inflammatory cytokines in the same system, as the majority 
of studies tend to centralise their investigation around the regulation of a single APP. 
Ultimately, more research is required to disentangle the complexity of the findings of the 
current study, which will briefly be addressed in the next and final section.  
4.5 Future directions 
While undertaking this study, several ideas for future research worth investigating surfaced. 
These future prospects include, optimising HepG2 cells as a human cell model to study APP 
regulation, further investigating the underlying mechanism of co-regulation by GCs and/or 
cytokines on APP expression, determining if the GCs are metabolised in our liver cell lines, 
investigating extracellular PAI-1 protein expression and using an alternative treatment regime 
and/or cell model system.  
4.5.1. Complete outstanding experimental work in HepG2 cells 
Due to time constraints, owing to the COVID-19 pandemic, some experimental work could not 
be performed in the human hepatoma (HepG2) cell line. This was due to difficulty experienced 
with the human PAI-1 and CRP primers, which prevented investigating PAI-1 and CRP mRNA 
expression in the HepG2 cell line. In addition, efforts to transiently transfect the HepG2 cells 
with our plasmid constructs, in order to perform a luciferase promotor-reporter assay, proved 
unsuccessful, as these cells tend to grow in clumps or clusters, stacking on top of each other, 
when culturing (Chapter 2, Fig. 2.1). As a result, minimal membrane surface is exposed, 
which could possibly compromise the uptake of the exogenous plasmid DNA. Future studies 
should consider attempting to overcome the above-mentioned challenges by perhaps i) 




and, ii) optimising transfection conditions to allow for greater transfection efficiency in the 
HepG2 cell line, such as cell density, length of exposure to transfection reagent or the amount 
of plasmid DNA.   
4.5.2. Are certain transcription factors, such as the GR, co-recruited 
to the promotor of the PAI-1 or CRP genes?  
In order to improve our understanding of PAI-1 and CRP co-regulation by GCs and pro-
inflammatory cytokines, the current study can be extended to investigating the possible 
mechanism of action behind this phenomenon. Firstly, future studies could therefore ascertain 
whether the GR is required via a knock down study, using silencing RNA (siRNA) targeting 
the nr3c1 gene. This gene specifically codes for the GR. Secondly, a chromatin 
immunoprecipitation assay (ChIP) could be performed to investigate the interaction between 
possible transcription factors involved and the promotor of the PAI-1 and CRP genes, i.e., to 
investigate if the GR binding site co-localises with sites for inflammatory transcription factors, 
such as NF-κB, C/EBP, or STATs. If these transcription factors are co-recruited to the PAI-1 
and CRP gene promotors, this would confirm the theory that a positive tethering mechanism 
whereby the GR interacts with other transcription factors is responsible for PAI-1 and CRP 
gene regulation.  
4.5.3. Are the GCs metabolized in the liver cell lines? 
To the best of our knowledge, the BWTG3 cells have not been fully characterized in regards 
to its liver enzyme expression profile. However, liver cell lines, such as HepG2, express both 
phase I and II metabolising enzymes [220], which can metabolise steroidal compounds. 
According to Gentile et al., Dex contains a 9α-fluorine group in its chemical structure, which 
is believed to disrupt the activity of the human liver enzyme, 11-β-hydrogenase type II, from 
metabolising Dex [221]. Taking this into consideration, it is understood that Dex would perhaps 
undergo less metabolic processing in vitro compared to the endogenous GCs, cortisol and 
corticosterone. In addition, there is evidence that liver enzymes transcript levels are much lower 
in carcinoma cell lines opposed to its levels in primary hepatocytes [25]. Nonetheless, mass 
spectrometry could be utilised to determine if the steroid substrates were metabolised to its 
respective metabolites in both liver cell lines. This would confirm if the GC ability of the 
steroids or its metabolites are responsible for the observed responses in the current study. If 
this proves that steroid metabolism did in fact occur, future studies could use liver enzyme 




4.5.4. Extracellular protein expression 
The lack of Dex-mediated effect on PAI-1 protein levels and the possible antagonistic 
behaviour displayed by Dex on both cytokine-induced PAI-1 protein expression, exclusively 
in the human liver cell line, is peculiar considering PAI-1 promoter activity was observed using 
a human PAI-1 promoter reporter construct. Nonetheless, this was not entirely unexpected, as 
GCs are well known to possess anti-inflammatory properties [23]. However, it cannot be 
dismissed that either the rate of Dex-induced PAI-1 protein synthesis or PAI-1 export might 
occur at a faster rate in HepG2 cells. Hence, future studies could explore this issue further by 
measuring extracellular PAI-1 protein levels (i.e., PAI-1 protein secreted into the media) in 
response to the test compounds via performing an enzyme-linked immunosorbent assay 
(ELISA) over time.  
4.5.5. Alternative treatment regime 
It is important to keep in mind that neither hormonal nor cytokine networks function in 
isolation. Their ratios in the body might be different, but these signalling molecules are still 
present in the system simultaneously. Therefore, examining the complicated interaction 
between GCs and pro-inflammatory cytokines are very relevant. Future studies should assess 
a combination (cocktail) of GCs and pro-inflammatory cytokines – for example treating cells 
with Dex plus TNF-α plus IL-6. Few studies have used this treatment-approach, where in most 
cases they observed an even bigger response in APP protein production [180][194][198].  
 
Furthermore, one could also include another early release pro-inflammatory cytokine, namely 
IL-1-β, which shares similar biological properties to TNF-α [222]. It would be a much closer 
physiological reflection of what occurs in the human body, if a combination of all three 
cytokines (TNF-α plus IL-1-β plus IL-6) were introduced to the cells. Multiple studies have 
reported how the presence of IL-1-β synergistically enhanced the effect of IL-6-induced APP 
expression [178][183]–[185][194][198][199]. It has become apparent to the author of this study 
that changes in the expression of many APPs are mediated not by IL-6 alone but instead by a 
combination of pro-inflammatory cytokines.  
 
In addition, most studies investigating APP expression in response to a combination of pro-
inflammatory cytokines, administered the cytokines in simultaneously. However, the 
sequential appearance of IL-1-β followed by IL-6 and thereafter TNF-α have been 




in vivo inflammatory environments. If future studies were to consider treating with a 
combination of cytokines, this order of cytokine release during the APR, should be kept in 
mind.  
 
The current study did have its limitations, as it showed the importance of optimizing conditions 
for both APPs at the different levels of regulation. As the only optimisation in regards with 
APP expression was in the form of a time course experiment at protein level, the mRNA (and 
by default promotor) results could possibly reflect differently had conditions for each 
individual parameter been optimised in terms of length of exposure to the test compounds. 
However, taking into account that the transcription process occurs before mRNA is translated 
into a functional protein, as described by the central dogma of molecular biology, a shorter 
treatment time than used for the protein expression experiments was chosen. Despite this, 
future studies should consider (i) performing a time course study for PAI-1 and CRP mRNA 
expression in response to single treatment with Dex and either TNF-α or IL-6. 
4.5.6. Alternative cell model system 
Although the human and murine hepatoma cell lines, HepG2 and BWTG3, are good models 
for studies investigating APP regulation, they may not mimic the functional response of 
primary cells. This is due to whole body conditions and physiological factors not being properly 
reflected by carcinoma cell lines. However, the current study was a pilot study, thus employing 
the above-mentioned cell lines were the best approach, since it provided a more controlled 
system for the research to be conducted within. Future studies could alternatively use primary 
hepatocytes, which resemble a truer representation of the in vivo environment. The current 
study could also be replicated in vivo using an animal (mouse or rat) model. Factors may be 
present in animal models but not in cell culture that counteract the upregulation of APP 
expression by pro-inflammatory cytokines. Furthermore, the effect of co-treatment with GCs 
and/pro-inflammatory cytokines on PAI-1 and CRP expression in other insulin-sensitive 
tissues, such as adipocytes or muscle cells, can be investigated.  
 
In summary, it is difficult to arrive at any concrete conclusions with regard to the complete 
comprehensive picture of PAI-1 and CRP regulation by both GCs and pro-inflammatory 
cytokines, without first addressing the short-comings of this study. The results from the 
additional future work mentioned above, would undoubtedly build upon and strengthen our 




answers to questions which surfaced during the course of this study. Nonetheless, the current 
study confirmed that combinatorial treatments with GCs and inflammatory mediators are 
generally capable of inducing PAI-1 and CRP expression in liver cells, even displaying 
cooperativity under certain experimental conditions. The promoter reporter results of the 
current study also suggest that regulation of these APPs occur at the promoter level, although 
the transcription factors involved remain to be elucidated.  
 
To conclude the potentiation, rather than suppression of cytokine-induced APP expression by 
GCs, which was generally observed, highlight the need for a paradigm shift in how GC- and 
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ADDENDUM A: Summaries of the literature 
pertaining to the regulation of the APPs 
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Protein increase 
2.5-fold (6 h) 
3.7-fold (24 h) 


















































Dex + TNF-α 
 
o  
o mRNA: Increase (4.8-fold) 




































In vitro: 100 nM 
In vivo: 4 mg/kg 
 
o  
o mRNA (FGG) 
o no effect in vitro 













































In vitro: 20 ng/ml 




o Primary murine hepatocytes: Increase 
in mRNA (5-fold) 
o HePG2: Increase in mRNA (2-fold) 
o  
o SAA (mice) 











o Primary murine hepatocytes: Increase 
in mRNA (7.5-fold) 
o HepG2: Increase in mRNA (3.5-fold) 
o  
o SAA (mice) 


























In vitro: 10 nM 
In vivo: 1 mg/kg 
 
o  
o In vitro: 
o mRNA: Increase of 10-fold 
(SerpinA3), slight increase (SAA1), 
no effect (SAA2) 
o Protein: Increase (SerpinA3) 
In vivo: 
mRNA: increase in both lung (2.2-





































































































































In vitro: 10 ug/ml 





o In vitro: 
mRNA: Increase of 25-fold 
(SerpinA3, SAA1), increase of 75-
fold (SAA2) 
Protein: Increase (SerpinA3) 
In vivo: 
mRNA: increase in both lung and 








Dex + TNF-α 
 
  
o In vitro: 
mRNA: synergistic increase of 85-
fold (SerpinA3), 200-fold (SAA1), 
400-fold (SAA2) 
Protein: synergistic increase 
(SerpinA3) 
In vivo: 
mRNA: additive increase in 




Cortisol + TNF-α 
 






































CRP / SAA 
Intra-and extracellular protein: 
Increase  












24 h (Dex) 
 
 












































Extracellular protein: ‘convergence 
of signal’ 
Intracellular protein: Dex decreased 
IL-6-induced CRP expression, but 
had no effect at extracellular protein 
or mRNA levels. IL-6 had no effect 
on the action of Dex.  
 
SAA 
Intra-and extracellular protein: 
increase, but not more than what was 
observed with either test compound 
alone   
mRNA: ‘in presence of Dex, IL-6-
induced SAA expression is higher 




























SAA1 – 100-fold (24 h) 
SAA2 – 25-fold (24 h) 
 
Secretion: Increase  






























































mRNA: Increase in both SAA1 and 




Keratinocytes: Slight increase  










































SAA1 – 300-fold 
SAA2 – 85-fold 
 
Secretion: Increase (SAA1) 
Keratinocytes: 40-fold 

















Figure B1. Mycoplasma negative (a) BWTG3 and (b) HepG2 cells. Cells were fixed with Carnoy’s fixative 
containing glacial acetic acid and methanol and in a 1:3 ratio. Subsequently, cells were stained with the Hoechst 
33258 dye (Sigma-Aldrich). The Hoechst-dye emits blue fluorescence when bound to dsDNA. Fluorescent images 
were obtained using the Olympus XI81 inverted fluorescent microscope. Both images show fluorescent nuclei of 



















ADDENDUM C: RNA isolation and semi-
quantitative real-time PCR 
C1: RNA isolated from BWTG3 cells were intact 
 
Figure C1. A representative 1% denaturing agarose gel indicating intact RNA isolated from BWTG3 cells. 
To confirm RNA integrity, the presence of intact 28S and 18S ribosomal RNA was determined. Cells were treated 
with 0.01% (v/v) ethanol combined with supplemented DMEM (vehicles), various concentrations of 
dexamethasone (Dex), 20 ng/ml TNF-α or IL-6, and various concentrations of Dex in the presence of TNF-α or 
IL-6. Total RNA was extracted from BWTG3 cells using Tri-reagent as described in Chapter 2, section 2.8. A 
total of 1 µg RNA of each sample was loaded onto a 1% (w/v) denaturing agarose gel, containing biocide, and 
















































































































Figure C2. Primer efficiency melting curve for each primer set (a) mouse PAI-1, (b) mouse CRP and (c) 
mouse 18S used in this study; and corresponding 2% denaturing agarose gel indicating qPCR products. To 
confirm the amplification of a single product, melting curve analysis was performed. The efficiency of each primer 
set was calculated by making a dilution curve from cDNA (vehicle control); To confirm the correct amplicon size 
of the amplified gene product, agarose gel electrophoresis was performed. PCR products were separated by 2% 
(w/v) agarose gel electrophoresis, stained with Nancy-520. 100 bp DNA ladder (ThermoFisher Scientific); Blue 






ADDENDUM D: Buffers and solutions 
10X TPE (Tris-phosphate-EDTA) (1 L) 
• 108 g 10.8 % (w/v) Tris  
• 15.5 ml 1.6% (v/v) 85%-Phosphoric acid (1.679 g/ml)  
• 40 ml 4% (v/v) 0.5 M Na2EDTA (pH 8.0) 
Final volume to 1 L using deionised water 
Store at room temperature   
Function: common buffer solution for gel electrophoresis; solubilizes RNA or DNA while 
protecting it from degradation. 
 
Passive Lysis Buffer (250 ml) 
• 25 ml 10% (v/v) glycerol  
• 7 ml 2.8% (v/v) 10X TPE 
• 0.5 ml 0.2% (v/v) Triton X-100  
Final volume to 250 ml using deionised water  
Store at 4 ºC 
Function: concentrated cell lysis buffer, which promotes rapid lysis of cultured mammalian 
cells without the requirement of freeze-thaw cycles; it elicits only minimal coenterazine 
auto-luminescence, making it the lytic reagent of choice when processing cells for 





5X SDS-Reducing Lysis Buffer (10 ml) 
• 5 ml 10% (w/v) SDS – break up membrane structures; important for high-quality protein 
separation; confers negative charge to polypeptide. 
• 2 ml 20% (v/v) glycerol - increases sample density in order to facilitate gel loading and 
to ensure that each sample remain at the bottom of the well, preventing it from 
overflowing. 
• 1 ml 10% (v/v) 1 M Tris-HCl buffer pH 6.8 – regulates the pH and osmolarity of lysate. 
• 0.01 g Bromophenol Blue – small anionic dye; provides migration front to monitor 
separation process.  
Final volume to 10 ml using deionised water  
Store at -20 ºC (0.5 ml aliquots) and add 25 µl Beta-Mercapto-Ethanol (reduces 
disulphide bridges) per aliquot  
Function: ionic denaturing detergent 
 
0.5 M Na2EDTA (pH 8.0)  
(Disodium ethylene diamine tetra-acetic acid) (100 ml) 
• 18.612 g 18.6% (w/v) Na2EDTA (MW = 372.24 g/mol)  
Final volume to 100 ml using deionised water  
Adjust pH to 8.0 with NaOH  
Sterilize by autoclaving and store at room temperature   






50X TAE (Tris-acetate-EDTA) (1 L) 
• 242 g 24.2% (w/v) Tris  
• 100 ml 10% (v/v) 0.5 M Na2EDTA (pH 8.0)  
• 57.1 ml 5.7% (v/v) glacial acetic acid 
Final volume to 1 L using deionised water  
Store at room temperature   
Function: electrophoresis buffer for nucleic acids in agarose gels. 
 
TE (Tris-EDTA) (500 ml) 
• 10 ml 2% (v/v) 0.5 M Tris-HCl (pH 8.0)  
• 100 µl Na2EDTA (pH 8.0)  
Final volume to 500 mL using DEPC-treated water. 
Store at room temperature   
Function: to solubilise DNA or RNA, while protecting it from degradation by DNase or 
RNases. 
 
10% APS (Ammonium persulfate) (10 ml) 
• 1 g 10% (v/v) APS  
Final volume to 10 ml using deionised water  
Store at -20 ºC 
Function: used in the preparation of polyacrylamide gels; oxidising agent used in 






10% (w/v) SDS (pH 7.2) (1 L) 
• Dissolve 100 g 10% (w/v) SDS at 68 ˚C and adjust pH to 7.2 with HCl  
Final volume to 1 L using reverse osmosis water  
Store at room temperature  
Function: Disrupts the tertiary structure of proteins allowing them to become linear; coats 
proteins to produce a uniform negative charge, in order for the charge to be proportional to 
the weight of the proteins. 
 
1 M Tris-HCl Buffer (pH 6.8) (1 L) 
• 121.4 g 12% (w/v) Tris  
Adjust pH to 6.8 with HCl  
Final volume to 1 L using reverse osmosis water 
Sterilize by autoclaving and store at room temperature 
Function: organic compound used in buffer solutions for electrophoresis gels; to maintain a 
stable pH to hinder shifts that may influence cellular factors. 
 
1.5 M Tris-HCl Buffer (pH 8.8) (1 L) 
• 182.1 g 18.2% (w/v) Tris 
Adjust pH to 8.8 with HCl  
Final volume to 1 L using reverse osmosis water 
Sterilize by autoclaving and store at room temperature 
Function: organic compound used in buffer solutions for electrophoresis gels; to maintain a 





10X Running buffer (pH 8.3) (2 L) 
• 60.6 g 3% (w/v) Tris  
• 288.2 g 14.4% (w/v) glycine  
Final volume to 2 L using reverse osmosis water 
Store at room temperature 
Function: provides ions that carry a current and helps maintain the pH at a relatively constant 
value. 
 
1X Transfer buffer (2 L) 
• 200 ml 10% (v/v) 10X Running buffer 
• 200 ml 10% (v/v) Methanol – assists with the dissociation of SDS from the protein and 
enhances the absorption of protein onto the membrane 
Final volume to 2 L using reverse osmosis water 
Store at 4 ˚C  
 
10X TBS (Tris Buffered Saline) (2 L) 
• 175.2 g 8.8% (w/v) NaCl 
• 48.456 g 2.4% (w/v) Tris (50 mM)  
Final volume to 2 L using reverse osmosis water 
Adjust pH to 7.5 with HCl  
Store at 4 ˚C (stable up to three months) 





1X TBS (Tris Buffered Saline) (1 L) 
• 100 ml 10% (v/v) 10X TBS 
Final volume to 1 L using reverse osmosis water 
Store at 4 ºC  
Function: wash buffer; removes residual protein and prevents the formation of non-specific 
bands. 
 
1X TBST (Tris Buffered Saline - 0.1% Tween) (1 L) 
• 100 ml 10% (v/v) 10X TBS 
• 1 ml 0.1% (v/v) Tween 20  
Final volume to 1 L using reverse osmosis water 
Store at 4 ºC 
Function: wash buffer; the presence of Tween 20, a soap/detergent, helps to reduce non-
specific protein-protein interaction without affecting antibody-antigen binding (blocking 
agent). 
 
LB (Lysogeny Broth) medium (1 L) 
• 20 g 2% (w/v) LB-broth  
Final volume to 1 L using deionised water  
Sterilize by autoclaving and store at room temperature 





Ampicillin stock (50 mg/ml) (15 ml) 
• 0.75 g 5% (w/v) ampicillin  
Final volume to 15 ml using deionised water  
Filter sterilize using a 0.22-micron filter  
Store at -20 °C  
Function: antibiotic  
 
LB Agar Plates (250 ml) 
• 11.25 g 4.5% (w/v) LB-agar  
Final volume to 250 ml using deionised water  
Sterilize by autoclaving  
Add ampicillin to a final concentration of 50 μg/ml 






ADDENDUM E: Validation of the Hsp90 loading 
control expression consistency   
When conducting Western blot analysis on target protein(s), a control is required to normalise 
to when quantifying the protein levels within a sample. This would allow for a more accurate 
representation of the levels of the protein(s) of interest and decrease the influence of human- 
or pipetting error (i.e., ensure equal loading of protein across all wells of the gel). In addition, 
it would compensate for if perhaps more protein was present in the one sample compared to 
the other. In theory, loading controls such as Hsp90 should not be regulated by different 
experimental conditions, as it is ubiquitously expressed in all eukaryotic cell types [223]. In 
the current study, we found that Hsp90 protein expression was minimally affected when 
exposed to the selected test compounds alone over various time points (Fig. E1) as well as 
stably expressed across all individual and combinatorial treatments for 48 hours (Fig. E2). 
Therefore, we can confirm that using Hsp90 as loading control in the current study, proved to 



















E1: The loading control was minimally affected in the time course 
















































Figure E1. The loading control, Hsp90, was minimally affected across all time points by the selected test 
compounds in the (a) BWTG3 and (b) HepG2 cells. To verify the expression stability of the loading control, 
Hsp90, in response to individual treatment with dexamethasone (Dex), corticosterone (Cort), cortisol (F), TNF-α 
or IL-6 over a period of 24-, 48- and 72 hours (h), the data were plotted as the densitometry value for each treated 
sample relative to the densitometry value for the untreated sample (vehicle), which was set to 1 (represented by 
the black dotted line). Results displayed are representative of five independent experiments (± SEM). Statistical 
analysis was performed using one-way ANOVA with Dunnett’s Multiple Comparison’s post-test (*: p<0.05). No 




E2: The loading control was stably expressed across all individual 




























Figure E2. The loading control, Hsp90, was stably expressed across all treatments in the (a) BWTG3 and 
(b) HepG2 cells. To verify the expression stability of the loading control, Hsp90, in response to treatment with a 
panel of test compounds alone and in combination for 48 hours (h), the data were plotted as the densitometry 
value for each treated sample relative to the densitometry value for the untreated sample (vehicle), which was set 
to 1 (represented by the black dotted line). Results displayed are representative of five independent experiments 
(± SEM). Statistical analysis was performed using one-way ANOVA with Dunnett’s Multiple Comparison’s post-




ADDENDUM F: Plasmid isolation and restriction 
enzyme digest 
F1: List of plasmids used in the current study 
 



























4242 + 871  
= 5113  
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5598 + 299  
= 5897 
 





















F2: Luciferase reporter vector maps  
 











































     
 
 






















































































































 Figure F1. Luciferase reporter vector maps. The PAI-1-Luc and WT CRP -300 plasmids were generated by 
ligating a part of the human PAI-1 or CRP promotor region with the (a) pGL.4.10[luc2] or (b) pLG2-Basic 
luciferase reporter vectors, respectively. Various restriction enzyme binding sites are displayed in each image. 
The luciferase vector map (back bone) for each plasmid used in the current study was created using SnapGene®. 
The restriction enzyme site where the SalI restriction enzyme would linearize each plasmid is boxed in blue. Note: 













F3: Plasmid Isolation  
To investigate which regulatory regions in the promotor of the APPs, PAI-1 and CRP might 
play a role in  GC and/or pro-inflammatory cytokine-induced regulation, plasmid DNA 
encoding the minimal PAI-1-Luc and  proximal WT CRP -300 promotor were isolated and 
purified. 
 




A260/280 ≥ 1.8: Pure DNA                                                                                               
A260/280 ≥ 2: Contamination with RNA  
A260/280 ≤ 1.8: Contamination with protein and aromatic substances  
 
The A260/A280 ratio indicate that pure, good-quality DNA was obtained. The plasmid 
isolation NucleoBond Xtra Maxiprep System used has an expected yield of up to 1000 µg of 
plasmid DNA per preparation. In each case a loss of yield (half of expected yield) was observed 
when isolating both PAI-1-Luc and WT CRP -300 plasmids, as displayed in Table F2. It is 
possible that the other half of the expected yield was lost due to vigorous pipetting.  
 
The success of further applications, such as transfection of cells followed by a promoter-
reporter assay, are dependent on the yield and purity of the isolated plasmid DNA. To assess if 
any DNA contamination occurred during the process of plasmid isolation, the absorbance 
readings of each plasmid were measured at 260- and 280 nm, using a BioDrop 
spectrophotometer. Both DNA and RNA absorb UV light at 260 nm, while proteins containing 
aromatic amino acids absorb UV light at 280 nm. Therefore, if either or both contaminants 
(RNA or proteins) were present in the plasmid DNA samples, it would contribute to their total 
absorbance. Pure DNA has an expected A260/A280 ratio of ≥1.8. An A260/A280 ratio of 1.92 
and 1.89 was obtained for PAI-1-Luc and WT CRP -300, respectively. These values indicate 
that pure, good-quality DNA was obtained.  
 Concentration (ng/µl) A260/280 Yield (µg) 
PAI-1-Luc 812 1.85 541 




F4: Restriction Enzyme Digest of the DNA plasmid constructs used 



















Figure F2. 0.5% Agarose gel containing Nancy-520 stain. The quality and integrity of the plasmid DNA for all 
constructs was assessed using restriction enzyme digestion and visualised on 1% agarose gel. Lane 1: 
O’GeneRuler 1 kb Plus DNA Ladder, Lane 2: PAI-1-Luc (single digest), Lane 3: PAI-1-Luc (undigested), Lane 
4: WT CRP -300 (single digest), Lane 5: WT CRP -300 (undigested). Pink boxes represent the presence of 
supercoiled plasmid DNA. 
 
Since pure plasmid DNA was obtained, next the quality and integrity (i.e., supercoiled, linear 
or nicked) of the plasmid DNA was determined. For this reason, a restriction enzyme (RE) 
digest was performed using the restriction enzyme, SalI-HF. Subsequently, agarose gel 
electrophoresis, using a 0.5% agarose gel, was performed to analyze the digested and 
undigested plasmid DNA (Fig. F2). The plasmid DNA would migrate differently in the agarose 
gel, depending on the size of the DNA fragment and its integity. Together with the PAI-1-Luc 
or WT CRP -300 inserts, each plasmid vector should have a size of 5113- and 5897 bp, 
respectively.  
 
















PAI-1-Luc:   5113 bp
WT CRP –300:  5897 bp
Observed size:
PAI-1-Luc:  5000 bp




Both plasmid sequences have a single recognition site for SalI, hence why this specific RE was 
chosen. Theoretically a single band was expected after both plasmids were subjected to a single 
digestion with the RE. Bands observed in lanes 2 and 4 are of correct size. In order for the 
BWTG3 cells to efficiently take up DNA, the isolated plasmid DNA should be supercoiled. 
Supercoiled DNA would migrate faster through the pores of the agarose gel as it is small and 
compact. Therefore, with the undigested plasmids we expected a single band, further down the 
agarose gel compared to the digested plasmids, to indicate their supercoiled integrity. A single 
band in lanes 3 and 5 (boxed in pink in Fig. F2) was observed, which appeared to represent 
mostly supercoiled DNA, although linear DNA is also present. Therefore, it is possible that 





ADDENDUM G: Summary of results 
Table G1. Summary of the overall effects of single and co-treatment with GCs and/or pro-inflammatory 
cytokines on PAI-1 and CRP, at mRNA, promotor, and intracellular protein level, in BWTG3- and HepG2 




One-way ANOVA with Dunnett’s Multiple Comparison’s post-test was used when comparing 
each treatment to the vehicle control (***: p<0.001, **: p <0.01, *: p<0.05, ns: p>0.05). 
 
              
PAI-1 CRP 





















Dex (10-8 M) - ↑ *** ↑ * - - ↑ *** ↑ * ↑ *** 
Dex (10-7 M) - ↑ ** ↑ ** - - ↑ *** ↑ *** ↑ *** 
Dex (10-6 M) - ↑ * ↑ ** - - ↑ *** ↑ *** ↑ ** 
TNF-α (20 ng/ml)  ↑ *** ↑ *** ↑ ***  ↑ *** ↑ *** ↑ *** 
IL-6 (20 ng/ml) ↑ ** ↑ *** ↑ ** ↑ ** - ↑ *** ↑ *** ↑ *** 
Dex (10-8 M) + TNF-α ↑ *** ↑ ** ↑ * - ↑ ** ↑ *** ↑ * ↑ *** 
Dex (10-7 M) + TNF-α - ↑ * ↑ * - - ↑ *** ↑ *** ↑ ** 
Dex (10-6 M) + TNF-α ↑ * ↑ ns ↑ ns ↓ ** ↑ * ↑ *** ↑ ** ↑ ** 
Dex (10-8 M) + IL-6 - ↑ * ↑ * - - ↑ *** ↑ ** ↑ ** 
Dex (10-7 M) + IL-6 - ↑ *** ↑ ** - ↓ ** ↑ *** ↑ ** ↑ *** 
Dex (10-6 M) + IL-6 - ↑ ** ↑ ns ↓ ns ↑ * ↑ *** ↑ ** ↑ *** 
 
Cort/F (10-8 M) ND ND - ↑ *** ND ND ↑ *** ↑ ** 
Cort/F (10-7 M) ND ND ↑ ** - ND ND ↑ *** ↑ *** 
Cort/F (10-6 M) ND ND ↑ * ↑ * ND ND ↑ ** ↑ ** 
TNF-α (20 ng/ml) ND ND ↑ *** ↑ *** ND ND ↑ *** ↑ ** 
IL-6 (20 ng/ml) ND ND ↑ ** ↑ *** ND ND ↑ *** ↑ *** 
Cort/F (10-8 M) + TNF-α ND ND ↑ * ↑ *** ND ND ↑ * - 
Cort/F (10-7 M) + TNF-α ND ND ↑ *** ↑ *** ND ND ↑ * ↑ ns 
Cort/F (10-6 M) + TNF-α ND ND ↑ *** ↑ *** ND ND ↑ * ↑ * 
Cort/F (10-8 M) + IL-6 ND ND ↑ *** ↑ *** ND ND ↑ ** - 
Cort/F (10-7 M) + IL-6 ND ND ↑ *** ↑ *** ND ND ↑ ** ↑ ** 
Cort/F (10-6 M) + IL-6 ND ND ↑ ** - ND ND ↑ * ↑ * 
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